<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8541031</article-id><article-id pub-id-type="pmcid-ver">PMC8541031.1</article-id><article-id pub-id-type="pmcaid">8541031</article-id><article-id pub-id-type="pmcaiid">8541031</article-id><article-id pub-id-type="pmid">34696180</article-id><article-id pub-id-type="doi">10.3390/vaccines9101072</article-id><article-id pub-id-type="publisher-id">vaccines-09-01072</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Plasmodium falciparum</italic> Malaria Vaccines and Vaccine Adjuvants</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2888-2418</contrib-id><name name-style="western"><surname>Bonam</surname><given-names initials="SR">Srinivasa Reddy</given-names></name><xref rid="af1-vaccines-09-01072" ref-type="aff">1</xref><xref rid="c1-vaccines-09-01072" ref-type="corresp">*</xref><xref rid="fn1-vaccines-09-01072" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0349-1557</contrib-id><name name-style="western"><surname>R&#233;nia</surname><given-names initials="L">Laurent</given-names></name><xref rid="af2-vaccines-09-01072" ref-type="aff">2</xref><xref rid="af3-vaccines-09-01072" ref-type="aff">3</xref><xref rid="af4-vaccines-09-01072" ref-type="aff">4</xref><xref rid="c1-vaccines-09-01072" ref-type="corresp">*</xref><xref rid="fn1-vaccines-09-01072" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tadepalli</surname><given-names initials="G">Ganesh</given-names></name><xref rid="af5-vaccines-09-01072" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0498-9808</contrib-id><name name-style="western"><surname>Bayry</surname><given-names initials="J">Jagadeesh</given-names></name><xref rid="af1-vaccines-09-01072" ref-type="aff">1</xref><xref rid="af6-vaccines-09-01072" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="HMS">Halmuthur Mahabalarao Sampath</given-names></name><xref rid="af5-vaccines-09-01072" ref-type="aff">5</xref><xref rid="c1-vaccines-09-01072" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Girolomoni</surname><given-names initials="G">Giampiero</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-09-01072"><label>1</label>Institut National de la Sant&#233; et de la Recherche M&#233;dicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Th&#233;rapeutique, Sorbonne Universit&#233;, Universit&#233; de Paris, F-75006 Paris, France; <email>jagadeesh.bayry@crc.jussieu.fr</email></aff><aff id="af2-vaccines-09-01072"><label>2</label>A*STAR Infectious Diseases Labs, 8A Biomedical Grove, Singapore 138648, Singapore</aff><aff id="af3-vaccines-09-01072"><label>3</label>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore</aff><aff id="af4-vaccines-09-01072"><label>4</label>School of Biological Sciences, Nanyang Technological University, Singapore 308232, Singapore</aff><aff id="af5-vaccines-09-01072"><label>5</label>Vaccine Immunology Laboratory, Organic Synthesis and Process Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; <email>ganeshbabutmln@gmail.com</email></aff><aff id="af6-vaccines-09-01072"><label>6</label>Biological Sciences &amp; Engineering, Indian Institute of Technology Palakkad, Palakkad 678623, India</aff><author-notes><corresp id="c1-vaccines-09-01072"><label>*</label>Correspondence: <email>bsrpharmacy90@gmail.com</email> (S.R.B.); <email>renia_laurent@idlabs.a-star.edu.sg</email> (L.R.); <email>sampath@iict.res.in</email> (H.M.S.K.)</corresp><fn id="fn1-vaccines-09-01072"><label>&#8224;</label><p>Equally contributed.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2021</year></pub-date><volume>9</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">392384</issue-id><elocation-id>1072</elocation-id><history><date date-type="received"><day>14</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>9</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>24</day><month>10</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-07 05:25:16.770"><day>07</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-09-01072.pdf"/><abstract><p>Malaria&#8212;a parasite vector-borne disease&#8212;is a global health problem, and <italic toggle="yes">Plasmodium falciparum</italic> has proven to be the deadliest among <italic toggle="yes">Plasmodium</italic> spp., which causes malaria in humans. Symptoms of the disease range from mild fever and shivering to hemolytic anemia and neurological dysfunctions. The spread of drug resistance and the absence of effective vaccines has made malaria disease an ever-emerging problem. Although progress has been made in understanding the host response to the parasite, various aspects of its biology in its mammalian host are still unclear. In this context, there is a pressing demand for the development of effective preventive and therapeutic strategies, including new drugs and novel adjuvanted vaccines that elicit protective immunity. The present article provides an overview of the current knowledge of anti-malarial immunity against <italic toggle="yes">P. falciparum</italic> and different options of vaccine candidates in development. A special emphasis has been made on the mechanism of action of clinically used vaccine adjuvants.</p></abstract><kwd-group><kwd>anti-malarial drugs</kwd><kwd>malaria vaccine</kwd><kwd><italic toggle="yes">Plasmodium falciparum</italic></kwd><kwd>vaccine adjuvants</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-09-01072"><title>1. Introduction</title><p>Malaria, caused by apicomplexan <italic toggle="yes">Plasmodium</italic> spp., remains one of the world&#8217;s most threatening diseases of humans and other animals with high morbidity and mortality rates [<xref rid="B1-vaccines-09-01072" ref-type="bibr">1</xref>]. The recent findings of the World Health Organization (WHO) recorded 228 million cases and 405,000 deaths globally in 2018 [<xref rid="B2-vaccines-09-01072" ref-type="bibr">2</xref>]. Although eight species of <italic toggle="yes">Plasmodium</italic> can infect humans, most malarial cases are due to <italic toggle="yes">P. falciparum</italic> or <italic toggle="yes">P. vivax,</italic> but deaths are mostly due to <italic toggle="yes">falciparum</italic> malaria. The African countries carry the highest share of the global malaria burden (~90% as per 2017 WHO reports) [<xref rid="B3-vaccines-09-01072" ref-type="bibr">3</xref>]. In Asian countries, e.g., India, which accounts for 4% of the global burden, malaria is still a serious health threat [<xref rid="B4-vaccines-09-01072" ref-type="bibr">4</xref>]. As an answer, the Special Programme for Research and Training in Tropical Diseases (TDR; co-sponsored by the WHO), US National Institutes of Health, UK department for international development, Bill &amp; Melinda Gates Foundation, and other organizations have increased funding for research and development and other control measures (including vaccination) to minimize the malaria cases [<xref rid="B2-vaccines-09-01072" ref-type="bibr">2</xref>,<xref rid="B5-vaccines-09-01072" ref-type="bibr">5</xref>]. WHO has also put more effort into implementing essential malaria commodities, such as rapid diagnostic tests, insecticide-treated mosquito nets, vector control, artemisinin-based combination therapy, and in defeating insecticide resistance of malaria vectors. These programs were highly successful and did reduce significantly the numbers of malaria-related deaths [<xref rid="B4-vaccines-09-01072" ref-type="bibr">4</xref>,<xref rid="B6-vaccines-09-01072" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-09-01072" ref-type="bibr">7</xref>]. </p><p>The malaria parasite has a complex life cycle (<xref rid="vaccines-09-01072-f001" ref-type="fig">Figure 1</xref>). The Ronald Ross and Giovanni Battista Grassi legacy laid the cornerstone for understanding the malaria parasite life cycle (<xref rid="vaccines-09-01072-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B8-vaccines-09-01072" ref-type="bibr">8</xref>]. There are pre-erythrocytic and erythrocytic stages in humans (host) and the sexual life cycle in the mosquito vector. (a) Pre-erythrocytic stage. When the infected mosquito bites the host for blood meal, it injects sporozoite mostly into the dermis or sometimes directly into the blood vessels [<xref rid="B9-vaccines-09-01072" ref-type="bibr">9</xref>]. Once sporozoite reaches the liver, it invades and infects the hepatocytes. Inside the hepatocytes, sporozoites multiply extensively, generating 10&#8211;30,000 merozoites [<xref rid="B10-vaccines-09-01072" ref-type="bibr">10</xref>]. (b) Erythrocytic stage. Merozoites enter the red blood cells (RBCs) and mature into trophozoite and schizont. Each schizont generates 6&#8211;12 merozoites, which are released into the circulation (remain one minute to the next infection) and infect more RBCs [<xref rid="B11-vaccines-09-01072" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-09-01072" ref-type="bibr">12</xref>]. During the process, a small number of parasites develop into male and female gametocytes. The formed gametocytes mature first in the bone marrow (I&#8211;IV stages) and then spleen (V stage) [<xref rid="B13-vaccines-09-01072" ref-type="bibr">13</xref>]. (c) Mosquito/sexual stage. In every progressing cycle, a small number of parasites deviates from asexual reproduction and develops into male and female gametocytes, which will enter the stomach of the <italic toggle="yes">Anopheles</italic> mosquito during the blood meal. The male and female gametocytes develop into flagellated microgametes (eight) and a single macrogamete respectively within the mosquito&#8217;s midgut. A zygote resulting from the fusion of a macrogamete and microgamete develops into ookinete via meiosis and penetrates the mosquito&#8217;s gut wall to form oocysts and produce sporozoites. These sporozoites travel to salivary glands after the rupture of oocysts and will infect a new host during a mosquito bite (<xref rid="vaccines-09-01072-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B12-vaccines-09-01072" ref-type="bibr">12</xref>,<xref rid="B14-vaccines-09-01072" ref-type="bibr">14</xref>].</p><p><italic toggle="yes">P. falciparum</italic> transmission can be managed through vector control approaches, such as spraying insecticides and/or using chemically-treated mosquito nets, and through the use of antimalarial drugs for prophylaxis and radical cure [<xref rid="B15-vaccines-09-01072" ref-type="bibr">15</xref>]. Early diagnosis, use of bed nets, and timely treatment with anti-malarial compounds are the global strategies for controlling <italic toggle="yes">P. falciparum</italic>. However, the parasite has developed resistance to all anti-malarial drugs which are in present use [<xref rid="B16-vaccines-09-01072" ref-type="bibr">16</xref>]. In the last century, chloroquine was an essential tool to eradicate malaria in many countries [<xref rid="B17-vaccines-09-01072" ref-type="bibr">17</xref>]. However, in the 1970s resistance to chloroquine monotherapy emerged, and nowadays, chloroquine-resistant <italic toggle="yes">P. falciparum</italic> parasites are present worldwide. Other drugs such as pyrimethamine, mefloquine, or artemisinin derivatives were also developed and replaced chloroquine progressively. Because resistance to these drugs also developed, combination therapies were set to treat <italic toggle="yes">P. falciparum</italic> infections [<xref rid="B18-vaccines-09-01072" ref-type="bibr">18</xref>]. Artemisinin-based combination therapies have been essential to decrease the death toll. However, resistance to artemisinin and its partner drugs has become a severe concern in the last decade [<xref rid="B19-vaccines-09-01072" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-09-01072" ref-type="bibr">20</xref>]. Thus, there is a need for novel drugs and vaccines, particularly for controlling and possibly eliminating <italic toggle="yes">P. falciparum</italic> malaria. The focus of this article is to review the current status of malaria vaccines research, with an emphasis of the use of adjuvants and their mechanisms of action. </p></sec><sec id="sec2-vaccines-09-01072"><title>2. Immunity against <italic toggle="yes">P. falciparum</italic></title><p>Knowledge on the interaction between the parasite and host immune system and how clinical immunity is acquired against malarial infection is critical for the development of effective vaccines, anti-malarial drugs, and immunomodulators. </p><sec id="sec2dot1-vaccines-09-01072"><title>2.1. Dendritic Cells and the Initiation of the Immune Response</title><p>Among the innate immune cells, professional antigen-presenting cells (APCs), such as dendritic cells (DCs), have a prominent role in antigen presentation [<xref rid="B21-vaccines-09-01072" ref-type="bibr">21</xref>]. Although each innate immune cell has a role in homeostasis and immunity, DCs&#8217; role in vaccine and vaccine adjuvant development has been extensively studied [<xref rid="B22-vaccines-09-01072" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-09-01072" ref-type="bibr">23</xref>]. Considering the central role of DCs in the activation and polarization of na&#239;ve T cells [<xref rid="B24-vaccines-09-01072" ref-type="bibr">24</xref>] and shaping the immune response to vaccine adjuvants (<xref rid="vaccines-09-01072-f002" ref-type="fig">Figure 2</xref>), we focused our discussion on DCs [<xref rid="B13-vaccines-09-01072" ref-type="bibr">13</xref>] in the innate immune system. </p><p>DCs appear to interact with the parasite at various anatomical locations of the host such as skin, liver, blood, and spleen. DCs recognize pathogens through specific receptors called pattern-recognition receptors (PRRs), such as toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), and others. PRRs recognize highly conserved structures of microorganisms, including parasites, via pathogen-associated molecular patterns (PAMPs). PAMPs are processed by the DCs and present the unique sequences of PAMPs to the T helper (Th) cells, which seeds the development of immunological memory [<xref rid="B22-vaccines-09-01072" ref-type="bibr">22</xref>]. Although a few PAMPs (e.g., <italic toggle="yes">Plasmodium</italic> multidomain scavenger receptor-like protein [PxSR], glycosylphosphatidylinositol [GPI], hemozoin, RNA, plasmodial DNA, CpG motifs, and others) (<xref rid="vaccines-09-01072-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B25-vaccines-09-01072" ref-type="bibr">25</xref>,<xref rid="B29-vaccines-09-01072" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-09-01072" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-09-01072" ref-type="bibr">31</xref>] have been identified in <italic toggle="yes">Plasmodium</italic> spp., their interaction with DCs and the related immune defense are still not fully elucidated [<xref rid="B32-vaccines-09-01072" ref-type="bibr">32</xref>]. Interestingly, PRRs (particularly TLRs) have an essential role in both immune defense and pathogenicity (<xref rid="vaccines-09-01072-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B33-vaccines-09-01072" ref-type="bibr">33</xref>]. In addition, DCs have differential functional capabilities (tolerogenic versus inflammatory/activated) based on the tissues they reside in and signals they receive from the pathogen and microenvironment [<xref rid="B34-vaccines-09-01072" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-09-01072" ref-type="bibr">35</xref>]. </p><p>The malaria parasite in the mammalian host interacts with different tissues (the skin dermis, the liver, blood capillaries, and vessels) and can be either extra- or intracellular. This dictates which types of DCs it will interact with (for an in depth-review, see [<xref rid="B35-vaccines-09-01072" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-09-01072" ref-type="bibr">36</xref>]).</p><p>In the dermis, the extracellular sporozoites are mostly phagocytosed by monocyte-derived macrophages (MDM) rather than by dermal DCs and monocyte-derived DCs. After sporozoites uptake, MDM display a regulatory phenotype, which negatively affects the antigen-presenting capacity of dermal APCs [<xref rid="B37-vaccines-09-01072" ref-type="bibr">37</xref>]. Nevertheless, some dermal DCs, after their interaction with sporozoites, could reach draining lymph nodes to prime CD4<sup>+</sup> or CD8<sup>+</sup> T cells [<xref rid="B38-vaccines-09-01072" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-09-01072" ref-type="bibr">39</xref>]. Of all the sporozoites entering the blood circulation in their mammalian hosts, only a fraction can invade liver cells since most of them are retained in the spleen [<xref rid="B40-vaccines-09-01072" ref-type="bibr">40</xref>]. They can be phagocytosed by splenic DCs and presented to T and B cells. For the intracellular liver parasites, it is not clear how DCs acquire newly synthetized liver-stage antigens. It was shown that monocyte-derived DCs are responsible for CD8<sup>+</sup> T cell priming [<xref rid="B41-vaccines-09-01072" ref-type="bibr">41</xref>]. However, the way they acquire antigen remains unknown. It has been proposed that DCs can either phagocyte apoptotic hepatocytes resulting from an aborted infection [<xref rid="B38-vaccines-09-01072" ref-type="bibr">38</xref>] or they can acquire antigens from infected hepatocytes [<xref rid="B42-vaccines-09-01072" ref-type="bibr">42</xref>]. It has long been known that intradermal immunization is less effective than the intravenous route when animals and humans have been injected with whole sporozoites [<xref rid="B43-vaccines-09-01072" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-09-01072" ref-type="bibr">44</xref>]. This suggests that the priming of DCs in the spleen or liver is more potent than the skin&#8217;s priming. Since it is the natural route of infection, malaria parasites have evolved immune escape mechanisms at the skin. Identifying the adjuvants that can antagonize these mechanisms may help in the development of whole sporozoite skin immunization protocols. Of note, liver-resident DCs, which produce high amounts of IL-10, are more tolerogenic than other DC subsets. Cracking this tolerance, possibly through the use of proper adjuvants, represents one of the rational approaches to target liver-stage malaria infection [<xref rid="B13-vaccines-09-01072" ref-type="bibr">13</xref>,<xref rid="B45-vaccines-09-01072" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-09-01072" ref-type="bibr">46</xref>]. </p><p>During the erythrocytic stage, the more likely site of priming of the immune response is the spleen [<xref rid="B47-vaccines-09-01072" ref-type="bibr">47</xref>]. During its blood-stage development, the parasites remodel the infected erythrocytes, leading to changes in deformability and rheological properties of the cells [<xref rid="B48-vaccines-09-01072" ref-type="bibr">48</xref>]. The infected red blood cells (iRBC), which cannot deform, go through small capillaries and accumulate in the spleen. These iRBCs are then recognized and destroyed by phagocytes [<xref rid="B49-vaccines-09-01072" ref-type="bibr">49</xref>]. <italic toggle="yes">P. falciparum</italic> parasites have evolved to avoid splenic clearance by expressing neoantigens at the surface of iRBC. These antigens, such as <italic toggle="yes">P. falciparum</italic> erythrocyte membrane protein 1 (PfEMP1), allow parasites to sequester in deep tissues by binding to a variety of receptors expressed on the surface of capillary endothelial cells [<xref rid="B50-vaccines-09-01072" ref-type="bibr">50</xref>]. Splenic DCs or blood DCs can capture iRBC through CD36 and present to na&#239;ve T cells [<xref rid="B51-vaccines-09-01072" ref-type="bibr">51</xref>]. However, iRBC binding to CD36 and CD54 on immature DCs limits the DC maturation [<xref rid="B52-vaccines-09-01072" ref-type="bibr">52</xref>]. In vitro experiments in fact have shown that infected erythrocytes reduce the expression of co-stimulatory molecules on DCs [<xref rid="B52-vaccines-09-01072" ref-type="bibr">52</xref>] and affect the antigen processing capacity of these professional APCs [<xref rid="B52-vaccines-09-01072" ref-type="bibr">52</xref>]. It was also found that malaria infection alters the expression of TLRs on DC subsets [<xref rid="B53-vaccines-09-01072" ref-type="bibr">53</xref>]. In one cross-sectional study, circulating DCs from acutely infected Papuan adults had DCs, which did not mature well in vitro after stimulation and were more prone to apoptosis. This immune dysregulation of DCs is associated with an increased level of IL-10. Antagonizing the IL-10 actions restored DC functions [<xref rid="B54-vaccines-09-01072" ref-type="bibr">54</xref>]. By decreasing DC maturation efficiency, the parasite prevents the establishment of a potent immune response and facilitates immune evasion. Nevertheless, blood and splenic DCs are effective in inducing inflammatory signals against <italic toggle="yes">Plasmodium</italic> infection. New vaccine platforms are harnessing DCs for the development of novel malaria vaccines [<xref rid="B55-vaccines-09-01072" ref-type="bibr">55</xref>]. In addition, any immunopotentiating substances such as adjuvants, which can enhance the antigen presentation capacity of circulating or tissue-specific DCs to induce a protective immune response, are needed. </p><p>Majority of the myeloid cells, such as monocytes, macrophages, NK cells, eosinophils, neutrophils, and DCs, participate in the antibody-dependent cell-mediated cytotoxicity (ADCC) functions. Previous studies have given a clue that passive transfer of immune sera has the capacity to activate ADCC to protect the host against malaria [<xref rid="B56-vaccines-09-01072" ref-type="bibr">56</xref>]. In vitro studies on RBCs, from infected and non-infected malaria, have confirmed that NK cell-mediated ADCC is essential for acquired immunity [<xref rid="B57-vaccines-09-01072" ref-type="bibr">57</xref>]. In addition, upon parasite exposure, NK cells are accompanied with an early capacity to produce copious amounts of cytokines (e.g., IFN-&#947;). Data from an RBC-supplemented, immune cell-optimized humanized mouse model have revealed that NK cells interact with <italic toggle="yes">P. falciparum</italic>-infected erythrocytes through lymphocyte-associated antigen 1 and kill the infected cells [<xref rid="B58-vaccines-09-01072" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-09-01072" ref-type="bibr">59</xref>].</p><p>A specialized type of NK cells called adaptive NK cells, which express CD56<sup>dim</sup> without the expression of promyelocytic leukemia zinc finger (PLZF) transcription factor and Fc receptor &#947;-chain (FcR&#947;) have been recently described. Studies conducted by Geoffrey et al., in children and young adults, have predicted that presence of adaptive NK cells is associated with protection against <italic toggle="yes">P. falciparum</italic>-induced malaria infection [<xref rid="B60-vaccines-09-01072" ref-type="bibr">60</xref>]. As NK cells are heterogeneous, further work is necessary to dissect the role of various subsets of NK cells in the protection against malaria. Nevertheless, based on the above discussion, ADCC function might play an essential role in blood-stage malaria. </p></sec><sec id="sec2dot2-vaccines-09-01072"><title>2.2. Adaptive Immunity</title><sec id="sec2dot2dot1-vaccines-09-01072"><title>2.2.1. T Cell-Mediated Immunity</title><p>T cells, such as CD4<sup>+</sup> (T helper, T follicular helper (Tfh) cells, cytotoxic CD4<sup>+</sup> T cells), cytotoxic CD8<sup>+</sup>, and non-classical T cells such as mucosal-associated invariant T (MAIT) cells and &#947;&#948; T cells have been shown to have a role in antimalarial immunity (for a comprehensive review, see [<xref rid="B61-vaccines-09-01072" ref-type="bibr">61</xref>]). </p></sec><sec id="sec2dot2dot2-vaccines-09-01072"><title>2.2.2. T Cell-Mediated Immunity against Liver-Stage Malaria Parasites</title><p>Most of the knowledge on T cell immunity against the malaria liver stage has been obtained in rodent malaria models of protection using whole parasite immunization either with irradiated sporozoites or live sporozoite under drug prophylaxis [<xref rid="B62-vaccines-09-01072" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-09-01072" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-09-01072" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-09-01072" ref-type="bibr">65</xref>] (<xref rid="vaccines-09-01072-t001" ref-type="table">Table 1</xref>). In these models, it has been shown that CD8<sup>+</sup> and CD4<sup>+</sup> T cells recognize peptide-derived antigens, which are presented by MHC class I and Class II on the surface of infected hepatocytes [<xref rid="B66-vaccines-09-01072" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-09-01072" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-09-01072" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-09-01072" ref-type="bibr">69</xref>]. T cells can eliminate infected parasites via different mechanisms [<xref rid="B70-vaccines-09-01072" ref-type="bibr">70</xref>]. They can produce IFN-&#947;, which induces nitric oxide synthase to produce nitric oxide, a toxic molecule, in response to liver parasites [<xref rid="B71-vaccines-09-01072" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-09-01072" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-09-01072" ref-type="bibr">73</xref>]. They can also eliminate infected hepatocytes through contact-dependent perforin-dependent mechanisms [<xref rid="B74-vaccines-09-01072" ref-type="bibr">74</xref>]. IL-4-secreting CD4<sup>+</sup> T cells have been shown to be critical for the induction of CD8<sup>+</sup> T-cell response to liver-stage malaria [<xref rid="B41-vaccines-09-01072" ref-type="bibr">41</xref>,<xref rid="B75-vaccines-09-01072" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-09-01072" ref-type="bibr">76</xref>]. Liver-resident CD8<sup>+</sup> T cells (CXCR6<sup>+</sup>CD69<sup>+</sup>) induced by vaccination with whole parasites or a subunit formulation of the <italic toggle="yes">Plasmodium</italic> ribosomal protein RPL6 are essential to confer protection in mice [<xref rid="B77-vaccines-09-01072" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-09-01072" ref-type="bibr">78</xref>]. Experimental vaccination experiments in models using irradiated sporozoites have also suggested that protection is dependent on the presence of liver-resident CD8<sup>+</sup> T cells [<xref rid="B79-vaccines-09-01072" ref-type="bibr">79</xref>]. In human vaccine experiments, CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses were induced after <italic toggle="yes">P. falciparum</italic> sporozoite immunization [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>]. Vaccine-induced protection was correlated with CD4<sup>+</sup> T cell responses [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>]. The route of infection is critical for optimum T cell-mediated immunity against liver parasite. In fact, intravenous but not the intradermal injection of irradiated sporozoites induced a full sterilizing immune response [<xref rid="B79-vaccines-09-01072" ref-type="bibr">79</xref>], possibly due to the induction of resident CD8<sup>+</sup> T cells [<xref rid="B44-vaccines-09-01072" ref-type="bibr">44</xref>,<xref rid="B79-vaccines-09-01072" ref-type="bibr">79</xref>]. Therefore, vaccines, delivery systems, or adjuvants which that can induce liver-resident T cells and increase antigen processing and presentation by MHC molecules at the surface of infected hepatocytes are highly desirable. This has led to strategies using viral vectors and heterologous prime-boost approaches [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-09-01072" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-09-01072" ref-type="bibr">82</xref>]. Recently, a novel and promising approach called &#8216;prime and target&#8217; has been shown to increase the frequency of tissue-resident memory CD8<sup>+</sup> T cells in the liver in a mouse model using intravenous injections of viral vectors or nanoparticles [<xref rid="B81-vaccines-09-01072" ref-type="bibr">81</xref>]. Other cell types, such as &#947;&#948; or MAIT cells, may also have a significant role in mediating the <italic toggle="yes">P. falciparum</italic> sporozoite vaccine-induced protection as suggested by the studies done with adults in the United States and Mali [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>,<xref rid="B83-vaccines-09-01072" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-09-01072" ref-type="bibr">84</xref>]. However, it is yet to be determined how these cells are induced during vaccination and what the best adjuvant will be to activate them to act synergistically with classical T cells for an effective protective immunity. </p></sec><sec id="sec2dot2dot3-vaccines-09-01072"><title>2.2.3. T Cell-Mediated Immunity against Asexual Blood-Stage Malaria Parasites</title><p>T cells are essential for the control and resolution of blood-stage infections. Experiments in rodent malaria models have shown that a CD4<sup>+</sup> Th1 response is needed to control the first phase of infection by limiting the parasitemia [<xref rid="B85-vaccines-09-01072" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-09-01072" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-09-01072" ref-type="bibr">87</xref>]. Resolution of the infection is mediated by Th2 and Tfh CD4<sup>+</sup> cells, which provide help for efficient protective antibody production [<xref rid="B85-vaccines-09-01072" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-09-01072" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-09-01072" ref-type="bibr">87</xref>]. &#947;&#948; T and NK cells have been shown to be able to kill the intraerythrocytic parasites in vitro, but their exact role in protection remains a debated question [<xref rid="B83-vaccines-09-01072" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-09-01072" ref-type="bibr">84</xref>,<xref rid="B88-vaccines-09-01072" ref-type="bibr">88</xref>,<xref rid="B89-vaccines-09-01072" ref-type="bibr">89</xref>].</p><p>Until recently, CD8<sup>+</sup> T cells were thought to have no role in the protection against blood-stage malaria. However, experiments in rodent models using mice deficient in programme death (PD)-1, a marker of T cell activation and exhaustion, have demonstrated an effector role for this T cell subset [<xref rid="B90-vaccines-09-01072" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-09-01072" ref-type="bibr">91</xref>]. Because normocytes, the mature erythrocytes, lack MHC molecules, T cells cannot directly eliminate the parasite inside RBC. Malaria-specific T cells secrete IFN-&#947;, which activates monocytes/macrophages for phagocytosis and elimination of iRBC [<xref rid="B90-vaccines-09-01072" ref-type="bibr">90</xref>,<xref rid="B92-vaccines-09-01072" ref-type="bibr">92</xref>]. A handful of studies in humans have shown that CD8<sup>+</sup> T cell activation occurs during falciparum infection. In a recent study in Ghanaian children, expansion of a subset of CD8<sup>+</sup> T cells expressing granzyme B correlated with an increase in parasitemia and was more pronounced in patients with severe disease [<xref rid="B93-vaccines-09-01072" ref-type="bibr">93</xref>]. Thus, it is likely that CD8<sup>+</sup> T cells may have a more pathogenic effect than protective role during falciparum infection. This is supported by immunohistopathology investigations on the brain vasculature of 31 children who died from human cerebral malaria. A substantial number of CD3<sup>+</sup> CD8<sup>+</sup> T cells was found adjacent to endothelial cells [<xref rid="B94-vaccines-09-01072" ref-type="bibr">94</xref>]. In a mouse model of cerebral malaria, pathogenic CD8<sup>+</sup> T cells are responsible for the neurological symptoms and ensuing lethality induced by infection with <italic toggle="yes">P. berghei</italic> ANKA [<xref rid="B95-vaccines-09-01072" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-09-01072" ref-type="bibr">96</xref>]. These cells recognize malaria antigens presented by endothelial cells and release granzyme B after engagement with the MHC molecules. Thus, for blood-stage vaccine development, induction of a strong immune response may not be desirable since it may induce unwanted pathology. Nevertheless, there is a need for well-calibrated T cell and well-targeted B cell responses.</p><p>As already mentioned above, malaria infection frequently induces immunosuppression through diverse mechanisms [<xref rid="B97-vaccines-09-01072" ref-type="bibr">97</xref>]. One of the active T cell suppression pathways involves the induction of regulatory T cells (Tregs). Tregs expressing specific markers such as cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), programmed cell death-1 (PD-1), and others function as immunosuppressive cells. Both in vitro studies in peripheral blood mononuclear cells (PBMCs) and longitudinal studies in humans have shown that the frequency of Tregs in the patients is negatively associated with the parasite load and/or disease severity [<xref rid="B96-vaccines-09-01072" ref-type="bibr">96</xref>,<xref rid="B98-vaccines-09-01072" ref-type="bibr">98</xref>] (extensively reviewed elsewhere [<xref rid="B61-vaccines-09-01072" ref-type="bibr">61</xref>]). Studies in humans and mice have shown that Tregs via CTLA-4 inhibit the development of a protective anti-blood-stage immunity [<xref rid="B99-vaccines-09-01072" ref-type="bibr">99</xref>]. Furthermore, clinical studies on malaria-infection/vaccination showed an increased Treg population in the acute and uncomplicated infection and during the convalescence phase [<xref rid="B100-vaccines-09-01072" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-09-01072" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-09-01072" ref-type="bibr">102</xref>]. In contrast, a decrease in the Treg population was also observed in children under chronic malaria exposure [<xref rid="B103-vaccines-09-01072" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-09-01072" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-09-01072" ref-type="bibr">105</xref>]. Thus, knowledge of the factors influencing Treg functions, such as age, level of exposure (high or low transmission intensity), and others, is needed to precisely define their role in the pathogenesis of malaria. Approaches using adjuvants to prevent induction or counteract Treg activity in individuals residing in endemic regions might help in the development of an effective anti-blood-stage vaccine. </p></sec><sec id="sec2dot2dot4-vaccines-09-01072"><title>2.2.4. Antibody-Mediated Immunity</title><p>In malaria infection, antibodies mediate protective immune responses via different mechanisms, such as inhibition of parasite motility, invasion, egress, adhesion and hepatocyte traversal ability, promotion of antibody-dependent complement-mediated sporozoite/merozoite lysis, phagocytosis, antibody-dependent cellular cytotoxicity, transmission-blocking activity, and others [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>,<xref rid="B106-vaccines-09-01072" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-09-01072" ref-type="bibr">107</xref>] (reviewed in [<xref rid="B108-vaccines-09-01072" ref-type="bibr">108</xref>]). Interestingly, the generation of natural immunity against <italic toggle="yes">P. falciparum</italic> is ethnicity dependent. The majority of non-immune Western travelers, if not all, require a single infection to induce invasion inhibitory antibodies against <italic toggle="yes">P. falciparum</italic> rather than endemic residents, who require two infections [<xref rid="B109-vaccines-09-01072" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-09-01072" ref-type="bibr">110</xref>]. Similarly, protection against malaria in infants born in the endemic regions correlate with the pre-existing antibodies (i.e., maternal antibodies) [<xref rid="B110-vaccines-09-01072" ref-type="bibr">110</xref>]. In addition, children (5 years) who are repeatedly exposed to the natural infection are more resistant to the severe clinical symptoms of malaria [<xref rid="B110-vaccines-09-01072" ref-type="bibr">110</xref>,<xref rid="B111-vaccines-09-01072" ref-type="bibr">111</xref>]. Development of <italic toggle="yes">P. falciparum</italic> antigen-specific B cells to secrete monoclonal antibodies and passive transfer of immunoglobulins have been attractive strategies in malaria research [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>,<xref rid="B112-vaccines-09-01072" ref-type="bibr">112</xref>].</p><p>Many malaria candidate vaccines have been designed to induce an effective antibody response. Antibodies against sporozoites or against neo-antigens expressed on the surface of infected hepatocytes mediate protection by preventing or limiting pre-erythrocytic-stage infection and development. Anti-sporozoite antibodies have been shown to inhibit sporozoite motility in the dermis and liver [<xref rid="B113-vaccines-09-01072" ref-type="bibr">113</xref>], destroy sporozoites in the skin [<xref rid="B114-vaccines-09-01072" ref-type="bibr">114</xref>], facilitate opsonization and phagocytosis by monocytes or macrophages in the spleen or the liver [<xref rid="B114-vaccines-09-01072" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-09-01072" ref-type="bibr">115</xref>], inhibit sporozoite invasion into hepatocytes [<xref rid="B116-vaccines-09-01072" ref-type="bibr">116</xref>], and inhibit sporozoite development inside the hepatocytes [<xref rid="B116-vaccines-09-01072" ref-type="bibr">116</xref>]. The type of functional antibodies produced during the infection illuminates the type of protection they offer. For example, IgG1 and IgG3 exhibit potent capacity to activate complement, Fc&#611;R signaling and opsonization compared to IgG2 and IgG4. The former function discriminates the IgG subclasses into cytophilic (IgG1, IgG3) and non-cytophilic (IgG2, IgG4) antibodies [<xref rid="B117-vaccines-09-01072" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-09-01072" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-09-01072" ref-type="bibr">119</xref>]. The above-mentioned antibody functional properties have been confirmed against the majority of <italic toggle="yes">Plasmodium</italic> spp., including <italic toggle="yes">P. falciparum</italic> in different life-cycle stages [<xref rid="B108-vaccines-09-01072" ref-type="bibr">108</xref>]. Although the role of IgG and its subclasses is significant in host to symptomatic malaria infection, the role of IgM must not be ignored. Particularly, the protective role of IgM against the blood-stage parasite of <italic toggle="yes">P. falciparum</italic> has been established [<xref rid="B120-vaccines-09-01072" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-09-01072" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-09-01072" ref-type="bibr">122</xref>]. </p><p>Antibodies against parasite neo-antigens, such as heat shock protein, expressed on the surface of infected hepatocytes induce liver parasite killing through an antibody-dependent cell-mediated mechanism, which is likely to involve Kupffer cells or NK cells [<xref rid="B123-vaccines-09-01072" ref-type="bibr">123</xref>]. Different in vitro assays have been developed to measure antibody functionality, but it is not yet clear which of the immune mechanisms described above are essential or associated with the protection. It might be that, in addition to the high level of neutralizing antibodies, the quality (i.e., avidity, affinity, isotype) of the antibodies is also important. This knowledge is of paramount importance to design better immunogen and use adequate adjuvant. </p><p>Antibody-mediated immunity against the blood stage is more complex than in the pre-erythrocytic stage. Anti-merozoite antibodies can (i) prevent merozoites from invading RBC [<xref rid="B124-vaccines-09-01072" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-09-01072" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-09-01072" ref-type="bibr">126</xref>] alone or in conjunction with complement factors [<xref rid="B118-vaccines-09-01072" ref-type="bibr">118</xref>], (ii) prevent merozoite egress from RBC, (iii) agglutinate free merozoites, (iv) facilitate phagocytosis of merozoites, and (v) promote clearance of iRBC by phagocytic cells through a mechanism called antibody-cell-dependent inhibition (ACDI) [<xref rid="B127-vaccines-09-01072" ref-type="bibr">127</xref>]. In ACDI, anti-merozoite IgG1 or IgG3 antibodies bind to merozoites, and the immune complexes promote phagocytes, such as monocytes/macrophages or neutrophils, to release cytokines (e.g., TNF-&#945;). This cytokine then stimulates the phagocytes to produce mediators, which leads to the killing of intra-erythrocytic parasites [<xref rid="B128-vaccines-09-01072" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-09-01072" ref-type="bibr">129</xref>]. As mentioned above <italic toggle="yes">P. falciparum</italic> parasites express antigens on the surface of iRBC. These antigens are mainly encoded by multigene families, such as the <italic toggle="yes">var</italic> [<xref rid="B130-vaccines-09-01072" ref-type="bibr">130</xref>], <italic toggle="yes">stevor</italic> [<xref rid="B131-vaccines-09-01072" ref-type="bibr">131</xref>], and <italic toggle="yes">rifin</italic> gene families [<xref rid="B132-vaccines-09-01072" ref-type="bibr">132</xref>]. These antigens are involved in cytoadherence to endothelial cells and in other adhesive phenomena, such as rosetting (the binding of an iRBC to non-infected RBC) and agglutination (the binding to iRBC through bridging by platelets) (for a review, see [<xref rid="B50-vaccines-09-01072" ref-type="bibr">50</xref>]). The cytoadherence ability of the malaria parasites is key to many of the pathologies induced by <italic toggle="yes">P. falciparum</italic> infection. Antibodies targeting the surface antigens may prevent cytoadherence and promote iRBC phagocytosis or iRBC agglutination [<xref rid="B133-vaccines-09-01072" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-09-01072" ref-type="bibr">134</xref>]. </p><p>Antibodies targeting parasite toxins could also protect from <italic toggle="yes">P. falciparum</italic>-induced disease. During the blood stage of the infection, diverse parasite toxins are released at the time of iRBC rupture. These toxins include hemozoin, a by-product of heme degradation by the parasite [<xref rid="B135-vaccines-09-01072" ref-type="bibr">135</xref>], GPI moieties, which are present in many merozoite proteins [<xref rid="B136-vaccines-09-01072" ref-type="bibr">136</xref>], a TatD-like DNase [<xref rid="B137-vaccines-09-01072" ref-type="bibr">137</xref>], and a tyrosine-t RNA synthase [<xref rid="B138-vaccines-09-01072" ref-type="bibr">138</xref>]. Protection from disease by anti-toxin antibodies has been achieved experimentally using synthetic glycans mimicking GPI [<xref rid="B139-vaccines-09-01072" ref-type="bibr">139</xref>]. </p><p>Gametocytes, the sexual forms of <italic toggle="yes">P. falciparum</italic> parasites, are also targets for antibody-mediated immunity [<xref rid="B140-vaccines-09-01072" ref-type="bibr">140</xref>]. Gametocytes express a range of antigens, which are targeted by antibodies [<xref rid="B141-vaccines-09-01072" ref-type="bibr">141</xref>]. The latter facilitates the complement-mediated killing of the gametocytes [<xref rid="B142-vaccines-09-01072" ref-type="bibr">142</xref>]. In the mosquito after feeding, anti-sexual form antibodies can prevent fusion of gametes [<xref rid="B143-vaccines-09-01072" ref-type="bibr">143</xref>], induce complement-killing of gametes or ookinetes [<xref rid="B144-vaccines-09-01072" ref-type="bibr">144</xref>], and prevent ookinete motility, penetration of the midgut wall, and formation of oocyst [<xref rid="B145-vaccines-09-01072" ref-type="bibr">145</xref>]. </p><p>Vaccination/infection determines the dominant IgG subtypes induced, which in turn are useful to predict the type of immune responses acquired. Among the IgG subtypes, opsonizing cytophilic antibodies have gained much attention for malaria vaccine development [<xref rid="B146-vaccines-09-01072" ref-type="bibr">146</xref>,<xref rid="B147-vaccines-09-01072" ref-type="bibr">147</xref>,<xref rid="B148-vaccines-09-01072" ref-type="bibr">148</xref>]. These antibodies recruit Fc&#611;R-containing immune cells (particularly macrophages and basophils) via their Fc domain and activate the parasite elimination procedures. Cytophilic antibodies both naturally acquired [<xref rid="B149-vaccines-09-01072" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-09-01072" ref-type="bibr">150</xref>,<xref rid="B151-vaccines-09-01072" ref-type="bibr">151</xref>,<xref rid="B152-vaccines-09-01072" ref-type="bibr">152</xref>] and vaccine-induced (IgG1 and IgG3 responses against blood-stage antigens) [<xref rid="B107-vaccines-09-01072" ref-type="bibr">107</xref>] have shown more protective responses in diverse studies. </p><p>During the vaccine design, it important to consider both naturally acquired and vaccine-induced immunity. The development of naturally acquired immunity depends on many factors such as region, age group, number of exposures (symptomatic or asymptomatic), number of targeted antigens, and others [<xref rid="B149-vaccines-09-01072" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-09-01072" ref-type="bibr">150</xref>]. The vaccine-induced immunity depends on the type of antigens targeted and the quality (type) and quantity of antibodies produced [<xref rid="B153-vaccines-09-01072" ref-type="bibr">153</xref>]. Although both have similar specificities, the duration and diversity of the immune response is more for naturally acquired immunity over vaccine-induced immunity [<xref rid="B154-vaccines-09-01072" ref-type="bibr">154</xref>]. Evidence from different studies suggests that naturally acquired immunity, unlike vaccine-induced immunity, reduces the risk of infection irrespective of age [<xref rid="B155-vaccines-09-01072" ref-type="bibr">155</xref>,<xref rid="B156-vaccines-09-01072" ref-type="bibr">156</xref>]. Moreover, children living in perennial transmission areas induce more protective natural antibodies (e.g., anti-erythrocyte binding antigen 175RIII&#8211;V) than in seasonal transmission areas [<xref rid="B149-vaccines-09-01072" ref-type="bibr">149</xref>]. However, development of naturally acquired immunity is the best bet in the host. Circumstantially, newborns and infants (&lt;6 months of age) are conferred protection against malaria infection due to the existence of maternal antibodies (extensively reviewed elsewhere [<xref rid="B157-vaccines-09-01072" ref-type="bibr">157</xref>]). </p><p>Antibodies&#8217; breadth (antibodies raised against number of antigens), magnitude (quality), and quantity (affinity and avidity) decide the protection efficiency against clinical malaria. However, it is difficult to estimate the quantity of antibodies that are required for protection, and it purely relies on the antigen specificity. A study conducted in Kenyan children (<italic toggle="yes">n</italic> = 119), for six months, confirmed that children who possess a breadth of naturally acquired antibodies against blood-stage antigens are inversely correlated with the risk of malaria [<xref rid="B158-vaccines-09-01072" ref-type="bibr">158</xref>]. With regard to the vaccine development, whole-sporozoite vaccines are ideal to obtain a breadth of antibodies against the parasite. Like natural exposure, whole-sporozoite vaccines increase the magnitude of antibodies due to the varying antigenic content [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>]. </p><p>Interestingly, it has been observed that antibody breadth and magnitude increase with age (4 years &lt; 14 years &lt; adults) [<xref rid="B159-vaccines-09-01072" ref-type="bibr">159</xref>]. Though not always, increased risk of infection has also been observed in the presence of antigen-specific antibodies (e.g., anti-AMA1) [<xref rid="B160-vaccines-09-01072" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-09-01072" ref-type="bibr">161</xref>]. However, additional studies are required to confirm the breadth, magnitude, affinity, and avidity of the protective antibodies in both asymptomatic and symptomatic infections [<xref rid="B162-vaccines-09-01072" ref-type="bibr">162</xref>,<xref rid="B163-vaccines-09-01072" ref-type="bibr">163</xref>]. </p><p>As mentioned above, passive transfer of neutralizing monoclonal antibodies is an alternative therapeutic strategy, which gives short-term protection. In addition, epitope-specific monoclonal antibodies have been generated against different stages of <italic toggle="yes">P. falciparum</italic> and evaluated in several models (reviewed, recently) [<xref rid="B112-vaccines-09-01072" ref-type="bibr">112</xref>]. At present, subunit, DNA, and viral vector vaccines are capable of inducing high antibody titers, though the potency and breadth are not sufficient to give complete protection [<xref rid="B164-vaccines-09-01072" ref-type="bibr">164</xref>]. To achieve more germinal center reaction and memory B cell generation, the addition of vaccine adjuvants and adjuvant delivery systems are essential (discussed in the later section). Finally, natural or vaccine-induced high antibody titers are needed to prevent the hepatic entry of the parasite and erythrocyte infection. </p></sec></sec></sec><sec id="sec3-vaccines-09-01072"><title>3. Vaccines</title><p>Vaccines are one of the most efficient prophylactic treatments for many diseases, ranging from smallpox to the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19)). With the ever-increasing knowledge of immunity, vaccine strategies have focused on identifying the target antigens and inducing a protective immune response with low to no side effects. Due to the complex antigenicity and immune attacking mechanisms of <italic toggle="yes">P. falciparum</italic>, the development of vaccine for this parasite has been and is still challenging (<xref rid="app1-vaccines-09-01072" ref-type="app">Appendix A</xref>) [<xref rid="B165-vaccines-09-01072" ref-type="bibr">165</xref>]. However, many traditional vaccine strategies do not answer the question of life-cycle complexity and polymorphism of parasite proteins, which are just two of the many reasons we do not yet have a highly effective malaria vaccine [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>].</p><p>A variety of malaria vaccines have been developed and evaluated from the past decades, ranging from classic approaches such as whole inactivated parasites to subunit vaccines and new delivery systems. Although adjuvants enhance vaccines&#8217; immune response, they are occasionally not efficacious in formulations with malarial antigens. Different recombinant malarial antigens have been produced (<xref rid="vaccines-09-01072-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-09-01072-t002" ref-type="table">Table 2</xref>) in various expression systems (e.g., <italic toggle="yes">E. coli</italic>, <italic toggle="yes">L. lactis</italic>, <italic toggle="yes">N. benthamiana</italic>, <italic toggle="yes">P. pastoris</italic>, <italic toggle="yes">S. cerevisiae</italic>, and others) with a variety of delivery platforms (e.g., conjugates, fusion proteins, virus-like particles, virosomes, and others). Over the years, researchers have used various antigens for vaccine development against the different stages (sporozoite, merozoite, and sexual) of the parasite life cycle [<xref rid="B166-vaccines-09-01072" ref-type="bibr">166</xref>]. However, it has been challenging to identify the ideal target antigen, among the 5000 proteins encoded in the <italic toggle="yes">P. falciparum</italic> genome [<xref rid="B167-vaccines-09-01072" ref-type="bibr">167</xref>]. Genomic, transcriptomics, and proteomics approaches have helped to define protein expression patterns during the <italic toggle="yes">P. falciparum</italic> life cycle [<xref rid="B168-vaccines-09-01072" ref-type="bibr">168</xref>]. Among the proteins identified, the uniqueness of sporozoite, trophozoite, merozoite, and gametocyte proteins are categorized [<xref rid="B168-vaccines-09-01072" ref-type="bibr">168</xref>]. The different protein targets (mentioned in <xref rid="vaccines-09-01072-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-09-01072-t002" ref-type="table">Table 2</xref>) are exploited in distinct ways for developing malaria vaccines: (i) pre-erythrocytic vaccines, (ii) erythrocytic vaccines, (iii) transmission-blocking vaccines (extensively reviewed elsewhere [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>,<xref rid="B110-vaccines-09-01072" ref-type="bibr">110</xref>,<xref rid="B169-vaccines-09-01072" ref-type="bibr">169</xref>]). Several candidates have been tested; several immunogens are at preclinical stage, among which 30 immunogens are in clinical evaluation though only 2 have crossed Phase IIb trials or beyond (without adjuvants; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</uri> accessed on 1 June 2020). </p><p>In the past 100 years, many adjuvants have been evaluated preclinically against diverse antigens of malaria (<xref rid="vaccines-09-01072-t002" ref-type="table">Table 2</xref>). Notably, RTS&#8217;S/AS01 (Mosquirix&#8482;) (<xref rid="app2-vaccines-09-01072" ref-type="app">Appendix B</xref>) and PAMAVAC vaccines have successfully entered advanced clinical trials.</p></sec><sec id="sec4-vaccines-09-01072"><title>4. Vaccine Adjuvants</title><p>In general, most vaccine-based antigens are inefficient at mounting protective immune responses due to the dearth of immunogenicity, even though they proved to be perfect target antigens. Nevertheless, an additional component, named adjuvant (<italic toggle="yes">adjuvare</italic> (Latin): To help) has proven to be critical in boosting the antigens&#8217; immunogenicity. Several reviews have covered the qualities of most vaccine adjuvants and their mechanism of action [<xref rid="B170-vaccines-09-01072" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-09-01072" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-09-01072" ref-type="bibr">172</xref>,<xref rid="B173-vaccines-09-01072" ref-type="bibr">173</xref>,<xref rid="B174-vaccines-09-01072" ref-type="bibr">174</xref>,<xref rid="B175-vaccines-09-01072" ref-type="bibr">175</xref>]. Like immune response in infections, adjuvants induce an immune response by triggering innate and adaptive immune responses. The type of immune response induced by the adjuvant is critical for the choice of vaccines. For example, adjuvants inducing Th1 response are preferable in vaccines against intracellular pathogens, and adjuvants inducing Th2 responses are preferable in vaccines against extracellular pathogens [<xref rid="B174-vaccines-09-01072" ref-type="bibr">174</xref>,<xref rid="B176-vaccines-09-01072" ref-type="bibr">176</xref>]. In both cases, Tfh cell responses are critical in inducing prolonged antibody responses [<xref rid="B177-vaccines-09-01072" ref-type="bibr">177</xref>]. Tfh cells are distinguished from the other T helper cells via expression of a CXCR5 receptor and a transcription factor B cell lymphoma 6 (Bcl-6). During the infection or vaccination (with or without adjuvants) [<xref rid="B178-vaccines-09-01072" ref-type="bibr">178</xref>], Tfh cells migrate to the secondary lymphoid organs and provide help to the germinal center B cells to induce high-affinity memory B cells and long-lived plasma cells [<xref rid="B177-vaccines-09-01072" ref-type="bibr">177</xref>,<xref rid="B179-vaccines-09-01072" ref-type="bibr">179</xref>]. The role of Tfh cells in humoral immunity has become more motivating in the design of subunit vaccines [<xref rid="B180-vaccines-09-01072" ref-type="bibr">180</xref>]. </p><p>Protective immunity against <italic toggle="yes">P. falciparum</italic> requires neutralizing antibodies [<xref rid="B181-vaccines-09-01072" ref-type="bibr">181</xref>,<xref rid="B182-vaccines-09-01072" ref-type="bibr">182</xref>] and optimal Th1-mediated immunity [<xref rid="B183-vaccines-09-01072" ref-type="bibr">183</xref>]. For enhancing, modulating, and prolonging the specified immune response against any <italic toggle="yes">P. falciparum</italic> vaccine candidate, vaccine adjuvants that facilitate these responses are needed. These adjuvants will reduce the antigen concentration and frequency of immunization to attain protective efficacy, thereby making vaccines more cost-effective. Though adjuvants face many challenges (physicochemical interactions, stability, pairing with partner antigen, and others), recent technologies in vaccine adjutants have come to the stage of increasing immune responses via immune synergy (use of multiple adjuvants) [<xref rid="B172-vaccines-09-01072" ref-type="bibr">172</xref>]. Reasonably, the immune synergy strategy has not been used extensively in the vaccines composed of parasitic antigens [<xref rid="B184-vaccines-09-01072" ref-type="bibr">184</xref>]. </p><p>Different types of adjuvants have been categorized, such as TLRs-, nucleotide-binding oligomerization domain-like receptors (NLRs)-, C-type lectin receptors (CLRs)-based, and some other non-specific PRRs agonists, NLR family pyrin domain containing 3 (NLRP3) activators, formulations including liposomes, Adjuvant System (AS), nano/micro particles-based adjuvants, immune-complexes, and others. Recent years have seen the approval of several new-generation adjuvants containing vaccines for human use [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>]. Inflammation (either specific receptor activation or non-specific activation) is the primary response to a majority of the adjuvants leading to antigen-specific cellular immunity [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>]. Among the long list, formulation vaccines have gained much attention with respect to their efficacy, such as AS01, AS02, AS03, AS04, MF59, and others. The majority of these systems have more than one immune-potentiator in them. The use of these formulations has induced a protective immune response against antigens and has also increased the immune responsiveness in an elderly population, e.g., influenza vaccine (MF59 or AS03) and herpes zoster vaccine (AS01) [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>]. Although many adjuvants, including alum (a century-old approved adjuvant), are used in clinical trials, the lack of a clear understanding of mechanisms of action against malaria has impaired the development of efficient immunogen/adjuvant formulation [<xref rid="B186-vaccines-09-01072" ref-type="bibr">186</xref>]. Viral vector-based vaccines have shown better immunogenicity than adjuvanted protein vaccines [<xref rid="B187-vaccines-09-01072" ref-type="bibr">187</xref>]. Herein, we discuss the importance of current adjuvants, which are being employed in developing malaria vaccines at the clinical stage, focusing on their outputs like immunological profile and mechanism of action of successful adjuvants.</p></sec><sec id="sec5-vaccines-09-01072"><title>5. Adjuvants under Clinical Evaluation</title><sec id="sec5dot1-vaccines-09-01072"><title>5.1. Alum</title><p>Alum (common name for aluminum potassium sulfate) is a 90-year-old gold standard vaccine adjuvant that produces primarily humoral immune responses [<xref rid="B188-vaccines-09-01072" ref-type="bibr">188</xref>,<xref rid="B189-vaccines-09-01072" ref-type="bibr">189</xref>]. A recent review detailed the physico-chemical and biological properties of alum adjuvants [<xref rid="B188-vaccines-09-01072" ref-type="bibr">188</xref>]. Mostly, two types of aluminum adjuvants (aluminum hydroxide (Al(OH)<sub>3</sub>) and aluminum phosphate (AlPO<sub>4</sub>)) are used in the clinically approved vaccines and these are the most widely applied adjuvants for evaluating the malaria vaccines [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>]. The merits of aluminum adjuvants include safety, amplification of antibody responses, and a comparatively easy process to produce on a large scale. It also has certain drawbacks like the inability to induce cell-mediated immune responses (Th1 and cytotoxic T lymphocytes (CTL)), which are essential for <italic toggle="yes">P. falciparum</italic> [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>]. Since alum induces Th2 biased cellular responses, it was administered concomitantly with other adjuvants (alum+CpG motifs (ODN) [<xref rid="B191-vaccines-09-01072" ref-type="bibr">191</xref>] alum+glucopyranosyl lipid adjuvant (GLA) [<xref rid="B192-vaccines-09-01072" ref-type="bibr">192</xref>]) or adjuvant formulations in the development of malaria vaccines. In preclinical studies, often, the antigen is mixed with alum before injection in mice [<xref rid="B193-vaccines-09-01072" ref-type="bibr">193</xref>,<xref rid="B194-vaccines-09-01072" ref-type="bibr">194</xref>]. Unlike other adjuvants, alum is the most successful single vial- or prefilled syringe-based vaccine adjuvant. Though intense research has been done on the alum, its precise mechanism of action, however, is still elusive. Interestingly, studies in mice showed that alum forms a depot at the injection site and enters the innate cells via phagocytosis. It activates the NLRP3 inflammasome via phagolysosomes followed by the activation of caspase-1 and release of IL-1&#946;. The known mechanism of action of alum was reviewed elsewhere [<xref rid="B189-vaccines-09-01072" ref-type="bibr">189</xref>]. Nevertheless, the proposed mechanism is not observed either in humans or in monkeys [<xref rid="B195-vaccines-09-01072" ref-type="bibr">195</xref>,<xref rid="B196-vaccines-09-01072" ref-type="bibr">196</xref>]. Thus, there should be another mechanism of action of alum in humans, which is yet to be identified [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>]. The vaccination of multistage antigen SpF66 combined with alum resulted in the development of short-lived antibodies and minimal cellular response with no or little protection. Further, the evaluation of pre-erythrocytic protein Pfcs102 with alum was not successful in enhancing an antigen-specific antibody response [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>,<xref rid="B197-vaccines-09-01072" ref-type="bibr">197</xref>]. Blood-stage vaccines (AMA1[PfAMA-1-FVO<sub>25&#8211;545</sub>], AMA1-C1, GLURP<sub>85&#8211;213</sub>, and MSP1-C1<sub>42</sub>) adjuvanted with alum induced modest antibody levels, a poor cellular response, and no protection in field clinical trials [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>]. In a randomized, double-blind, placebo-controlled study, one vaccine (PRIMVAC) adjuvanted either with alhydrogel (aluminum hydroxide wet gel suspension; regularly 2% Al(OH)<sub>3</sub> is used) or GLA-SE had a significant immunogenic response and VAR2CSA-specific antibodies with the desired inhibitory properties [<xref rid="B198-vaccines-09-01072" ref-type="bibr">198</xref>]. </p><p>The transmission-blocking Pf25, a sexual-stage vaccine, has been clinically evaluated in combination with alum. It induced local reactogenicity and limited immunogenicity [<xref rid="B199-vaccines-09-01072" ref-type="bibr">199</xref>,<xref rid="B200-vaccines-09-01072" ref-type="bibr">200</xref>]. Altogether, it is clear that alum alone is not sufficient to induce effective responses to malaria vaccines [<xref rid="B201-vaccines-09-01072" ref-type="bibr">201</xref>]. </p></sec><sec id="sec5dot2-vaccines-09-01072"><title>5.2. Vaccine Delivery Systems/Formulations</title><p>Although effective or moderately effective protein vaccine candidates have been developed for malaria, they have poor immunogenicity. Targeted delivery of subunit vaccines via systems possessing adjuvant properties is of paramount importance and a very classical approach. It ensures their effective delivery as well as the ability to increase protective immunity [<xref rid="B166-vaccines-09-01072" ref-type="bibr">166</xref>]. However, like alum, the mechanism of adjuvanticity of emulsion-type delivery systems remains to be identified [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>]. </p><sec id="sec5dot2dot1-vaccines-09-01072"><title>5.2.1. Liposomes </title><p>They are synthetic phospholipid models (nm to &#181;m size), which carry antigens encapsulated into the aqueous core (hydrophilic molecules), adsorbed to the surface (lipophilic molecules), or integrated into the lipid layers (amphiphilic molecules) [<xref rid="B202-vaccines-09-01072" ref-type="bibr">202</xref>]. The adjuvanticity of liposome is mainly reliant on size, charge, preparation method, and number of lipid layers [<xref rid="B203-vaccines-09-01072" ref-type="bibr">203</xref>]. Cationic adjuvant formulations made of dimethyl dioctadecyl ammonium combined with the stabilizer glycolipid trehalosedibehenate (TDB) were found to be immunogenic liposome forms [<xref rid="B204-vaccines-09-01072" ref-type="bibr">204</xref>]. The disadvantages of liposomes are stability, manufacturing process, high costs, pain at the injection site, and the addition of immunostimulatory molecules like AS01 [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>]. Because of the instability of liposomal vaccine delivery systems in a single vial liquid format, the formulation should be admixed with the vaccine before administration, e.g., Mosquirix<sup>&#174;</sup> vaccine [<xref rid="B201-vaccines-09-01072" ref-type="bibr">201</xref>]. </p></sec><sec id="sec5dot2dot2-vaccines-09-01072"><title>5.2.2. AS01</title><p>AS01 is a liposome-based vaccine adjuvant system containing two immunostimulants: 3-O-desacyl-4&#8242;-monophosphoryl lipid A (MPL) and the saponin QS-21. It has been extensively studied for vaccines against various infectious diseases, including <italic toggle="yes">catarrhalis</italic>, influenza, tuberculosis, HIV, and others [<xref rid="B205-vaccines-09-01072" ref-type="bibr">205</xref>]. Interestingly, unlike other vaccine adjuvant systems, AS01 has a recognized mechanism of action. It activates the resident macrophages, followed by draining to the lymph nodes, where it activates the NK cells to release IFN-&#947;. The released IFN-&#947; activates DCs, which induce an antigen-specific Th1 response (i.e., IL-2, IFN-&#947;, and TNF-&#945;) [<xref rid="B206-vaccines-09-01072" ref-type="bibr">206</xref>,<xref rid="B207-vaccines-09-01072" ref-type="bibr">207</xref>,<xref rid="B208-vaccines-09-01072" ref-type="bibr">208</xref>]. The above-mentioned mechanism of action is due to the synergistic effect of two immunostimulants, i.e., MPL (monophosphoryl lipid A) and QS-21, present in AS01 (<xref rid="vaccines-09-01072-f003" ref-type="fig">Figure 3</xref>). Both the molecules induce Th1-mediated immune responses [<xref rid="B209-vaccines-09-01072" ref-type="bibr">209</xref>]. In addition, in delayed fractional doses AS01/RTS, S has been shown to induce IL-21-secreting antigen-specific peripheral Tfh cells with protective B cell responses [<xref rid="B210-vaccines-09-01072" ref-type="bibr">210</xref>]. However, individual components have their specific effects (see the relevant text). QS-21 delivered via liposomes protects the cells from QS-21-induced cell death [<xref rid="B211-vaccines-09-01072" ref-type="bibr">211</xref>]. This might be the reason that QS-21-containing AS01 has exhibited more improved efficacy than other formulations. In addition, malaria vaccine clinical trials have used different forms of AS01, i.e., AS01B full dose of immunostimulants for adults and AS01E half dose of immunostimulants for children [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>,<xref rid="B212-vaccines-09-01072" ref-type="bibr">212</xref>] (<xref rid="vaccines-09-01072-t002" ref-type="table">Table 2</xref>).</p><p><bold>Note: Glucopyranosyl Lipid Adjuvant (GLA) is a synthetic hexaacylated lipid A derivative</bold>. Monophosphoryl lipid A (MPL<sup>&#174;</sup>) is primarily produced from <italic toggle="yes">Salmonella minnesota</italic> R595 by eliminating phosphate from the reducing-end glucosamine, core carbohydrate group, and the acyl chain from the 39-position of the disaccharide backbone [<xref rid="B213-vaccines-09-01072" ref-type="bibr">213</xref>].</p></sec><sec id="sec5dot2dot3-vaccines-09-01072"><title>5.2.3. Emulsions</title><p>Emulsions are biphasic liquid dosage forms composed of three main components, oil phase, aqueous phase, and emulsifying agents (surfactants), and classified under conventional, widely used vaccine delivery systems. They are water-in-oil (W/O), oil-in-water (O/W), and multiple emulsions (water-in-oil-in-water (W/O/W) and oil-in-water-in-oil (O/W/O)). Among the emulsion types, O/W type emulsions are highly preferred because of less reactogenicity and sustained release. For example, oleic acid O/W emulsion with monophosphoryl lipid A (MPLA) and squalene-based O/W emulsion with murabutide induce a significant cellular as well as high avidity humoral immune response in mouse models [<xref rid="B214-vaccines-09-01072" ref-type="bibr">214</xref>,<xref rid="B215-vaccines-09-01072" ref-type="bibr">215</xref>]. A potent O/W emulsion-based immunological adjuvant, MF59, which is composed of squalene droplets stabilized with Tween 80 and Span 85, elicited higher antibody titers with balanced antibody subclasses than those observed in alum studies. In contrast to conventional emulsions, MF59 is composed of metabolizable oils (squalene; component in cholesterol synthesis pathway), making MF59 much safer. Strikingly, although MF59 is more highly efficacious, stable, and potent than other vaccine adjuvants (alum and CpG) with ease of scale-up competence [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>,<xref rid="B216-vaccines-09-01072" ref-type="bibr">216</xref>], it did not offer reasonable results in malaria vaccines; hence, there was no further progress with MF59 in developing malaria vaccine [<xref rid="B217-vaccines-09-01072" ref-type="bibr">217</xref>,<xref rid="B218-vaccines-09-01072" ref-type="bibr">218</xref>,<xref rid="B219-vaccines-09-01072" ref-type="bibr">219</xref>,<xref rid="B220-vaccines-09-01072" ref-type="bibr">220</xref>]. Irrespective of antigens, O/W emulsions elicit Th1/Th2 responses rather than Th1/Th17 responses [<xref rid="B221-vaccines-09-01072" ref-type="bibr">221</xref>]. Other emulsion-based adjuvants have been developed and have shown to be more efficient. </p></sec><sec id="sec5dot2dot4-vaccines-09-01072"><title>5.2.4. AS02</title><p>It is composed of two immunostimulants: QS-21 and MPL (3-deacylated monophosphoryl lipid A) in squalene O/W emulsion. Preliminary results in rodents and non-human primates have shown that AS02 is efficacious [<xref rid="B222-vaccines-09-01072" ref-type="bibr">222</xref>,<xref rid="B223-vaccines-09-01072" ref-type="bibr">223</xref>]. Further, early clinical trials of AS02 with different malarial antigens, such as PfCS102 (a <italic toggle="yes">P. falciparum</italic> circumsporozoite protein immunogen) and LSA-1 (liver-stage antigen) have shown an increased Th1 response [<xref rid="B224-vaccines-09-01072" ref-type="bibr">224</xref>]. Initial trials with RTS, S/AS02 formulation (AS02A and AS02D are varying doses of formulation for adults and infants, respectively) have found that the vaccine is safe, well-tolerated, and immunogenic in adults, infants, children, and semi-immune adults [<xref rid="B225-vaccines-09-01072" ref-type="bibr">225</xref>,<xref rid="B226-vaccines-09-01072" ref-type="bibr">226</xref>,<xref rid="B227-vaccines-09-01072" ref-type="bibr">227</xref>,<xref rid="B228-vaccines-09-01072" ref-type="bibr">228</xref>,<xref rid="B229-vaccines-09-01072" ref-type="bibr">229</xref>]. Interestingly, RTS, S/AS02 formulation exhibited effective cellular immunity and significant protection against sporozoite-challenge malaria infection when compared to other AS formulations [<xref rid="B186-vaccines-09-01072" ref-type="bibr">186</xref>,<xref rid="B212-vaccines-09-01072" ref-type="bibr">212</xref>,<xref rid="B230-vaccines-09-01072" ref-type="bibr">230</xref>]. However, further trials, with distinct dosage regimens have reported no or minimal protection [<xref rid="B186-vaccines-09-01072" ref-type="bibr">186</xref>,<xref rid="B212-vaccines-09-01072" ref-type="bibr">212</xref>,<xref rid="B231-vaccines-09-01072" ref-type="bibr">231</xref>]. In view of these outcomes, among the AS formulations for malaria vaccines, AS01 holds a superior efficacy and has been selected for further clinical trials [<xref rid="B186-vaccines-09-01072" ref-type="bibr">186</xref>,<xref rid="B212-vaccines-09-01072" ref-type="bibr">212</xref>,<xref rid="B225-vaccines-09-01072" ref-type="bibr">225</xref>]. </p></sec><sec id="sec5dot2dot5-vaccines-09-01072"><title>5.2.5. Montanides (ISA 51, ISA 720)</title><p>Montanide ISA 51 and ISA 720 are W/O type emulsions, which are composed of mineral oil and non-mineral oil, respectively, with mannide monooleate as an emulsifier. ISA 51 was approved for lung cancer due to its high CTL responses. Clinical studies on ISA 51 adjuvant with mosquito-stage antigen (<xref rid="vaccines-09-01072-t002" ref-type="table">Table 2</xref>) yielded unexpected systemic adverse events (erythema nodosum), which stopped further exploratory studies in malarial vaccines [<xref rid="B232-vaccines-09-01072" ref-type="bibr">232</xref>]. ISA 720 has been extensively studied in malaria vaccines because of its ability to induce high antibody production rather than T cell responses. In most of the malaria vaccines, ISA 720 has been shown to induce a strong immune response, but with associated problems such as pain and unacceptable reactogenicity at the site of injection and formulation instability [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>,<xref rid="B233-vaccines-09-01072" ref-type="bibr">233</xref>]. All these findings further support that O/W emulsions are preferred in human vaccines. </p></sec></sec><sec id="sec5dot3-vaccines-09-01072"><title>5.3. Immune Potentiators or Immunomodulators</title><p>Substances, such as particulate materials, complexes, delivery systems, and others, which modulate the immune responses either by targeting the innate immune system or skewing the Th1- and Th2-dependent antibody production, are referred to as immune potentiators. Many molecules derived from the classes of structure-guided vaccine adjuvants or immune potentiators, e.g., PamCysk4 analogues (TLR2 agonists), &#945;-Glactosylceramide analogues (CD1d-iNKT linkers), saponins/glycolipids, and others, show immune-modulating potential [<xref rid="B193-vaccines-09-01072" ref-type="bibr">193</xref>,<xref rid="B194-vaccines-09-01072" ref-type="bibr">194</xref>,<xref rid="B234-vaccines-09-01072" ref-type="bibr">234</xref>,<xref rid="B235-vaccines-09-01072" ref-type="bibr">235</xref>,<xref rid="B236-vaccines-09-01072" ref-type="bibr">236</xref>,<xref rid="B237-vaccines-09-01072" ref-type="bibr">237</xref>,<xref rid="B238-vaccines-09-01072" ref-type="bibr">238</xref>,<xref rid="B239-vaccines-09-01072" ref-type="bibr">239</xref>]. In this section, we describe different potent immunomodulators, which are potent inducers of Th1 responses and have been used in malaria vaccines, either alone or in combinations.</p><sec id="sec5dot3dot1-vaccines-09-01072"><title>5.3.1. QS-21</title><p>QS-21 saponin is derived from a natural source, the bark of <italic toggle="yes">Quillaja saponaria</italic> Molina. Very recently, the mode of action of QS-21 was documented. After injection, it is drained to the lymph nodes and activates subcapsular macrophages (CD11b<sup>+</sup>CD169<sup>+</sup>), where activated macrophages recruit neutrophils and DCs. DCs undergo maturation and induce antigen-specific T cell (CD4<sup>+</sup> and CD8<sup>+</sup>) and antibody responses. Interestingly, further studies confirmed that QS-21, like ISCOMATRIX and alum, induces the activation of inflammasome and the release of IL-1&#946;. Inflammasome activation is mediated via the MyD88 pathway with the partial activation of high-mobility group protein B1-TLR4 (<xref rid="vaccines-09-01072-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B240-vaccines-09-01072" ref-type="bibr">240</xref>]. QS-21 (in AS01)-dependent DC activation is mediated through cathepsin B. Moreover, QS-21-mediated Syk kinase activation and lysosomal destabilization are essential for monocyte-derived DC activation and antigen-specific immune response (<xref rid="vaccines-09-01072-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B241-vaccines-09-01072" ref-type="bibr">241</xref>]. Nevertheless, a structural-activity relationship clearly suggests that triterpene aldehyde and fatty acyl side chains are the vital moieties for QS-21 action. Strikingly, deacylation reduces the induction of Th1-type responses [<xref rid="B211-vaccines-09-01072" ref-type="bibr">211</xref>].</p><p>Though it is effective in inducing immunity and widely used in many vaccines, including malaria, HIV-1, and cancer, QS-21 also possesses certain limitations, such as complex steps of manufacture/synthesis, hemolytic effects, biodiversity problems (due to the cutting down of trees), the dose to efficacy ratio, and others [<xref rid="B174-vaccines-09-01072" ref-type="bibr">174</xref>]. Considering all these limitations, novel structural mimics and alternative or simplified structures are under progress [<xref rid="B239-vaccines-09-01072" ref-type="bibr">239</xref>]. Due to the virtue of its immune response, many formulations are use QS-21 as a discrete component in the composition [<xref rid="B185-vaccines-09-01072" ref-type="bibr">185</xref>]. Interestingly, QS-21 containing nanopatch&#8211;skin delivery systems have been shown to be effective for influenza protein antigen. In this study, a nanopatch, which contains a 30-fold lower dose of QS-21, has exhibited an equal antigen-specific humoral response to QS-21 alone, given intramuscularly [<xref rid="B242-vaccines-09-01072" ref-type="bibr">242</xref>]. This clearly suggests that in the future, QS-21 with malarial antigen must be tested in nanopatches or a similar delivery system to spare the doses of both antigen and adjuvant.</p></sec><sec id="sec5dot3dot2-vaccines-09-01072"><title>5.3.2. Other Saponin Based Adjuvants (Quil-A and ISCOMs)</title><p><italic toggle="yes">Quillaja saponaria</italic> is the base for Quil-A and is the most widely used adjuvant from the saponin group. It exhibits lower toxic effects but enhanced adjuvanticity. Further, complex saponin adjuvant, immunostimulating complexes (ISCOMs; Matrix-M&#8482;) (spherical, open, and cage-like structures) formed by the cholesterol and phospholipids with the adjuvant (Quil-A or QS-21), trigger both cell-mediated and humoral-mediated immune responses. On the other hand, Quil-A is complicated on account of its chemical-related problems plus local reactogenicity. Although malaria vaccine candidates combined with ISCOMs have shown good results in preclinical investigations [<xref rid="B243-vaccines-09-01072" ref-type="bibr">243</xref>], very few clinical trials have been conducted with malarial vaccines composed of ISCOMs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02905019">NCT02905019</ext-link>), probably due to the pain at the injection site and other drawbacks such as flu-like symptoms, fever, and malaise with less reactogenicity [<xref rid="B190-vaccines-09-01072" ref-type="bibr">190</xref>,<xref rid="B244-vaccines-09-01072" ref-type="bibr">244</xref>,<xref rid="B245-vaccines-09-01072" ref-type="bibr">245</xref>].</p></sec><sec id="sec5dot3dot3-vaccines-09-01072"><title>5.3.3. CpG ODN</title><p>Oligodeoxynucleotides (ODNs) adjuvants are single standard DNA molecules with varying degrees of unmethylated <bold>CpG</bold> motifs. Like most vaccine adjuvants, CpG ODN also enhances the innate immune cell (pDCs, monocytes, NK cells)-dependent adaptive immune responses (Th1 and B cells) against the co-administered antigens [<xref rid="B246-vaccines-09-01072" ref-type="bibr">246</xref>]. Considering the strong immunomodulatory properties, especially Th1 responses, CpG ODNs are widely used in various diseases such as infections, cancer, and allergies [<xref rid="B246-vaccines-09-01072" ref-type="bibr">246</xref>]. Based on their structural-activity relationship, CpG ODNs are divided into different types: class A (Type D), class B (Type K), and class C [<xref rid="B174-vaccines-09-01072" ref-type="bibr">174</xref>,<xref rid="B246-vaccines-09-01072" ref-type="bibr">246</xref>] (reviewed in [<xref rid="B174-vaccines-09-01072" ref-type="bibr">174</xref>]). Among the ODNs, ODN 2006 (7909) is widely used because of its immunostimulatory properties. It comes under the class B category, and it stimulates pDCs to secrete IFN-&#945; via binding to the TLR9 receptor. The detailed mechanism of action of CpG ODNs has been reviewed in the literature [<xref rid="B174-vaccines-09-01072" ref-type="bibr">174</xref>,<xref rid="B246-vaccines-09-01072" ref-type="bibr">246</xref>]. Many preclinical studies, either alone or in combination, have documented the efficacy of CpG in <italic toggle="yes">P. falciparum</italic> infection [<xref rid="B247-vaccines-09-01072" ref-type="bibr">247</xref>]. This ODN has successfully entered the malaria vaccine clinical trials and has been used as an adjuvant for malarial antigens, such as AMA1, MSP1(42), and their different combinations (<xref rid="vaccines-09-01072-t002" ref-type="table">Table 2</xref>). In one of the clinical studies, na&#239;ve human volunteers who received AMA1-based blood-stage malaria vaccine along with CpG ODN, either alone or in combination with alhydrogel, exhibited enhanced and long-lasting antigen-specific antibody responses. In addition, antigen-specific antibody (IgG) showed enhanced growth inhibition of homologous <italic toggle="yes">P. falciparum</italic>, in vitro [<xref rid="B248-vaccines-09-01072" ref-type="bibr">248</xref>]. However, subsequent studies with semi-immune adults living in Mali did not give encouraging results [<xref rid="B249-vaccines-09-01072" ref-type="bibr">249</xref>]. The above results perhaps depend on the refractory/chemistry of CpG ODNs and should be taken into consideration for the future use of CpG ODN-containing vaccines in malaria endemic areas. One more blood-stage vaccine candidate, serine repeat antigen 5 (SERA5), has shown protective immunity in <italic toggle="yes">Aotus</italic> and squirrel monkeys. A recombinant antigen, SE36 (which lacks serine repeats of SERA5), was absorbed into alhydrogel and evaluated in clinical trials. Surprisingly, it did not induce high antigen-specific antibody titers in clinical trials [<xref rid="B250-vaccines-09-01072" ref-type="bibr">250</xref>]. Further, SE36/alhydrogel was tested in rodents and non-human primates (monkeys) with or without CpG ODNs. Among the CpG ODNs tested, K3 CpG ODN (K3 CpG ODN is a subclass of ODNs under class B (Type K)) has exhibited safe, efficacious, and immunogenic properties [<xref rid="B251-vaccines-09-01072" ref-type="bibr">251</xref>]. However, with CpG ODN, these positive preclinical data are still not translated into clinics [<xref rid="B252-vaccines-09-01072" ref-type="bibr">252</xref>].</p></sec></sec></sec><sec id="sec6-vaccines-09-01072"><title>6. Concluding Remarks</title><p><italic toggle="yes">P. falciparum</italic> is an infectious agent of malaria, which kills millions of people around the globe. A vigorous effort has been made for the global elimination of <italic toggle="yes">P. falciparum</italic> malaria, but asymptomatic individuals are regarded as reservoirs for parasite transmission due to the lack of effective diagnostic methods for detecting the parasite in endemic areas.</p><p>For the treatment of malaria, the spread of anti-malarial drug resistance has become a major problem. If it is not handled appropriately, it could reverse the malaria control program and worldwide containment achieved so far. Therefore, more research is necessary to find new anti-malarial drugs for combating multidrug-resistant <italic toggle="yes">P. falciparum</italic> [<xref rid="B253-vaccines-09-01072" ref-type="bibr">253</xref>].</p><p>The factors like complex life cycle, genetic diversity, and the various immune escape mechanisms developed by these parasites, i.e., antigenic variations in <italic toggle="yes">P. falciparum</italic> [<xref rid="B97-vaccines-09-01072" ref-type="bibr">97</xref>], are the major obstacles responsible for the delay in the development of a suitable vaccine. Because of the high number of polymorphism or allele-specific variations in the proteins, single protein-based vaccines have limited success [<xref rid="B254-vaccines-09-01072" ref-type="bibr">254</xref>]. Vaccines composed of a chimeric molecule of the pre-erythrocytic target have shown protective responses in mice models [<xref rid="B255-vaccines-09-01072" ref-type="bibr">255</xref>]. The current efforts towards malaria parasite and vector control should be complemented with an effective <italic toggle="yes">P. falciparum</italic> vaccine for the successful fight against the malaria burden. Presently, vaccines from different stages of <italic toggle="yes">P. falciparum</italic> are in development and in the coming days, they might be combined (multivalent vaccines) to overcome the parasitic immune control mechanism attributed to antigenic polymorphism. A better understanding of the <italic toggle="yes">P. falciparum</italic> life cycle and the parasites&#8217; interaction with the host should provide guidelines for the future vaccine development programs. The ideal malaria vaccine should be safe, highly effective, stable, easy to administer, and must provide long-term immunity. Such vaccines should also be cost-effective and affordable in poor malaria endemic areas.</p><p>Nowadays, researchers are fully aware of using suitable adjuvants for the development of novel vaccines. With regard to malaria, as mentioned above, an effective vaccine requires long-lasting primary and memory antigen-specific CD4<sup>+</sup> T cell, B cell, and CTL responses. However, age-old adjuvants like alum, which skews the immune response to Th2, are not suitable for malaria vaccine development. Importantly, a combination of Th1 and Th2 adjuvants with a proper delivery system is needed for malaria vaccine development. Many prediction models have confirmed that activation of the IFN-&#947; signaling pathway is the best target to confer vaccine-induced protection against <italic toggle="yes">P. falciparum</italic> [<xref rid="B256-vaccines-09-01072" ref-type="bibr">256</xref>]. Next-generation vaccines should have wide spectrum activity against parasites, as some of the endemic residents encounter infection with more than one parasite simultaneously [<xref rid="B257-vaccines-09-01072" ref-type="bibr">257</xref>]. On top of that, vaccines should not induce suppressive Tregs, which are shown to aid in the parasite immune evasion mechanisms [<xref rid="B110-vaccines-09-01072" ref-type="bibr">110</xref>]. Further, an ideal adjuvant should be able to produce a protective immune response with a less frequent number of administrations. Nevertheless, we noticed that many adjuvants enhance effective immune responses with experimental antigens or model antigens, whereas a similar trend might not happen with the real antigens and unpaired antigens (Bonam, SR and Kumar HMS, personal observation; unpublished data). All the above details should help in the selection of specific adjuvant systems for the development of novel vaccines that elicit the highest humoral and cellular responses. Nowadays, analytical characterization of formulations to obtain vital information (i.e., particle size, morphology, and concentration of components, physicochemical interactions, stability, and others) are routinely performed. On the other hand, detailed studies are required to establish the biological interactions and determine the exact mechanism of action [<xref rid="B201-vaccines-09-01072" ref-type="bibr">201</xref>]. Systems vaccinology has helped considerably to uncover the unidentified vaccine adjuvant mechanism(s). Finally, the repository of novel Th1/Th2 adjuvants should be available to vaccine researchers to test their antigens for developing novel, promising malaria vaccines.</p><p>In summary, there is a need to coordinate research in multiple directions to develop an efficient malaria vaccine, such as (1) clear understanding of the life cycle of the malaria parasite, (2) identification and characterization of targets of interest with a broad range of strains covered, (3) identification of suitable adjuvant, which could enhance the magnitude and quality of the immunogenicity of antigen(s) without age factor [<xref rid="B172-vaccines-09-01072" ref-type="bibr">172</xref>], and (4) characterization and selection of a suitable &#8216;perfect mix&#8217; (e.g., emulsion, liposomes, nanoparticles, etc.) for the delivery of the final vaccine to the host [<xref rid="B173-vaccines-09-01072" ref-type="bibr">173</xref>]. In essence, a detailed spatiotemporal analysis of parasite invasion biology will provide more information for effective targets. By tackling all these parameters, we could also support the poor responders in the vaccination.</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors would like to thank Samarchith P. Kurup (Center for Tropical and Emerging Global Diseases &amp; Department of Cellular Biology, The University of Georgia, US) and Giuseppe Del Giudice (Translational Science Leader, R&amp;D Center Italy&#8212;GSK Vaccines Srl, Siena, Italy) for scientific discussion. G.T. and H.M.S.K. are thankful to Director CSIR&#8212;Indian Institute of Chemical Technology (IICT) for the support (IICT/Pubs./2020/080). J.B. acknowledges the support of the European Union Horizon H2020 programme under Grant Agreement No. H2020-SC1-2019-874653-INDIGO and the Department of Biotechnology (DBT), Government of India. (<xref rid="vaccines-09-01072-f002" ref-type="fig">Figure 2</xref>) was created with BioRender.com under a paid subscription.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>S.R.B., L.R. and G.T. came up with the idea and wrote the first draft. The draft was revised by L.R., J.B. and H.M.S.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>Laurent R&#233;nia was supported by core funding to the A*STAR ID labs given by the Agency of Science, Technology and Research (A*STAR). G.T. is a Research Associate-II funded by the Department of Biotechnology (DBT), Government of India, India.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>We declare that the research was conducted in the absence of any relationships that could construe as a potential conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADCC</td><td align="left" valign="middle" rowspan="1" colspan="1">antibody-dependent cell cytotoxicity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIM2</td><td align="left" valign="middle" rowspan="1" colspan="1">absent in melanoma 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">activator protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASC</td><td align="left" valign="middle" rowspan="1" colspan="1">apoptosis-associated speck-like protein containing a CARD (caspase activation and recruitment domains)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CCL2/MCP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">monocyte chemoattractant protein-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CCL4/MIP-1&#946;</td><td align="left" valign="middle" rowspan="1" colspan="1">macrophage inflammatory protein-1&#946;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">cGAS</td><td align="left" valign="middle" rowspan="1" colspan="1">cyclic GMP-AMP synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DAMPs</td><td align="left" valign="middle" rowspan="1" colspan="1">damage-associated molecular patterns</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCs</td><td align="left" valign="middle" rowspan="1" colspan="1">dendritic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">dsDNA</td><td align="left" valign="middle" rowspan="1" colspan="1">double-stranded DNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERK</td><td align="left" valign="middle" rowspan="1" colspan="1">extracellular signal-regulated kinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPI</td><td align="left" valign="middle" rowspan="1" colspan="1">glycosylphosphatidylinositol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IKK</td><td align="left" valign="middle" rowspan="1" colspan="1">I&#954;B kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IRF</td><td align="left" valign="middle" rowspan="1" colspan="1">IFN (interferon) regulatory factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL</td><td align="left" valign="middle" rowspan="1" colspan="1">interleukin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JNK</td><td align="left" valign="middle" rowspan="1" colspan="1">c-Jun N-terminal kinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPK</td><td align="left" valign="middle" rowspan="1" colspan="1">mitogen-activated protein kinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDA5</td><td align="left" valign="middle" rowspan="1" colspan="1">melanoma differentiation-associated gene 5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MHC</td><td align="left" valign="middle" rowspan="1" colspan="1">major histocompatibility complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF-kB</td><td align="left" valign="middle" rowspan="1" colspan="1">nuclear factor kappa-light-chain-enhancer of activated B cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NK cells</td><td align="left" valign="middle" rowspan="1" colspan="1">natural killer cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLRP3</td><td align="left" valign="middle" rowspan="1" colspan="1">NOD-, LRR- and pyrin domain-containing 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PAMPs</td><td align="left" valign="middle" rowspan="1" colspan="1">pathogen-associated molecular patterns</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PRRs</td><td align="left" valign="middle" rowspan="1" colspan="1">pathogen-recognition receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">STING</td><td align="left" valign="middle" rowspan="1" colspan="1">stimulator of IFN genes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCR</td><td align="left" valign="middle" rowspan="1" colspan="1">T cell receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tfh</td><td align="left" valign="middle" rowspan="1" colspan="1">follicular T cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF</td><td align="left" valign="middle" rowspan="1" colspan="1">transforming growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Th</td><td align="left" valign="middle" rowspan="1" colspan="1">helper T cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLRs</td><td align="left" valign="middle" rowspan="1" colspan="1">toll-like receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF</td><td align="left" valign="middle" rowspan="1" colspan="1">tumor-necrosis factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRAF6</td><td align="left" valign="middle" rowspan="1" colspan="1">tumor necrosis factor receptor-associated factor 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Treg</td><td align="left" valign="middle" rowspan="1" colspan="1">regulatory T cell</td></tr></tbody></array></glossary><app-group><app id="app1-vaccines-09-01072"><title>Appendix A</title><sec><title>Key Points in Malaria Vaccine Development</title><list list-type="bullet"><list-item><p>Spatiotemporal relation between liver anatomy and sporozoite biology should be explored in detail [<xref rid="B258-vaccines-09-01072" ref-type="bibr">258</xref>].</p></list-item><list-item><p>Invasion strategies of sporozoites (in liver) and merozoites (in RBCs) should be elucidated [<xref rid="B259-vaccines-09-01072" ref-type="bibr">259</xref>,<xref rid="B260-vaccines-09-01072" ref-type="bibr">260</xref>].</p></list-item><list-item><p>Unlike other infections, vaccine adjuvants, which induces both Th1 and Th2 mediated immunity is essential against <italic toggle="yes">P. falciparum</italic> malaria.</p></list-item><list-item><p>Dominant MHC I-presenting antigen epitopes should be selected for cell-mediated, especially CD8<sup>+</sup> T cells and tissue-resident memory T cells in the liver, which are essential to confer vaccine-induced protection [<xref rid="B261-vaccines-09-01072" ref-type="bibr">261</xref>].</p></list-item><list-item><p>Protective malaria vaccines should elicit IgG1 and IgG3 antibody responses, which are protective against <italic toggle="yes">P. falciparum</italic> malaria [<xref rid="B147-vaccines-09-01072" ref-type="bibr">147</xref>,<xref rid="B262-vaccines-09-01072" ref-type="bibr">262</xref>,<xref rid="B263-vaccines-09-01072" ref-type="bibr">263</xref>].</p></list-item><list-item><p>Protective vaccines (e.g., RTS,S) to pre-erythrocytic stage infections are greatly needed [<xref rid="B264-vaccines-09-01072" ref-type="bibr">264</xref>].</p></list-item><list-item><p>In malaria vaccines, along with target antigen, development of adjuvants (e.g., AS01) is also considered as major discipline of research [<xref rid="B240-vaccines-09-01072" ref-type="bibr">240</xref>,<xref rid="B265-vaccines-09-01072" ref-type="bibr">265</xref>].</p></list-item><list-item><p>Prime-boost and/or prime-target immunization strategies are probably better options to confer protection against liver-stage infections [<xref rid="B266-vaccines-09-01072" ref-type="bibr">266</xref>].</p></list-item><list-item><p>Subcutaneous vaccination has shown increased response than the intradermal vaccination [<xref rid="B267-vaccines-09-01072" ref-type="bibr">267</xref>]. In addition, vaccines are preferably effective, if given by intravenous route [<xref rid="B79-vaccines-09-01072" ref-type="bibr">79</xref>].</p></list-item></list></sec></app><app id="app2-vaccines-09-01072"><title>Appendix B</title><sec id="secBdot1-vaccines-09-01072"><title>Appendix B.1. RTS, S Malaria Vaccine</title><list list-type="bullet"><list-item><p>RTS, S is a genetically engineered vaccine where &#8220;RT&#8221; denotes C-terminal (190 amino acids) part of <italic toggle="yes">P. falciparum</italic> (strain NF54) circumsporozoite protein (CSP) protein, which contains both T and B cell epitopes (central repeat region). &#8220;S&#8221; is a surface antigen of hepatitis-B virus and the combination is expressed in <italic toggle="yes">Saccharomyces cerevisiae</italic> (S) [<xref rid="B268-vaccines-09-01072" ref-type="bibr">268</xref>].</p></list-item><list-item><p>RTS, S was produced by Walter Reed Army Institute of Research (WRAIR) in collaboration with GlaxoSmithKline (GSK) biologicals and the Programs for Appropriate Technologies in Health (PATH) Malaria Vaccine Initiative (MVI).</p></list-item><list-item><p>The idea behind the development of the RTS, S vaccine is, like other vaccines (e.g., ChAd63/MVA ME-TRAP), to inhibit sporozoite motility at pre-erythrocytic stage and preventing the entry to liver cells.</p></list-item><list-item><p>The first licensed vaccine for children living in endemic areas in sub-Saharan Africa, and is also approved by European Medicines Agency (EMA) in 2015 [<xref rid="B269-vaccines-09-01072" ref-type="bibr">269</xref>].</p></list-item><list-item><p>Presently under clinical evaluation in infants and children in Africa (Phase IV/<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00866619">NCT00866619</ext-link>). Previous regimens are partly effective, now four dose- schedule have been initiated in Kenya [<xref rid="B270-vaccines-09-01072" ref-type="bibr">270</xref>].</p></list-item><list-item><p>Individuals vaccinated with RTS,S/AS01 has shown increased NK cell activation in response to increased T cell activation [<xref rid="B58-vaccines-09-01072" ref-type="bibr">58</xref>,<xref rid="B265-vaccines-09-01072" ref-type="bibr">265</xref>].</p></list-item><list-item><p>Studies in infants and children vaccinated with RTS, S/AS01 confirmed the antibody (IgG subclass)-mediated protection against <italic toggle="yes">P. falciparum</italic> malaria by altering the natural acquired immunity [<xref rid="B147-vaccines-09-01072" ref-type="bibr">147</xref>].</p></list-item><list-item><p>Safe, immunogenic and potent for individuals who experienced malaria.</p></list-item><list-item><p>Like other majority vaccines, RTS, S also has hurdles in the stability maintenance of specified temperatures (2&#8211;8 &#176;C), which is certainly expensive in developing countries.</p></list-item><list-item><p>RTS, S vaccine with nearly or entirely different adjuvants also exhibit promising results against malaria <italic toggle="yes">P. falciparum</italic> [<xref rid="B264-vaccines-09-01072" ref-type="bibr">264</xref>,<xref rid="B271-vaccines-09-01072" ref-type="bibr">271</xref>,<xref rid="B272-vaccines-09-01072" ref-type="bibr">272</xref>].</p></list-item><list-item><p>Adult vaccination regimen containing RTS,S/AS01B vaccine with ChAd63/MVA ME-TRAP vaccine has not shown interesting results [<xref rid="B273-vaccines-09-01072" ref-type="bibr">273</xref>].</p></list-item></list></sec><sec id="secBdot2-vaccines-09-01072"><title>Appendix B.2. Highlights</title><list list-type="bullet"><list-item><p>Fine strategies to eradicate and eliminate malaria through drugs or vaccines have gained momentum.</p></list-item><list-item><p>Fundamental functions of CD8<sup>+</sup> T cells and NK cells have proven their effective role in preventing malaria transmission.</p></list-item><list-item><p>Majority of prophylactic/therapeutic malaria vaccines are in the clinical evaluation.</p></list-item><list-item><p>RTS, S/AS01 is the only licensed malaria vaccine.</p></list-item><list-item><p>Novel delivery systems of malarial vaccines with QS-21 have yielded increased potency and reduced toxicity.</p></list-item><list-item><p>Though subunit vaccines are an effective strategy, the search for novel approaches like live and/or whole parasite vaccinations should be evaluated in detail.</p></list-item></list></sec><sec id="secBdot3-vaccines-09-01072"><title>Appendix B.3. Glossary</title><p>
<bold>
<italic toggle="yes">Plasmodium falciparum</italic>
</bold>
</p><p><italic toggle="yes">P. falciparum</italic> is a parasite protozoan and one of the most infectious species among the other <italic toggle="yes">Plasmodium</italic> such as <italic toggle="yes">P. malariae</italic>, <italic toggle="yes">P. vivax</italic>, <italic toggle="yes">P. ovale</italic> and <italic toggle="yes">P. knowlesi</italic>, which causes malaria in humans by using female anopheles&#8217; mosquito as a vector.</p><p>
<bold>Cerebral malaria</bold>
</p><p>Cerebral malaria caused by <italic toggle="yes">P. falciparum,</italic> affects total neurological functions, and leads to death. Two hypotheses have tried to elucidate the pathogenesis of disease: mechanical and inflammatory. According to mechanical hypothesis, impaired cerebral blood flow due to sequestration of erythrocytes leads to hypoxia whereas inflammatory theory suggests that <italic toggle="yes">P. falciparum infection alters brain function</italic> via Th1 inflammatory immune response. Symptoms of cerebral malaria include headache, behavioral changes, confusion, coma, and mortality (rate exceeding 10%) [<xref rid="B274-vaccines-09-01072" ref-type="bibr">274</xref>,<xref rid="B275-vaccines-09-01072" ref-type="bibr">275</xref>].</p><p>
<bold>Heterologous prime-boost strategy</bold>
</p><p>Multiple immunization of vaccine with or without discrete antigens in DNA vectored priming followed by protein boosting. Strategy is useful in targeting highly complex and pathogenic infections for inducing both humoral and cell-mediated immune responses.</p><p>
<bold>Danger-associated molecular patterns (DAMPs)</bold>
</p><p>Signals from the damaged or dying cells or necrotic cells, which alert the immune system via acting on PRRs.</p><p>
<bold>Clinical immunity</bold>
</p><p>Natural antibody response developed against <italic toggle="yes">P. falciparum</italic> following repeated infection. It reduces the parasite load and regulates the inflammatory responses.</p><p>
<bold>Sterile immunity</bold>
</p><p>A cent percent immunity achieved by malaria vaccine is termed as sterile immunity. Clinically immune individuals can still act as a reservoir for the parasite. Thus, to confer complete protection against the <italic toggle="yes">P. falciparum</italic> malaria sterile immunity is needed.</p><p>
<bold>Pre-erythrocytic vaccine</bold>
</p><p>This vaccine with respective antigens prevents the generation of sporozoites into merozoites in the liver thereby reduce the clinically asymptomatic pre-erythrocytic infection. Some of the examples include RTS, S/AS01 (CSP), ChAd63/MVA ME&#8211;TRAP (TRAP, CSP, TRAP, CSP, and others), PfSPZ (whole sporozoites), CVac (whole sporozoites), GAP (whole sporozoites), PfCelTOS FMP012 (PfCelTOS), CSVAC (CSP), R21 (CSP), R21/ME&#8211;TRAP (TRAP, CSP, and others).</p><p>
<bold>Erythrocytic stage vaccine</bold>
</p><p>This vaccine with respective antigens prevents merozoites&#8217; entry into the RBCs, thereby reducing the clinical symptoms and mortality. Examples include GMZ2 (GLURP MSP3), pfAMA1-DiCo, (AMA1) P27A (P27A), MSP3 (MSP3), SE36 (SERA5), PfPEBS, CHAd63RH5/MVARH5 (RH5), PRIMVAC (Var2CSA), and PAMVAC (Var2CSA) [<xref rid="B80-vaccines-09-01072" ref-type="bibr">80</xref>].</p><p>
<bold>Transmission-blocking vaccines</bold>
</p><p>These vaccines with respective antigens interrupt malaria transmission by impeding the parasite cycle in the mosquito. Antigens like Pfs25 (Pfs25 VLP &amp; Pfs25-EPA), Pfs28, Pfs48/45, and Pfs230 (Pfs25-EPA) have been assessed as vaccine candidates among which ookinetes of <italic toggle="yes">P. falciparum</italic> Pfs25 expressed in <italic toggle="yes">S. cerevisiae</italic> have shown moderate immunogenicity and suboptimal levels of transmission-blocking activity in Phase Ia trials [<xref rid="B165-vaccines-09-01072" ref-type="bibr">165</xref>,<xref rid="B276-vaccines-09-01072" ref-type="bibr">276</xref>].</p><p>
<bold>TLRs</bold>
</p><p>Class of PRRs located on the surface and in the cytosol of the cells. Upon recognition of PAMPs/DAMPs, these receptors activate the downstream signaling to secrete diverse inflammatory mediators.</p><p>
<bold>Antibody-dependent cell-mediated cytotoxicity (ADCC)</bold>
</p><p>Antigen-binding fragment (Fab) of antibodies (developed against target protein) binds to the target cells and recruit&#8217;s effector cells, which possess receptors for the fragment crystallizable region (Fc) of the antibody (Fc&#947;R) to interact with target cell. Activated myeloid effector cells kill the target cells via various mechanisms (release of cytotoxic granule, Fas signaling, induction of reactive oxygen species).</p><p>
<bold>Vaccine delivery systems</bold>
</p><p>These are antigenic formulations (emulsions, liposomes, polymeric particles, adenoviral systems, and others) with or without immunostimulants for targeted delivery and inducing protective immunity (cellular and humoral immunity).</p><p>
<bold>Adjuvant systems (mostly licensed by GlaxoSmithKline plc)</bold>
</p><p>Liposomes and emulsion formulations, which contain one or more immunostimulants to induce antigen-specific immune responses.</p><p>
<bold>QS-21</bold>
</p><p>A water-soluble triterpene glycoside obtained from the purified fractions (fraction 21) of mixture of Quil-A saponins. Quil-A saponins are sourced from the bark of <italic toggle="yes">Quillaja saponaria</italic> tree. It is potent inducer of both cellular and humoral immunity. QS-21 induces the MHC I antigen cross-presentation followed by the activation of CD8<sup>+</sup> T cells.</p><p>
<bold>AS01</bold>
</p><p>Liposomal formulation composed of two synergistic discrete immunostimulatory components, i.e., synthetic 3-<italic toggle="yes">O</italic>-desacyl-4&#8242;-monophosphoryl lipid A (MPL) (a TLR4 ligand) and natural QS-21.</p><p>
<bold>Virosomes</bold>
</p><p>Virosomes are derived from the inactivated/non-replicating virus. Virosomes are composed of bilayer phospholipids, like liposomes and viral glycoproteins. The targeted antigen of interest is encapsulated or cross-linked to the virosomes for effective delivery.</p><p>
<bold>CpG</bold>
</p><p>ODN sequences containing unmethylated CpG motifs (highly methylated in vertebrates); cytosine triphosphate deoxynucleotide (C) linked to the guanine triphosphate deoxynucleotide (G) via phosphodiester bond (p), which specifically binds to TLR9 to trigger immune response. Synthetic CpG ODN over the natural ones has a different level of phosphorothioate backbone.</p><p>
<bold>Structural-activity relationship</bold>
</p><p>It defines the relationship between the chemical structure of a compound to its pharmacological activity and toxicity.</p></sec><sec id="secBdot4-vaccines-09-01072"><title>Appendix B.4. Outstanding Questions: P. falciparum Vaccines and Vaccine Adjuvants</title><list list-type="bullet"><list-item><p>Knowledge on the optimum combination of multi-stage malarial antigens for the vaccines</p></list-item><list-item><p>Influence of natural immunity towards vaccine response and performance in endemic countries</p></list-item><list-item><p>Fine incorporation of parameters of anti-disease immunity of the host to conceive effective and safe anti-malarial vaccines.</p></list-item><list-item><p>The role of genetic background of the population in determining the vaccine response to malaria.</p></list-item><list-item><p>Need of appropriate experimental models that closely mimic human for the pre-screening of malaria vaccine candidates.</p></list-item></list></sec></app></app-group><ref-list><title>References</title><ref id="B1-vaccines-09-01072"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Skinner-Adams</surname><given-names>T.S.</given-names></name></person-group><article-title>Drug repurposing and human parasitic protozoan diseases</article-title><source>Int. J. Parasitol. Drugs Drug Resist.</source><year>2014</year><volume>4</volume><fpage>95</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.ijpddr.2014.02.002</pub-id><pub-id pub-id-type="pmid">25057459</pub-id><pub-id pub-id-type="pmcid">PMC4095053</pub-id></element-citation></ref><ref id="B2-vaccines-09-01072"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>The &#8220;World Malaria Report 2019&#8221; at a Glance</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/world-malaria-report-2019" ext-link-type="uri">https://www.who.int/news-room/feature-stories/detail/world-malaria-report-2019</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B3-vaccines-09-01072"><label>3.</label><element-citation publication-type="webpage"><article-title>Key Points: World Malaria Report 2017</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/malaria/media/world-malaria-report-2017/en/" ext-link-type="uri">https://www.who.int/malaria/media/world-malaria-report-2017/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-01">(accessed on 1 January 2021)</date-in-citation></element-citation></ref><ref id="B4-vaccines-09-01072"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>This Year&#8217;s World Malaria Report at a Glance</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/malaria/media/world-malaria-report-2018/en/" ext-link-type="uri">https://www.who.int/malaria/media/world-malaria-report-2018/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B5-vaccines-09-01072"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Head</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Goss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gelister</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Alegana</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Fitchett</surname><given-names>J.R.A.</given-names></name><name name-style="western"><surname>Atun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.A.G.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Global funding trends for malaria research in sub-Saharan Africa: A systematic analysis</article-title><source>Lancet Glob. Health</source><year>2017</year><volume>5</volume><fpage>e772</fpage><lpage>e781</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30245-0</pub-id><pub-id pub-id-type="pmid">28668230</pub-id><pub-id pub-id-type="pmcid">PMC5567191</pub-id></element-citation></ref><ref id="B6-vaccines-09-01072"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valecha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>A.P.</given-names></name></person-group><article-title>Burden of malaria in india: Retrospective and prospective view</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2007</year><volume>77</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2007.77.69</pub-id><pub-id pub-id-type="pmid">18165477</pub-id></element-citation></ref><ref id="B7-vaccines-09-01072"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemingway</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shretta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Djimde</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Achee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>G.</given-names></name></person-group><article-title>Tools and strategies for malaria control and elimination: What do we need to achieve a grand convergence in malaria?</article-title><source>PLoS Biol.</source><year>2016</year><volume>14</volume><elocation-id>e1002380</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1002380</pub-id><pub-id pub-id-type="pmid">26934361</pub-id><pub-id pub-id-type="pmcid">PMC4774904</pub-id></element-citation></ref><ref id="B8-vaccines-09-01072"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>F.E.G.</given-names></name></person-group><article-title>History of the discovery of the malaria parasites and their vectors</article-title><source>Parasite Vector</source><year>2010</year><volume>3</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-3-5</pub-id><pub-id pub-id-type="pmid">20205846</pub-id><pub-id pub-id-type="pmcid">PMC2825508</pub-id></element-citation></ref><ref id="B9-vaccines-09-01072"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krettli</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.H.</given-names></name></person-group><article-title>Malaria: A sporozoite runs through it</article-title><source>Curr. Biol.</source><year>2001</year><volume>11</volume><fpage>R409</fpage><lpage>R412</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(01)00221-4</pub-id><pub-id pub-id-type="pmid">11378408</pub-id></element-citation></ref><ref id="B10-vaccines-09-01072"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klotz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Schnieder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frevert</surname><given-names>U.</given-names></name></person-group><article-title>Release of hepatic <italic toggle="yes">Plasmodium yoelii</italic> merozoites into the pulmonary microvasculature</article-title><source>PLoS Pathog.</source><year>2007</year><volume>3</volume><elocation-id>e171</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0030171</pub-id><pub-id pub-id-type="pmid">17997605</pub-id><pub-id pub-id-type="pmcid">PMC2065874</pub-id></element-citation></ref><ref id="B11-vaccines-09-01072"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomes</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rivera-Correa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Freire-De-Lima</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Morrot</surname><given-names>A.</given-names></name></person-group><article-title>Immune escape strategies of malaria parasites</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><fpage>1617</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2016.01617</pub-id><pub-id pub-id-type="pmid">27799922</pub-id><pub-id pub-id-type="pmcid">PMC5066453</pub-id></element-citation></ref><ref id="B12-vaccines-09-01072"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Manyando</surname><given-names>C.</given-names></name></person-group><article-title>Nature reviews disease primers</article-title><source>Malaria</source><year>2017</year><volume>3</volume><fpage>17050</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.50</pub-id><pub-id pub-id-type="pmid">28770814</pub-id></element-citation></ref><ref id="B13-vaccines-09-01072"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Lundie</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Beeson</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>O&#8217;Keeffe</surname><given-names>M.</given-names></name></person-group><article-title>Dendritic cell responses and function in malaria</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>357</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00357</pub-id><pub-id pub-id-type="pmid">30886619</pub-id><pub-id pub-id-type="pmcid">PMC6409297</pub-id></element-citation></ref><ref id="B14-vaccines-09-01072"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cowman</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Healer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marapana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>K.</given-names></name></person-group><article-title>Malaria: Biology and disease</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>610</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.055</pub-id><pub-id pub-id-type="pmid">27768886</pub-id></element-citation></ref><ref id="B15-vaccines-09-01072"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thu</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Phyo</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Landier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Nosten</surname><given-names>F.H.</given-names></name></person-group><article-title>Combating multidrug-resistant <italic toggle="yes">Plasmodium falciparum</italic> malaria</article-title><source>FEBS J.</source><year>2017</year><volume>284</volume><fpage>2569</fpage><lpage>2578</lpage><pub-id pub-id-type="doi">10.1111/febs.14127</pub-id><pub-id pub-id-type="pmid">28580606</pub-id><pub-id pub-id-type="pmcid">PMC5575457</pub-id></element-citation></ref><ref id="B16-vaccines-09-01072"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>D.A.</given-names></name></person-group><article-title>Elucidating mechanisms of drug-resistant <italic toggle="yes">Plasmodium falciparum</italic></article-title><source>Cell Host Microbe</source><year>2019</year><volume>26</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.06.001</pub-id><pub-id pub-id-type="pmid">31295423</pub-id><pub-id pub-id-type="pmcid">PMC6639022</pub-id></element-citation></ref><ref id="B17-vaccines-09-01072"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dagen</surname><given-names>M.</given-names></name></person-group><article-title>History of malaria and its treatment</article-title><source>Antimalarial Agents</source><person-group person-group-type="editor"><name name-style="western"><surname>Patrick</surname><given-names>G.L.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2020</year><fpage>1</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/b978-0-08-101210-9.00001-9</pub-id></element-citation></ref><ref id="B18-vaccines-09-01072"><label>18.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Guidelines for the Treatment of Malaria</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf" ext-link-type="uri">https://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref><ref id="B19-vaccines-09-01072"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasco</surname><given-names>B.</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>D.A.</given-names></name></person-group><article-title>Antimalarial drug resistance: Linking <italic toggle="yes">Plasmodium falciparum</italic> parasite biology to the clinic</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>917</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1038/nm.4381</pub-id><pub-id pub-id-type="pmid">28777791</pub-id><pub-id pub-id-type="pmcid">PMC5747363</pub-id></element-citation></ref><ref id="B20-vaccines-09-01072"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubell</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dondorp</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Day</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>White</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.J.</given-names></name></person-group><article-title>Artemisinin resistance&#8212;Modelling the potential human and economic costs</article-title><source>Malar. J.</source><year>2014</year><volume>13</volume><fpage>452</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-13-452</pub-id><pub-id pub-id-type="pmid">25418416</pub-id><pub-id pub-id-type="pmcid">PMC4254187</pub-id></element-citation></ref><ref id="B21-vaccines-09-01072"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hannan</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Behboudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sinden</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name></person-group><article-title>Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses</article-title><source>Immunol. Cell Biol.</source><year>2005</year><volume>83</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1711.2005.01325.x</pub-id><pub-id pub-id-type="pmid">15877610</pub-id></element-citation></ref><ref id="B22-vaccines-09-01072"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id></element-citation></ref><ref id="B23-vaccines-09-01072"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bousheri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name></person-group><article-title>New insight into the role of dendritic cells in malaria immune pathogenesis</article-title><source>Trends Parasitol.</source><year>2008</year><volume>24</volume><fpage>199</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2008.02.003</pub-id><pub-id pub-id-type="pmid">18406209</pub-id></element-citation></ref><ref id="B24-vaccines-09-01072"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draheim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wlodarczyk</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Crozat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saliou</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Alayi</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Tomavo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salvioni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Demarta-Gatsi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Profiling mhc ii immunopeptidome of blood-stage malaria reveals that cDC1 control the functionality of parasite-specific CD4 T cells</article-title><source>EMBO Mol. Med.</source><year>2017</year><volume>9</volume><fpage>1605</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.15252/emmm.201708123</pub-id><pub-id pub-id-type="pmid">28935714</pub-id><pub-id pub-id-type="pmcid">PMC5666312</pub-id></element-citation></ref><ref id="B25-vaccines-09-01072"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gazzinelli</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Kalantari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name></person-group><article-title>Innate sensing of malaria parasites</article-title><source>Nat. Rev. Immunol.</source><year>2014</year><volume>14</volume><fpage>744</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1038/nri3742</pub-id><pub-id pub-id-type="pmid">25324127</pub-id></element-citation></ref><ref id="B26-vaccines-09-01072"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liehl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zuzarte-Lu&#237;s</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zillinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baptista</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carapau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Konert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Carret</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lassnig</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Host-cell sensors for plasmodium activate innate immunity against liver-stage infection</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nm.3424</pub-id><pub-id pub-id-type="pmid">24362933</pub-id><pub-id pub-id-type="pmcid">PMC4096771</pub-id></element-citation></ref><ref id="B27-vaccines-09-01072"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osii</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Garside</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ndungu</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>J.M.</given-names></name></person-group><article-title>The impact of malaria parasites on dendritic cell&#8211;T cell interaction</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1597</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01597</pub-id><pub-id pub-id-type="pmid">32793231</pub-id><pub-id pub-id-type="pmcid">PMC7393936</pub-id></element-citation></ref><ref id="B28-vaccines-09-01072"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>deWalick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amante</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>McSweeney</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuns</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Engwerda</surname><given-names>C.R.</given-names></name></person-group><article-title>Cutting edge: Conventional dendritic cells are the critical required for the induction of experimental cerebral malaria</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>6033</fpage><lpage>6037</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.10.6033</pub-id><pub-id pub-id-type="pmid">17475826</pub-id></element-citation></ref><ref id="B29-vaccines-09-01072"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claudianos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dessens</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Trueman</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Butcher</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Crompton</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sinden</surname><given-names>R.E.</given-names></name></person-group><article-title>A malaria scavenger receptor-like protein essential for parasite development</article-title><source>Mol. Microbiol.</source><year>2002</year><volume>45</volume><fpage>1473</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2002.03118.x</pub-id><pub-id pub-id-type="pmid">12354219</pub-id></element-citation></ref><ref id="B30-vaccines-09-01072"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowda</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>Parasite recognition and signaling mechanisms in innate immune responses to malaria</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>3006</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.03006</pub-id><pub-id pub-id-type="pmid">30619355</pub-id><pub-id pub-id-type="pmcid">PMC6305727</pub-id></element-citation></ref><ref id="B31-vaccines-09-01072"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalantari</surname><given-names>P.</given-names></name></person-group><article-title>The emerging role of pattern recognition receptors in the pathogenesis of malaria</article-title><source>Vaccines</source><year>2018</year><volume>6</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines6010013</pub-id><pub-id pub-id-type="pmcid">PMC5874654</pub-id><pub-id pub-id-type="pmid">29495555</pub-id></element-citation></ref><ref id="B32-vaccines-09-01072"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuinness</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Dehal</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Pleass</surname><given-names>R.J.</given-names></name></person-group><article-title>Pattern recognition molecules and innate immunity to parasites</article-title><source>Trends Parasitol.</source><year>2003</year><volume>19</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/S1471-4922(03)00123-5</pub-id><pub-id pub-id-type="pmid">12855382</pub-id></element-citation></ref><ref id="B33-vaccines-09-01072"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jide</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wenyue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fusheng</surname><given-names>H.</given-names></name></person-group><article-title>Toll-like receptors, a double-edged sword in immunity to malaria</article-title><source>J. Med. Coll. PLA</source><year>2009</year><volume>24</volume><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S1000-1948(09)60027-7</pub-id></element-citation></ref><ref id="B34-vaccines-09-01072"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wykes</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>S.R.</given-names></name></person-group><article-title>Immune checkpoint blockade in infectious diseases</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.112</pub-id><pub-id pub-id-type="pmid">28990586</pub-id><pub-id pub-id-type="pmcid">PMC5991909</pub-id></element-citation></ref><ref id="B35-vaccines-09-01072"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Hustin</surname><given-names>L.S.P.</given-names></name><name name-style="western"><surname>Sauerwein</surname><given-names>R.W.</given-names></name></person-group><article-title>Th1-polarized tfh cells delay naturally-acquired immunity to malaria</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1096</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01096</pub-id><pub-id pub-id-type="pmid">31156642</pub-id><pub-id pub-id-type="pmcid">PMC6533880</pub-id></element-citation></ref><ref id="B36-vaccines-09-01072"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauduit</surname><given-names>M.</given-names></name><name name-style="western"><surname>See</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ginhoux</surname><given-names>F.</given-names></name></person-group><article-title>Dendritic cells and the malaria pre-erythrocytic stage</article-title><source>Immunol. Res.</source><year>2012</year><volume>53</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s12026-012-8269-7</pub-id><pub-id pub-id-type="pmid">22418726</pub-id></element-citation></ref><ref id="B37-vaccines-09-01072"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkel</surname><given-names>B.M.F.</given-names></name><name name-style="western"><surname>Pelgrom</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>van Schuijlenburg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baalbergen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Gerritsma</surname><given-names>H.</given-names></name><name name-style="western"><surname>de Korne</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Duszenko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Langenberg</surname><given-names>M.C.C.</given-names></name><name name-style="western"><surname>Chevalley-Maurel</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Plasmodium sporozoites</italic> induce regulatory macrophages</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008799</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008799</pub-id><pub-id pub-id-type="pmid">32898164</pub-id><pub-id pub-id-type="pmcid">PMC7500643</pub-id></element-citation></ref><ref id="B38-vaccines-09-01072"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiriao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mota</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name></person-group><article-title>Apoptotic plasmodium-infected hepatocytes provide antigens to liver dendritic cells</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>191</volume><fpage>1576</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1086/429635</pub-id><pub-id pub-id-type="pmid">15838783</pub-id></element-citation></ref><ref id="B39-vaccines-09-01072"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cockburn</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Kuk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Overstreet</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sacci</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Zavala</surname><given-names>F.</given-names></name></person-group><article-title>CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>1035</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1038/nm1628</pub-id><pub-id pub-id-type="pmid">17704784</pub-id></element-citation></ref><ref id="B40-vaccines-09-01072"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Enea</surname><given-names>V.</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>V.</given-names></name></person-group><article-title>Infectivity of <italic toggle="yes">Plasmodium berghei</italic> sporozoites measured with a DNA probe</article-title><source>Mol. Biochem. Parasitol.</source><year>1986</year><volume>19</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/0166-6851(86)90114-3</pub-id><pub-id pub-id-type="pmid">3523238</pub-id></element-citation></ref><ref id="B41-vaccines-09-01072"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurup</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hancox</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Vijay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pewe</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Moioffer</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sompallae</surname><given-names>R.</given-names></name><name name-style="western"><surname>Janse</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>J.T.</given-names></name></person-group><article-title>Monocyte-derived CD11c<sup>+</sup> cells acquire plasmodium from hepatocytes to prime CD8 T cell immunity to liver-stage malaria</article-title><source>Cell Host Microbe</source><year>2019</year><volume>25</volume><fpage>565</fpage><lpage>577.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.02.014</pub-id><pub-id pub-id-type="pmid">30905437</pub-id><pub-id pub-id-type="pmcid">PMC6459714</pub-id></element-citation></ref><ref id="B42-vaccines-09-01072"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#233;nia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mara&#241;&#243;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hosmalin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gr&#252;ner</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Silvie</surname><given-names>O.</given-names></name><name name-style="western"><surname>Snounou</surname><given-names>G.</given-names></name></person-group><article-title>Do apoptotic plasmodium-infected hepatocytes initiate protective immune responses?</article-title><source>J. Infect. Dis.</source><year>2006</year><volume>193</volume><fpage>163</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1086/498536</pub-id><pub-id pub-id-type="pmid">16323145</pub-id></element-citation></ref><ref id="B43-vaccines-09-01072"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nussenzweig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.F.</given-names></name></person-group><article-title>Sporozoite-induced immunity in mammalian malaria</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1972</year><volume>21</volume><fpage>722</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1972.21.722</pub-id><pub-id pub-id-type="pmid">4561520</pub-id></element-citation></ref><ref id="B44-vaccines-09-01072"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Zephir</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Sarwar</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>James</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Gunasekera</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>1359</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1126/science.1241800</pub-id><pub-id pub-id-type="pmid">23929949</pub-id></element-citation></ref><ref id="B45-vaccines-09-01072"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A.S.P.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Jennison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lopaticki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Armistead</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Ellisdon</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Whisstock</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Cell traversal activity is important for <italic toggle="yes">Plasmodium falciparum</italic> liver infection in humanized mice</article-title><source>Cell Rep.</source><year>2017</year><volume>18</volume><fpage>3105</fpage><lpage>3116</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.03.017</pub-id><pub-id pub-id-type="pmid">28355563</pub-id></element-citation></ref><ref id="B46-vaccines-09-01072"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sack</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Mikolajczak</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Fishbaugher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Flannery</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Betz</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jane Navarro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foquet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Steel</surname><given-names>R.W.J.</given-names></name><etal/></person-group><article-title>Humoral protection against mosquito bite-transmitted <italic toggle="yes">Plasmodium falciparum</italic> infection in humanized mice</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0028-2</pub-id><pub-id pub-id-type="pmid">29263882</pub-id><pub-id pub-id-type="pmcid">PMC5634440</pub-id></element-citation></ref><ref id="B47-vaccines-09-01072"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huisjes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bogdanova</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Solinge</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Schiffelers</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Kaestner</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Wijk</surname><given-names>R.</given-names></name></person-group><article-title>Squeezing for life&#8212;Properties of red blood cell deformability</article-title><source>Front. Physiol.</source><year>2018</year><volume>9</volume><fpage>656</fpage><pub-id pub-id-type="doi">10.3389/fphys.2018.00656</pub-id><pub-id pub-id-type="pmid">29910743</pub-id><pub-id pub-id-type="pmcid">PMC5992676</pub-id></element-citation></ref><ref id="B48-vaccines-09-01072"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooke</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nash</surname><given-names>G.B.</given-names></name></person-group><article-title>The cellular and molecular rheology of malaria</article-title><source>Biorheology</source><year>2014</year><volume>51</volume><fpage>99</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.3233/BIR-140654</pub-id><pub-id pub-id-type="pmid">24819866</pub-id></element-citation></ref><ref id="B49-vaccines-09-01072"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buffet</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Safeukui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Deplaine</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brousse</surname><given-names>V.</given-names></name><name name-style="western"><surname>Prendki</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thellier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Mercereau-Puijalon</surname><given-names>O.</given-names></name></person-group><article-title>The pathogenesis of <italic toggle="yes">Plasmodium falciparum</italic> malaria in humans: Insights from splenic physiology</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-202911</pub-id><pub-id pub-id-type="pmid">20852127</pub-id><pub-id pub-id-type="pmcid">PMC3031473</pub-id></element-citation></ref><ref id="B50-vaccines-09-01072"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name></person-group><article-title>Sticking for a cause: The falciparum malaria parasites cytoadherence paradigm</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1444</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01444</pub-id><pub-id pub-id-type="pmid">31316507</pub-id><pub-id pub-id-type="pmcid">PMC6610498</pub-id></element-citation></ref><ref id="B51-vaccines-09-01072"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Willcox</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>D.J.</given-names></name></person-group><article-title>A role for CD36 in the regulation of dendritic cell function</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>8750</fpage><lpage>8755</lpage><pub-id pub-id-type="doi">10.1073/pnas.151028698</pub-id><pub-id pub-id-type="pmid">11447263</pub-id><pub-id pub-id-type="pmcid">PMC37507</pub-id></element-citation></ref><ref id="B52-vaccines-09-01072"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Pain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Willcox</surname><given-names>N.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Austyn</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>D.J.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium falciparum</italic>-infected erythrocytes modulate the maturation of dendritic cells</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/21900</pub-id><pub-id pub-id-type="pmid">10403251</pub-id></element-citation></ref><ref id="B53-vaccines-09-01072"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loharungsikul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Troye-Blomberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amoudruz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pichyangkul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yongvanitchit</surname><given-names>K.</given-names></name><name name-style="western"><surname>Looareesuwan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mahakunkijcharoen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sarntivijai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khusmith</surname><given-names>S.</given-names></name></person-group><article-title>Expression of Toll-like receptors on antigen-presenting cells in patients with falciparum malaria</article-title><source>Acta Trop.</source><year>2008</year><volume>105</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2007.08.002</pub-id><pub-id pub-id-type="pmid">17854755</pub-id></element-citation></ref><ref id="B54-vaccines-09-01072"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinzon-Charry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Woodberry</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kienzle</surname><given-names>V.</given-names></name><name name-style="western"><surname>McPhun</surname><given-names>V.</given-names></name><name name-style="western"><surname>Minigo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lampah</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Engwerda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>N.M.</given-names></name><etal/></person-group><article-title>Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria</article-title><source>J. Exp. Med.</source><year>2013</year><volume>210</volume><fpage>1635</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1084/jem.20121972</pub-id><pub-id pub-id-type="pmid">23835848</pub-id><pub-id pub-id-type="pmcid">PMC3727318</pub-id></element-citation></ref><ref id="B55-vaccines-09-01072"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Kooyk</surname><given-names>Y.</given-names></name></person-group><article-title>Next-generation malarial vaccines</article-title><source>Nat. Mater.</source><year>2019</year><volume>18</volume><fpage>94</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/s41563-018-0267-2</pub-id><pub-id pub-id-type="pmid">30670833</pub-id></element-citation></ref><ref id="B56-vaccines-09-01072"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smalley</surname><given-names>M.E.</given-names></name></person-group><article-title>Specific antibody-dependent cellular cytotoxicity in human malaria</article-title><source>Clin. Exp. Immunol.</source><year>1980</year><volume>41</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">7002397</pub-id><pub-id pub-id-type="pmcid">PMC1537024</pub-id></element-citation></ref><ref id="B57-vaccines-09-01072"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Manzella-Lapeira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Doritchamou</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Narum</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Brzostowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rajagopalan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doumbo</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Traore</surname><given-names>B.</given-names></name></person-group><article-title>NK cells inhibit <italic toggle="yes">Plasmodium falciparum</italic> growth in red blood cells via antibody-dependent cellular cytotoxicity</article-title><source>eLife</source><year>2018</year><volume>7</volume><fpage>e36806</fpage><pub-id pub-id-type="doi">10.7554/eLife.36806</pub-id><pub-id pub-id-type="pmid">29943728</pub-id><pub-id pub-id-type="pmcid">PMC6019063</pub-id></element-citation></ref><ref id="B58-vaccines-09-01072"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Sherratt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>E.M.</given-names></name></person-group><article-title>NK cells: Uncertain allies against malaria</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>212</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00212</pub-id><pub-id pub-id-type="pmid">28337195</pub-id><pub-id pub-id-type="pmcid">PMC5343013</pub-id></element-citation></ref><ref id="B59-vaccines-09-01072"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Amaladoss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dummler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Loo</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Loh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.Q.</given-names></name></person-group><article-title>Human natural killer cells control <italic toggle="yes">Plasmodium falciparum</italic> infection by eliminating infected red blood cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>1479</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1073/pnas.1323318111</pub-id><pub-id pub-id-type="pmid">24474774</pub-id><pub-id pub-id-type="pmcid">PMC3910619</pub-id></element-citation></ref><ref id="B60-vaccines-09-01072"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Theorell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schlums</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rajagopalan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sangala</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Traore</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>S.K.</given-names></name></person-group><article-title>Adaptive NK cells in people exposed to <italic toggle="yes">Plasmodium falciparum</italic> correlate with protection from malaria</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>1280</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1084/jem.20181681</pub-id><pub-id pub-id-type="pmid">30979790</pub-id><pub-id pub-id-type="pmcid">PMC6547858</pub-id></element-citation></ref><ref id="B61-vaccines-09-01072"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurup</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>J.T.</given-names></name></person-group><article-title>T cell-mediated immunity to malaria</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>457</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0158-z</pub-id><pub-id pub-id-type="pmid">30940932</pub-id><pub-id pub-id-type="pmcid">PMC6599480</pub-id></element-citation></ref><ref id="B62-vaccines-09-01072"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Villaquiran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schellekens</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>V.</given-names></name></person-group><article-title>Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites</article-title><source>Nature</source><year>1987</year><volume>330</volume><fpage>664</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1038/330664a0</pub-id><pub-id pub-id-type="pmid">3120015</pub-id></element-citation></ref><ref id="B63-vaccines-09-01072"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Sedegah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beaudoin</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Good</surname><given-names>M.F.</given-names></name></person-group><article-title>CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1988</year><volume>85</volume><fpage>573</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.2.573</pub-id><pub-id pub-id-type="pmid">2963334</pub-id><pub-id pub-id-type="pmcid">PMC279593</pub-id></element-citation></ref><ref id="B64-vaccines-09-01072"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silvie</surname><given-names>O.</given-names></name><name name-style="western"><surname>Amino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hafalla</surname><given-names>J.C.</given-names></name></person-group><article-title>Tissue-specific cellular immune responses to malaria pre-erythrocytic stages</article-title><source>Curr. Opin. Microbiol.</source><year>2017</year><volume>40</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2017.12.001</pub-id><pub-id pub-id-type="pmid">29217460</pub-id></element-citation></ref><ref id="B65-vaccines-09-01072"><label>65.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Druilhe</surname><given-names>P.</given-names></name><name name-style="western"><surname>R&#233;nia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>D.</given-names></name></person-group><article-title>Immunity to Liver Stages</article-title><source>Malaria: Parasite Biology, Pathogenesis, and Protection</source><person-group person-group-type="editor"><name name-style="western"><surname>Sherman</surname><given-names>I.</given-names></name></person-group><publisher-name>ASM Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>1998</year></element-citation></ref><ref id="B66-vaccines-09-01072"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#233;nia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marussig</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Grillot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pied</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miltgen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mazier</surname><given-names>D.</given-names></name></person-group><article-title>In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1991</year><volume>88</volume><fpage>7963</fpage><lpage>7967</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.18.7963</pub-id><pub-id pub-id-type="pmid">1680235</pub-id><pub-id pub-id-type="pmcid">PMC52425</pub-id></element-citation></ref><ref id="B67-vaccines-09-01072"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grillot</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marussig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miltgen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Mazier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Delgiudice</surname><given-names>G.</given-names></name></person-group><article-title>Effector functions of circumsporozoite peptide-primed CD4+ T-cell clones against plasmodium-yoelii liver stages</article-title><source>J. Immunol.</source><year>1993</year><volume>150</volume><fpage>1471</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">7679428</pub-id></element-citation></ref><ref id="B68-vaccines-09-01072"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bongfen</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Torgler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium berghei</italic>-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>7054</fpage><lpage>7063</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.11.7054</pub-id><pub-id pub-id-type="pmid">17513754</pub-id></element-citation></ref><ref id="B69-vaccines-09-01072"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doll</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Pewe</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>J.T.</given-names></name></person-group><article-title>Discriminating protective from nonprotective plasmodium-specific CD8+ T cell responses</article-title><source>J. Immunol.</source><year>2016</year><volume>196</volume><fpage>4253</fpage><lpage>4262</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600155</pub-id><pub-id pub-id-type="pmid">27084099</pub-id><pub-id pub-id-type="pmcid">PMC4868661</pub-id></element-citation></ref><ref id="B70-vaccines-09-01072"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockburn</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Amino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kelemen</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mac-Daniel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ganusov</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Zavala</surname><given-names>F.</given-names></name><name name-style="western"><surname>M&#233;nard</surname><given-names>R.</given-names></name></person-group><article-title>In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>9090</fpage><lpage>9095</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303858110</pub-id><pub-id pub-id-type="pmid">23674673</pub-id><pub-id pub-id-type="pmcid">PMC3670364</pub-id></element-citation></ref><ref id="B71-vaccines-09-01072"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nussler</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Beger</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.Z.</given-names></name><name name-style="western"><surname>Billiar</surname><given-names>T.R.</given-names></name></person-group><article-title>Nitric oxide, hepatocytes and inflammation</article-title><source>Res. Immunol.</source><year>1995</year><volume>146</volume><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/0923-2494(96)84915-7</pub-id><pub-id pub-id-type="pmid">8852608</pub-id></element-citation></ref><ref id="B72-vaccines-09-01072"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belnoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Frankenberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vigario</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Voza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Landau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Snounou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name></person-group><article-title>Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>2487</fpage><lpage>2495</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.4.2487</pub-id><pub-id pub-id-type="pmid">14764721</pub-id></element-citation></ref><ref id="B73-vaccines-09-01072"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belnoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Voza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Gruner</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mauduit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Depinay</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kayibanda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vigario</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Mazier</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Vaccination with live <italic toggle="yes">Plasmodium yoelii</italic> blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>8552</fpage><lpage>8558</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.12.8552</pub-id><pub-id pub-id-type="pmid">19050274</pub-id><pub-id pub-id-type="pmcid">PMC5551044</pub-id></element-citation></ref><ref id="B74-vaccines-09-01072"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trimnell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richie</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name></person-group><article-title>Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of <italic toggle="yes">Plasmodium yoelii</italic> liver stage-infected hepatocytes</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>5870</fpage><lpage>5878</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900302</pub-id><pub-id pub-id-type="pmid">19812194</pub-id></element-citation></ref><ref id="B75-vaccines-09-01072"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hafalla</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Morrot</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Lafaille</surname><given-names>M.A.C.</given-names></name><name name-style="western"><surname>Zavala</surname><given-names>F.</given-names></name></person-group><article-title>Il-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages</article-title><source>Nat. Med.</source><year>2002</year><volume>8</volume><fpage>166</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/nm0202-166</pub-id><pub-id pub-id-type="pmid">11821901</pub-id></element-citation></ref><ref id="B76-vaccines-09-01072"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>J.T.</given-names></name></person-group><article-title>You shall not pass: Memory CD8 T cells in liver-stage malaria</article-title><source>Trends Parasitol.</source><year>2020</year><volume>36</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2019.11.004</pub-id><pub-id pub-id-type="pmid">31843536</pub-id><pub-id pub-id-type="pmcid">PMC6937381</pub-id></element-citation></ref><ref id="B77-vaccines-09-01072"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valencia-Hernandez</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Ghazanfari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghilas</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Menezes</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Holz</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>English</surname><given-names>K.</given-names></name><name name-style="western"><surname>Naung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>A natural peptide antigen within the <italic toggle="yes">Plasmodium ribosomal</italic> protein RPL6 confers liver T<sub>RM</sub> cell-mediated immunity against malaria in mice</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>950</fpage><lpage>962.e7</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.010</pub-id><pub-id pub-id-type="pmid">32396839</pub-id></element-citation></ref><ref id="B78-vaccines-09-01072"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Ruiz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Holz</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Mollard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cozijnsen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Liver-resident memory CD8<sup>+</sup> T cells form a front-line defense against malaria liver-stage infection</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>889</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.011</pub-id><pub-id pub-id-type="pmid">27692609</pub-id></element-citation></ref><ref id="B79-vaccines-09-01072"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Tewari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Laurens</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Gunasekera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>S.</given-names></name><name name-style="western"><surname>James</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Sedegah</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Live attenuated malaria vaccine designed to protect through hepatic CD8<sup>+</sup> T cell immunity</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>475</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1126/science.1211548</pub-id><pub-id pub-id-type="pmid">21903775</pub-id></element-citation></ref><ref id="B80-vaccines-09-01072"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockburn</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Malaria prevention: From immunological concepts to effective vaccines and protective antibodies</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>1199</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0228-6</pub-id><pub-id pub-id-type="pmid">30333613</pub-id></element-citation></ref><ref id="B81-vaccines-09-01072"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uderhardt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salman</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Halbroth</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bowyer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Powlson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Prime and target immunization protects against liver-stage malaria in mice</article-title><source>Sci. Transl. Med.</source><year>2018</year><volume>10</volume><fpage>eaap9128</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aap9128</pub-id><pub-id pub-id-type="pmid">30257955</pub-id></element-citation></ref><ref id="B82-vaccines-09-01072"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Hara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lawrie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nicosia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Folgori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colloca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Prime-boost vectored malaria vaccines: Progress and prospects</article-title><source>Hum Vaccin</source><year>2010</year><volume>6</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.4161/hv.6.1.10116</pub-id><pub-id pub-id-type="pmid">20061802</pub-id></element-citation></ref><ref id="B83-vaccines-09-01072"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutishauser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lepore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Blasi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dangy</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jongo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramadhani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>B.K.L.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Activation of tcr v&#948;1<sup>+</sup> and v&#948;1<sup>&#8722;</sup>v&#948;2<sup>&#8722;</sup> &#947;&#948; T cells upon controlled infection with <italic toggle="yes">Plasmodium falciparum</italic> in tanzanian volunteers</article-title><source>J. Immunol.</source><year>2019</year><pub-id pub-id-type="doi">10.4049/jimmunol.1900669</pub-id><pub-id pub-id-type="pmid">31801816</pub-id></element-citation></ref><ref id="B84-vaccines-09-01072"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mpina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maurice</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Yajima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Slichter</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>M.</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>McNevin</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Controlled human malaria infection leads to long-lasting changes in innate and innate-like lymphocyte populations</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601989</pub-id><pub-id pub-id-type="pmid">28576979</pub-id><pub-id pub-id-type="pmcid">PMC5528886</pub-id></element-citation></ref><ref id="B85-vaccines-09-01072"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Mazliah</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langhorne</surname><given-names>J.</given-names></name></person-group><article-title>CD4 T-cell subsets in malaria: Th1/th2 revisited</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>671</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00671</pub-id><pub-id pub-id-type="pmid">25628621</pub-id><pub-id pub-id-type="pmcid">PMC4290673</pub-id></element-citation></ref><ref id="B86-vaccines-09-01072"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Mazliah</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Hosking</surname><given-names>C.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Tumwine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Langhorne</surname><given-names>J.</given-names></name></person-group><article-title>Follicular helper T cells are essential for the elimination of plasmodium infection</article-title><source>EBioMedicine</source><year>2017</year><volume>24</volume><fpage>216</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.08.030</pub-id><pub-id pub-id-type="pmid">28888925</pub-id><pub-id pub-id-type="pmcid">PMC5652023</pub-id></element-citation></ref><ref id="B87-vaccines-09-01072"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soon</surname><given-names>M.S.F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Straube</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Pernold</surname><given-names>C.P.S.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Laohamonthonkul</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haldar</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.G.</given-names></name><etal/></person-group><article-title>Transcriptome dynamics of CD4<sup>+</sup> T cells during malaria maps gradual transit from effector to memory</article-title><source>Nat. Immunol.</source><year>2020</year><volume>21</volume><fpage>1597</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0800-8</pub-id><pub-id pub-id-type="pmid">33046889</pub-id></element-citation></ref><ref id="B88-vaccines-09-01072"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deroost</surname><given-names>K.</given-names></name><name name-style="western"><surname>Langhorne</surname><given-names>J.</given-names></name></person-group><article-title>Gamma/delta T cells and their role in protection against malaria</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2973</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02973</pub-id><pub-id pub-id-type="pmid">30619330</pub-id><pub-id pub-id-type="pmcid">PMC6306408</pub-id></element-citation></ref><ref id="B89-vaccines-09-01072"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodier</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>E.M.</given-names></name></person-group><article-title>Differentiation and adaptation of natural killer cells for anti-malarial immunity</article-title><source>Immunol. Rev.</source><year>2020</year><volume>293</volume><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1111/imr.12798</pub-id><pub-id pub-id-type="pmid">31762040</pub-id></element-citation></ref><ref id="B90-vaccines-09-01072"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horne-Debets</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Faleiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karunarathne</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Lineburg</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Grotenbreg</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Good</surname><given-names>M.F.</given-names></name><etal/></person-group><article-title>Pd-1 dependent exhaustion of CD8<sup>+</sup> T cells drives chronic malaria</article-title><source>Cell Rep.</source><year>2013</year><volume>5</volume><fpage>1204</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.11.002</pub-id><pub-id pub-id-type="pmid">24316071</pub-id></element-citation></ref><ref id="B91-vaccines-09-01072"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horne-Debets</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Karunarathne</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Faleiro</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wykes</surname><given-names>M.N.</given-names></name></person-group><article-title>Mice lacking programmed cell death-1 show a role for CD8<sup>+</sup> T cells in long-term immunity against blood-stage malaria</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>26210</fpage><pub-id pub-id-type="doi">10.1038/srep26210</pub-id><pub-id pub-id-type="pmid">27217330</pub-id><pub-id pub-id-type="pmcid">PMC4877649</pub-id></element-citation></ref><ref id="B92-vaccines-09-01072"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shimokawa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hisaeda</surname><given-names>H.</given-names></name></person-group><article-title>Cytotoxic activities of CD8<sup>+</sup> T cells collaborate with macrophages to protect against blood-stage murine malaria</article-title><source>eLife</source><year>2015</year><volume>4</volume><fpage>e04232</fpage><pub-id pub-id-type="doi">10.7554/eLife.04232</pub-id><pub-id pub-id-type="pmcid">PMC4366679</pub-id><pub-id pub-id-type="pmid">25760084</pub-id></element-citation></ref><ref id="B93-vaccines-09-01072"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminski</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Riehn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steeg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yar</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Addai-Mensah</surname><given-names>O.</given-names></name><name name-style="western"><surname>Aminkiah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Owusu Dabo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mackroth</surname><given-names>M.S.</given-names></name></person-group><article-title>Cytotoxic T cell-derived granzyme B is increased in severe <italic toggle="yes">Plasmodium falciparum</italic> malaria</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2917</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02917</pub-id><pub-id pub-id-type="pmid">31921176</pub-id><pub-id pub-id-type="pmcid">PMC6918797</pub-id></element-citation></ref><ref id="B94-vaccines-09-01072"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riggle</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Manglani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maric</surname><given-names>D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Neto</surname><given-names>O.L.A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Seydel</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>CD8+ T cells target cerebrovasculature in children with cerebral malaria</article-title><source>J. Clin. Investig.</source><year>2020</year><volume>130</volume><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1172/JCI133474</pub-id><pub-id pub-id-type="pmid">31821175</pub-id><pub-id pub-id-type="pmcid">PMC7269583</pub-id></element-citation></ref><ref id="B95-vaccines-09-01072"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belnoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kayibanda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vigario</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Deschemin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Viguier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Snounou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name></person-group><article-title>On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><fpage>6369</fpage><lpage>6375</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.11.6369</pub-id><pub-id pub-id-type="pmid">12444144</pub-id></element-citation></ref><ref id="B96-vaccines-09-01072"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engwerda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Belnoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gruner</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name></person-group><article-title>Experimental models of cerebral malaria</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2005</year><volume>297</volume><fpage>103</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">16265904</pub-id></element-citation></ref><ref id="B97-vaccines-09-01072"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>Y.S.</given-names></name></person-group><article-title>Malaria parasites: The great escape</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>463</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00463</pub-id><pub-id pub-id-type="pmid">27872623</pub-id><pub-id pub-id-type="pmcid">PMC5098170</pub-id></element-citation></ref><ref id="B98-vaccines-09-01072"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholzen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mittag</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rogerson</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium falciparum</italic>-mediated induction of human CD25<sup>hi</sup>Foxp3<sup>hi</sup> CD4 T cells is independent of direct tcr stimulation and requires IL-2, IL-10 and TGF&#946;</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000543</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000543</pub-id><pub-id pub-id-type="pmid">19680449</pub-id><pub-id pub-id-type="pmcid">PMC2718810</pub-id></element-citation></ref><ref id="B99-vaccines-09-01072"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurup</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Obeng-Adjei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Traore</surname><given-names>B.</given-names></name><name name-style="western"><surname>Doumbo</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Crompton</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>J.T.</given-names></name></person-group><article-title>Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>1220</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1038/nm.4395</pub-id><pub-id pub-id-type="pmid">28892065</pub-id><pub-id pub-id-type="pmcid">PMC5649372</pub-id></element-citation></ref><ref id="B100-vaccines-09-01072"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyirenda</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Molyneux</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Kenefeck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Heyderman</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Mandala</surname><given-names>W.L.</given-names></name></person-group><article-title>T-regulatory cells and inflammatory and inhibitory cytokines in malawian children residing in an area of high and an area of low malaria transmission during acute uncomplicated malaria and in convalescence</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2015</year><volume>4</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1093/jpids/piu140</pub-id><pub-id pub-id-type="pmid">26335932</pub-id><pub-id pub-id-type="pmcid">PMC4554200</pub-id></element-citation></ref><ref id="B101-vaccines-09-01072"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncalves</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Salmazi</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Boscardin</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Silber</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kallas</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Scopel</surname><given-names>K.K.</given-names></name></person-group><article-title>CD4<sup>+</sup> CD25<sup>+</sup> Foxp3<sup>+</sup> regulatory T cells, dendritic cells, and circulating cytokines in uncomplicated malaria: Do different parasite species elicit similar host responses?</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>4763</fpage><lpage>4772</lpage><pub-id pub-id-type="doi">10.1128/IAI.00578-10</pub-id><pub-id pub-id-type="pmid">20713627</pub-id><pub-id pub-id-type="pmcid">PMC2976362</pub-id></element-citation></ref><ref id="B102-vaccines-09-01072"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todryk</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bejon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mwangi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>K.L.</given-names></name></person-group><article-title>Correlation of memory T cell responses against trap with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e2027</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002027</pub-id><pub-id pub-id-type="pmid">18446217</pub-id><pub-id pub-id-type="pmcid">PMC2323567</pub-id></element-citation></ref><ref id="B103-vaccines-09-01072"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illingworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Roetynck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mwacharo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Bejon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crompton</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ndungu</surname><given-names>F.M.</given-names></name></person-group><article-title>Chronic exposure to <italic toggle="yes">Plasmodium falciparum</italic> is associated with phenotypic evidence of B and T cell exhaustion</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>1038</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202438</pub-id><pub-id pub-id-type="pmid">23264654</pub-id><pub-id pub-id-type="pmcid">PMC3549224</pub-id></element-citation></ref><ref id="B104-vaccines-09-01072"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Braeckel-Budimir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>J.T.</given-names></name></person-group><article-title>Regulatory issues in immunity to liver and blood-stage malaria</article-title><source>Curr. Opin. Immunol.</source><year>2016</year><volume>42</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2016.06.008</pub-id><pub-id pub-id-type="pmid">27351448</pub-id></element-citation></ref><ref id="B105-vaccines-09-01072"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jagannathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Farrington</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Eccles-James</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wamala</surname><given-names>S.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nankya</surname><given-names>F.</given-names></name><name name-style="western"><surname>Auma</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Decline of Foxp3+ regulatory CD4 T cells in peripheral blood of children heavily exposed to malaria</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005041</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005041</pub-id><pub-id pub-id-type="pmid">26182204</pub-id><pub-id pub-id-type="pmcid">PMC4504515</pub-id></element-citation></ref><ref id="B106-vaccines-09-01072"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dups</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Pepper</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cockburn</surname><given-names>I.A.</given-names></name></person-group><article-title>Antibody and B cell responses to <italic toggle="yes">Plasmodium sporozoites</italic></article-title><source>Front. Microbiol.</source><year>2014</year><volume>5</volume><fpage>625</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2014.00625</pub-id><pub-id pub-id-type="pmid">25477870</pub-id><pub-id pub-id-type="pmcid">PMC4235289</pub-id></element-citation></ref><ref id="B107-vaccines-09-01072"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><name name-style="western"><surname>F&#252;rle</surname><given-names>K.</given-names></name><name name-style="western"><surname>J&#228;schke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#252;sing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heiss</surname><given-names>K.</given-names></name><name name-style="western"><surname>Giese</surname><given-names>T.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><name name-style="western"><surname>B&#246;hnlein</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Immunization with full-length <italic toggle="yes">Plasmodium falciparum</italic> merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0160-2</pub-id><pub-id pub-id-type="pmid">32025341</pub-id><pub-id pub-id-type="pmcid">PMC6994672</pub-id></element-citation></ref><ref id="B108-vaccines-09-01072"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aitken</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Mahanty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rogerson</surname><given-names>S.J.</given-names></name></person-group><article-title>Antibody effector functions in malaria and other parasitic diseases: A few needles and many haystacks</article-title><source>Immunol. Cell Biol.</source><year>2020</year><volume>98</volume><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/imcb.12320</pub-id><pub-id pub-id-type="pmid">32003072</pub-id></element-citation></ref><ref id="B109-vaccines-09-01072"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermsen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Verhage</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Telgt</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Teelen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bousema</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Roestenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bolad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berzins</surname><given-names>K.</given-names></name><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>O.</given-names></name></person-group><article-title>Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of <italic toggle="yes">Plasmodium falciparum</italic> in a phase 1 malaria vaccine trial</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>2930</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.081</pub-id><pub-id pub-id-type="pmid">16914240</pub-id></element-citation></ref><ref id="B110-vaccines-09-01072"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Locke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kazura</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Coppel</surname><given-names>R.L.</given-names></name></person-group><article-title>Malaria vaccines: Into a mirror, darkly?</article-title><source>Trends Parasitol.</source><year>2008</year><volume>24</volume><fpage>532</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2008.09.006</pub-id><pub-id pub-id-type="pmid">18938108</pub-id></element-citation></ref><ref id="B111-vaccines-09-01072"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snow</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>C.</given-names></name></person-group><article-title>Immunity to non-cerebral severe malaria is acquired after one or two infections</article-title><source>Nat. Med.</source><year>1999</year><volume>5</volume><fpage>340</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/6560</pub-id><pub-id pub-id-type="pmid">10086393</pub-id></element-citation></ref><ref id="B112-vaccines-09-01072"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Julien</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Wardemann</surname><given-names>H.</given-names></name></person-group><article-title>Antibodies against <italic toggle="yes">Plasmodium falciparum</italic> malaria at the molecular level</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>761</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0209-5</pub-id><pub-id pub-id-type="pmid">31462718</pub-id></element-citation></ref><ref id="B113-vaccines-09-01072"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderberg</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Frevert</surname><given-names>U.</given-names></name></person-group><article-title>Intravital microscopy demonstrating antibody-mediated immobilisation of <italic toggle="yes">Plasmodium berghei</italic> sporozoites injected into skin by mosquitoes</article-title><source>Int. J. Parasitol.</source><year>2004</year><volume>34</volume><fpage>991</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2004.05.005</pub-id><pub-id pub-id-type="pmid">15313126</pub-id></element-citation></ref><ref id="B114-vaccines-09-01072"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aliprandini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>J.</given-names></name><name name-style="western"><surname>Panatieri</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Thiberge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Silvie</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ishino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dartevelle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Traincard</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin</article-title><source>Nat. Microbiol.</source><year>2018</year><volume>3</volume><fpage>1224</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0254-z</pub-id><pub-id pub-id-type="pmid">30349082</pub-id></element-citation></ref><ref id="B115-vaccines-09-01072"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwenk</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lumsden</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Juompan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Krzych</surname><given-names>U.</given-names></name></person-group><article-title>Immunization with the RTS,S/AS malaria vaccine induces IFN-&#947;<sup>+</sup> CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>8847</fpage><lpage>8854</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.098</pub-id><pub-id pub-id-type="pmid">21983360</pub-id></element-citation></ref><ref id="B116-vaccines-09-01072"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nudelman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Charoenvit</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miltgen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Beaudoin</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Mazier</surname><given-names>D.</given-names></name></person-group><article-title>Dual action of anti-sporozoite antibodies in vitro</article-title><source>J. Immunol.</source><year>1989</year><volume>143</volume><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">2745980</pub-id></element-citation></ref><ref id="B117-vaccines-09-01072"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidarsson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rispens</surname><given-names>T.</given-names></name></person-group><article-title>IgG subclasses and allotypes: From structure to effector functions</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>520</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00520</pub-id><pub-id pub-id-type="pmid">25368619</pub-id><pub-id pub-id-type="pmcid">PMC4202688</pub-id></element-citation></ref><ref id="B118-vaccines-09-01072"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Reiling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Osier</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Aspeling-Jones</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Stubbs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tetteh</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Conway</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Human antibodies fix complement to inhibit <italic toggle="yes">Plasmodium falciparum</italic> invasion of erythrocytes and are associated with protection against malaria</article-title><source>Immunity</source><year>2015</year><volume>42</volume><fpage>580</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.012</pub-id><pub-id pub-id-type="pmid">25786180</pub-id><pub-id pub-id-type="pmcid">PMC4372259</pub-id></element-citation></ref><ref id="B119-vaccines-09-01072"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osier</surname><given-names>F.H.A.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>McCallum</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Reiling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jaworowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>R.F.</given-names></name><etal/></person-group><article-title>Opsonic phagocytosis of <italic toggle="yes">Plasmodium falciparum</italic>merozoites: Mechanism in human immunity and a correlate of protection against malaria</article-title><source>BMC Med.</source><year>2014</year><volume>12</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7015-12-108</pub-id><pub-id pub-id-type="pmid">24980799</pub-id><pub-id pub-id-type="pmcid">PMC4098671</pub-id></element-citation></ref><ref id="B120-vaccines-09-01072"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Handayuni</surname><given-names>I.</given-names></name><name name-style="western"><surname>Reiling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kurtovic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oyong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piera</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>IgM in human immunity to <italic toggle="yes">Plasmodium falciparum</italic> malaria</article-title><source>Sci. Adv.</source><year>2019</year><volume>5</volume><fpage>eaax4489</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aax4489</pub-id><pub-id pub-id-type="pmid">31579826</pub-id><pub-id pub-id-type="pmcid">PMC6760923</pub-id></element-citation></ref><ref id="B121-vaccines-09-01072"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barfod</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dalgaard</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Pleman</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Ofori</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Pleass</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hviid</surname><given-names>L.</given-names></name></person-group><article-title>Evasion of immunity to <italic toggle="yes">Plasmodium falciparum</italic> malaria by IgM masking of protective IgG epitopes in infected erythrocyte surface-exposed pfemp1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>12485</fpage><lpage>12490</lpage><pub-id pub-id-type="doi">10.1073/pnas.1103708108</pub-id><pub-id pub-id-type="pmid">21746929</pub-id><pub-id pub-id-type="pmcid">PMC3145728</pub-id></element-citation></ref><ref id="B122-vaccines-09-01072"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopp</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Diouf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sekar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tipton</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Plasmodium falciparum</italic>-specific IgM B cells dominate in children, expand with malaria and produce parasite inhibitory IgM</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.12.030049</pub-id><pub-id pub-id-type="pmcid">PMC7938365</pub-id><pub-id pub-id-type="pmid">33661303</pub-id></element-citation></ref><ref id="B123-vaccines-09-01072"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pied</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miltgen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nussler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matile</surname><given-names>H.</given-names></name><name name-style="western"><surname>Menegaux</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gentilini</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A malaria heat-shock-like determinant expressed on the infected hepatocyte surface is the target of antibody-dependent cell-mediated cytotoxic mechanisms by nonparenchymal liver cells</article-title><source>Eur. J. Immunol.</source><year>1990</year><volume>20</volume><fpage>1445</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1002/eji.1830200706</pub-id><pub-id pub-id-type="pmid">2201546</pub-id></element-citation></ref><ref id="B124-vaccines-09-01072"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Ware</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Narula</surname><given-names>A.</given-names></name><name name-style="western"><surname>Upadhyaya</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>D.E.</given-names></name></person-group><article-title>Merozoite surface protein 1 of plasmodium vivax induces a protective response against plasmodium cynomolgi challenge in rhesus monkeys</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>5936</fpage><lpage>5944</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.9.5936-5944.2005</pub-id><pub-id pub-id-type="pmid">16113314</pub-id><pub-id pub-id-type="pmcid">PMC1231099</pub-id></element-citation></ref><ref id="B125-vaccines-09-01072"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>L&#243;pez-Barrag&#225;n</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Felsenfeld</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.H.</given-names></name></person-group><article-title>Epigenetic control of the variable expression of a <italic toggle="yes">Plasmodium falciparum</italic> receptor protein for erythrocyte invasion</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>2224</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1073/pnas.0913396107</pub-id><pub-id pub-id-type="pmid">20080673</pub-id><pub-id pub-id-type="pmcid">PMC2836689</pub-id></element-citation></ref><ref id="B126-vaccines-09-01072"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>J.H.</given-names></name></person-group><article-title>Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the plasmodium vivax duffy binding protein</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>3164</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.6.3164-3171.2000</pub-id><pub-id pub-id-type="pmid">10816459</pub-id><pub-id pub-id-type="pmcid">PMC97553</pub-id></element-citation></ref><ref id="B127-vaccines-09-01072"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kinyanjui</surname><given-names>S.</given-names></name></person-group><article-title>Immune effector mechanisms in malaria</article-title><source>Parasite Immunol.</source><year>2006</year><volume>28</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.2006.00808.x</pub-id><pub-id pub-id-type="pmid">16438676</pub-id></element-citation></ref><ref id="B128-vaccines-09-01072"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouharoun-Tayoun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oeuvray</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lunel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Druilhe</surname><given-names>P.</given-names></name></person-group><article-title>Mechanisms underlying the monocyte-mediated antibody-dependent killing of <italic toggle="yes">Plasmodium falciparum</italic> asexual blood stages</article-title><source>J. Exp. Med.</source><year>1995</year><volume>182</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1084/jem.182.2.409</pub-id><pub-id pub-id-type="pmid">7629503</pub-id><pub-id pub-id-type="pmcid">PMC2192140</pub-id></element-citation></ref><ref id="B129-vaccines-09-01072"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouharoun-Tayoun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Attanath</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sabchareon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chongsuphajaisiddhi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Druilhe</surname><given-names>P.</given-names></name></person-group><article-title>Antibodies that protect humans against <italic toggle="yes">Plasmodium falciparum</italic> blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes</article-title><source>J. Exp. Med.</source><year>1990</year><volume>172</volume><fpage>1633</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1084/jem.172.6.1633</pub-id><pub-id pub-id-type="pmid">2258697</pub-id><pub-id pub-id-type="pmcid">PMC2188756</pub-id></element-citation></ref><ref id="B130-vaccines-09-01072"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Heatwole</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Wertheimer</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Guinet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Herrfeldt</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wellems</surname><given-names>T.E.</given-names></name></person-group><article-title>The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of <italic toggle="yes">Plasmodium falciparum</italic>-infected erythrocytes</article-title><source>Cell</source><year>1995</year><volume>82</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90055-1</pub-id><pub-id pub-id-type="pmid">7606788</pub-id></element-citation></ref><ref id="B131-vaccines-09-01072"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cloonan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waine</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lanzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A.</given-names></name></person-group><article-title>Stevor and rif are <italic toggle="yes">Plasmodium falciparum</italic> multicopy gene families which potentially encode variant antigens</article-title><source>Mol. Biochem. Parasitol.</source><year>1998</year><volume>97</volume><fpage>161</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/S0166-6851(98)00144-3</pub-id><pub-id pub-id-type="pmid">9879895</pub-id></element-citation></ref><ref id="B132-vaccines-09-01072"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyes</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kriek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>C.I.</given-names></name></person-group><article-title>Rifins: A second family of clonally variant proteins expressed on the surface of red cells infected with <italic toggle="yes">Plasmodium falciparum</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>9333</fpage><lpage>9338</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.16.9333</pub-id><pub-id pub-id-type="pmid">10430943</pub-id><pub-id pub-id-type="pmcid">PMC17783</pub-id></element-citation></ref><ref id="B133-vaccines-09-01072"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Beeson</surname><given-names>J.G.</given-names></name></person-group><article-title>Surface antigens of <italic toggle="yes">Plasmodium falciparum</italic>-infected erythrocytes as immune targets and malaria vaccine candidates</article-title><source>Cell. Mol. Life Sci.</source><year>2014</year><volume>71</volume><fpage>3633</fpage><lpage>3657</lpage><pub-id pub-id-type="doi">10.1007/s00018-014-1614-3</pub-id><pub-id pub-id-type="pmid">24691798</pub-id><pub-id pub-id-type="pmcid">PMC4160571</pub-id></element-citation></ref><ref id="B134-vaccines-09-01072"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>K.</given-names></name><name name-style="western"><surname>Piccoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abdi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tully</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Jarrossay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maina Ndungu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wambua</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens</article-title><source>Nature</source><year>2016</year><volume>529</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature16450</pub-id><pub-id pub-id-type="pmid">26700814</pub-id><pub-id pub-id-type="pmcid">PMC4869849</pub-id></element-citation></ref><ref id="B135-vaccines-09-01072"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Den Ham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shio</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kassa</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Fougeray</surname><given-names>S.</given-names></name></person-group><article-title>Malarial pigment hemozoin and the innate inflammatory response</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00025</pub-id><pub-id pub-id-type="pmid">24550911</pub-id><pub-id pub-id-type="pmcid">PMC3913902</pub-id></element-citation></ref><ref id="B136-vaccines-09-01072"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tachado</surname><given-names>S.D.</given-names></name></person-group><article-title>Regulation of host cell function by glycosylphosphatidylinositols of the parasitic protozoa</article-title><source>Immunol. Cell Biol.</source><year>1996</year><volume>74</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/icb.1996.89</pub-id><pub-id pub-id-type="pmid">8989594</pub-id></element-citation></ref><ref id="B137-vaccines-09-01072"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wahlgren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>The tatd-like dnase of plasmodium is a virulence factor and a potential malaria vaccine candidate</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>11537</fpage><pub-id pub-id-type="doi">10.1038/ncomms11537</pub-id><pub-id pub-id-type="pmid">27151551</pub-id><pub-id pub-id-type="pmcid">PMC4859065</pub-id></element-citation></ref><ref id="B138-vaccines-09-01072"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Banday</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandele</surname><given-names>A.</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ribas de Pouplana</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory responses</article-title><source>Nat. Commun.</source><year>2011</year><volume>2</volume><fpage>530</fpage><pub-id pub-id-type="doi">10.1038/ncomms1522</pub-id><pub-id pub-id-type="pmid">22068597</pub-id></element-citation></ref><ref id="B139-vaccines-09-01072"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Siomos</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Seeberger</surname><given-names>P.H.</given-names></name></person-group><article-title>Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1038/nature00937</pub-id><pub-id pub-id-type="pmid">12181569</pub-id></element-citation></ref><ref id="B140-vaccines-09-01072"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Jong</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Tebeje</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Meerstein-Kessel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tadesse</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Jore</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bousema</surname><given-names>T.</given-names></name></person-group><article-title>Immunity against sexual stage <italic toggle="yes">Plasmodium falciparum</italic> and plasmodium vivax parasites</article-title><source>Immunol. Rev.</source><year>2020</year><volume>293</volume><fpage>190</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/imr.12828</pub-id><pub-id pub-id-type="pmid">31840844</pub-id><pub-id pub-id-type="pmcid">PMC6973022</pub-id></element-citation></ref><ref id="B141-vaccines-09-01072"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dantzler</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ngotho</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>W.J.R.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rijpma</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Niz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nilsson Bark</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Jore</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Raaijmakers</surname><given-names>T.K.</given-names></name><etal/></person-group><article-title>Naturally acquired immunity against immature <italic toggle="yes">Plasmodium falciparum</italic> gametocytes</article-title><source>Sci. Transl. Med.</source><year>2019</year><volume>11</volume><fpage>eaav3963</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aav3963</pub-id><pub-id pub-id-type="pmid">31167926</pub-id><pub-id pub-id-type="pmcid">PMC6653583</pub-id></element-citation></ref><ref id="B142-vaccines-09-01072"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Read</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lensen</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Begarnie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>R.</given-names></name></person-group><article-title>Transmission-blocking antibodies against multiple, non-variant target epitopes of the <italic toggle="yes">Plasmodium falciparum</italic> gamete surface antigen Pfs230 are all complement-fixing</article-title><source>Parasite Immunol.</source><year>1994</year><volume>16</volume><fpage>511</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.1994.tb00305.x</pub-id><pub-id pub-id-type="pmid">7532850</pub-id></element-citation></ref><ref id="B143-vaccines-09-01072"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blagborough</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sinden</surname><given-names>R.E.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium berghei</italic> HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5187</fpage><lpage>5194</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.069</pub-id><pub-id pub-id-type="pmid">19596419</pub-id></element-citation></ref><ref id="B144-vaccines-09-01072"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volohonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Steinert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Levashina</surname><given-names>E.A.</given-names></name></person-group><article-title>Focusing on complement in the antiparasitic defense of mosquitoes</article-title><source>Trends Parasitol.</source><year>2010</year><volume>26</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2009.10.003</pub-id><pub-id pub-id-type="pmid">19853513</pub-id></element-citation></ref><ref id="B145-vaccines-09-01072"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sauerwein</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Richie</surname><given-names>T.L.</given-names></name></person-group><article-title>Malaria vaccines getting close to clinical reality</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>7423</fpage><lpage>7424</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.10.092</pub-id><pub-id pub-id-type="pmid">26518403</pub-id></element-citation></ref><ref id="B146-vaccines-09-01072"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwenti</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Kukwah</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kwenti</surname><given-names>T.D.B.</given-names></name><name name-style="western"><surname>Nyassa</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Dilonga</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Enow-Orock</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tendongfor</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anong</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Wanji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Njunda</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Comparative analysis of IgG and IgG subclasses against <italic toggle="yes">Plasmodium falciparum</italic> MSP-1<sub>19</sub> in children from five contrasting bioecological zones of cameroon</article-title><source>Malar. J.</source><year>2019</year><volume>18</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/s12936-019-2654-9</pub-id><pub-id pub-id-type="pmid">30670064</pub-id><pub-id pub-id-type="pmcid">PMC6341684</pub-id></element-citation></ref><ref id="B147-vaccines-09-01072"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Santano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jairoce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ubillos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dosoo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Diez-Padrisa</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Differential patterns of IgG subclass responses to <italic toggle="yes">Plasmodium falciparum</italic> antigens in relation to malaria protection and RTS,S vaccination</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>439</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00439</pub-id><pub-id pub-id-type="pmid">30930896</pub-id><pub-id pub-id-type="pmcid">PMC6428712</pub-id></element-citation></ref><ref id="B148-vaccines-09-01072"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanisic</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>McCallum</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Michon</surname><given-names>P.</given-names></name><name name-style="western"><surname>King</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Schoepflin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gilson</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Immunoglobulin g subclass-specific responses against <italic toggle="yes">Plasmodium falciparum</italic> merozoite antigens are associated with control of parasitemia and protection from symptomatic illness</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>1165</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1128/IAI.01129-08</pub-id><pub-id pub-id-type="pmid">19139189</pub-id><pub-id pub-id-type="pmcid">PMC2643653</pub-id></element-citation></ref><ref id="B149-vaccines-09-01072"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abagna</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Acquah</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Okonu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aryee</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amoah</surname><given-names>L.E.</given-names></name></person-group><article-title>Assessment of the quality and quantity of naturally induced antibody responses to EBA175RIII&#8211;V in ghanaian children living in two communities with varying malaria transmission patterns</article-title><source>Malar. J.</source><year>2018</year><volume>17</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s12936-017-2167-3</pub-id><pub-id pub-id-type="pmid">29310662</pub-id><pub-id pub-id-type="pmcid">PMC5759240</pub-id></element-citation></ref><ref id="B150-vaccines-09-01072"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kana</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Garcia-Senosiain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Tiendrebeogo</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Chourasia</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cytophilic antibodies against key <italic toggle="yes">Plasmodium falciparum</italic> blood stage antigens contribute to protection against clinical malaria in a high transmission region of eastern India</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>956</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy258</pub-id><pub-id pub-id-type="pmid">29733355</pub-id></element-citation></ref><ref id="B151-vaccines-09-01072"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lusingu</surname><given-names>J.P.A.</given-names></name><name name-style="western"><surname>Vestergaard</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Alifrangis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mmbando</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kitua</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Lemnge</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Theander</surname><given-names>T.G.</given-names></name></person-group><article-title>Cytophilic antibodies to <italic toggle="yes">Plasmodium falciparum</italic> glutamate rich protein are associated with malaria protection in an area of holoendemic transmission</article-title><source>Malar. J.</source><year>2005</year><volume>4</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-4-48</pub-id><pub-id pub-id-type="pmid">16194274</pub-id><pub-id pub-id-type="pmcid">PMC1262760</pub-id></element-citation></ref><ref id="B152-vaccines-09-01072"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oesterholt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huismans</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kusi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Milet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Badaut</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gaye</surname><given-names>O.</given-names></name><name name-style="western"><surname>Roeffen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Remarque</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Sauerwein</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The quantity and quality of african children&#8217;s IgG responses to merozoite surface antigens reflect protection against <italic toggle="yes">Plasmodium falciparum</italic> malaria</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7590</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007590</pub-id><pub-id pub-id-type="pmid">19859562</pub-id><pub-id pub-id-type="pmcid">PMC2763201</pub-id></element-citation></ref><ref id="B153-vaccines-09-01072"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Souza</surname><given-names>J.B.</given-names></name></person-group><article-title>Protective immunity against malaria after vaccination</article-title><source>Parasite Immunol.</source><year>2014</year><volume>36</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1111/pim.12086</pub-id><pub-id pub-id-type="pmid">24188045</pub-id></element-citation></ref><ref id="B154-vaccines-09-01072"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinkevych</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petravic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chelimo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kazura</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>M.P.</given-names></name></person-group><article-title>The dynamics of naturally acquired immunity to <italic toggle="yes">Plasmodium falciparum</italic> infection</article-title><source>PLoS Comp. Biol.</source><year>2012</year><volume>8</volume><elocation-id>e1002729</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002729</pub-id><pub-id pub-id-type="pmcid">PMC3475668</pub-id><pub-id pub-id-type="pmid">23093922</pub-id></element-citation></ref><ref id="B155-vaccines-09-01072"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Pregibon</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Sumba</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Narum</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Schluchter</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Kazura</surname><given-names>J.W.</given-names></name></person-group><article-title>Correlation of high levels of antibodies to multiple pre-erythrocytic <italic toggle="yes">Plasmodium falciparum</italic> antigens and protection from infection</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2005</year><volume>73</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2005.73.222</pub-id><pub-id pub-id-type="pmid">16014863</pub-id></element-citation></ref><ref id="B156-vaccines-09-01072"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Tande</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sumba</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Min</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Kazura</surname><given-names>J.W.</given-names></name></person-group><article-title>Antibodies to pre-erythrocytic <italic toggle="yes">Plasmodium falciparum</italic> antigens and risk of clinical malaria in Kenyan children</article-title><source>J. Infect. Dis.</source><year>2008</year><volume>197</volume><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1086/526787</pub-id><pub-id pub-id-type="pmid">18275273</pub-id><pub-id pub-id-type="pmcid">PMC2607240</pub-id></element-citation></ref><ref id="B157-vaccines-09-01072"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobbs</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Dent</surname><given-names>A.E.</given-names></name></person-group><article-title>Plasmodium malaria and antimalarial antibodies in the first year of life</article-title><source>Parasitology</source><year>2016</year><volume>143</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1017/S0031182015001626</pub-id><pub-id pub-id-type="pmid">26743626</pub-id><pub-id pub-id-type="pmcid">PMC4825094</pub-id></element-citation></ref><ref id="B158-vaccines-09-01072"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osier</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Fegan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Polley</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Murungi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Verra</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tetteh</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mwangi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bull</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>Breadth and magnitude of antibody responses to multiple <italic toggle="yes">Plasmodium falciparum</italic> merozoite antigens are associated with protection from clinical malaria</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>2240</fpage><lpage>2248</lpage><pub-id pub-id-type="doi">10.1128/IAI.01585-07</pub-id><pub-id pub-id-type="pmid">18316390</pub-id><pub-id pub-id-type="pmcid">PMC2346713</pub-id></element-citation></ref><ref id="B159-vaccines-09-01072"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dent</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moormann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sumba</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Vulule</surname><given-names>J.</given-names></name><name name-style="western"><surname>Babineau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Randall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>D.H.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Plasmodium falciparum</italic> protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><fpage>1429</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv224</pub-id><pub-id pub-id-type="pmid">25883384</pub-id><pub-id pub-id-type="pmcid">PMC4601912</pub-id></element-citation></ref><ref id="B160-vaccines-09-01072"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanisic</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Koinari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Javati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kiniboro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kazura</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Acquisition of antibodies against <italic toggle="yes">Plasmodium falciparum</italic> merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>646</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1128/IAI.02398-14</pub-id><pub-id pub-id-type="pmid">25422270</pub-id><pub-id pub-id-type="pmcid">PMC4294228</pub-id></element-citation></ref><ref id="B161-vaccines-09-01072"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusi</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Manu</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Manful Gwira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kyei-Baafour</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Amponsah</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Remarque</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Faber</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kocken</surname><given-names>C.H.M.</given-names></name><name name-style="western"><surname>Dodoo</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of northern Ghana</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0185303</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185303</pub-id><pub-id pub-id-type="pmid">28945794</pub-id><pub-id pub-id-type="pmcid">PMC5612719</pub-id></element-citation></ref><ref id="B162-vaccines-09-01072"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGregor</surname><given-names>I.A.</given-names></name></person-group><article-title>The Passive Transfer of Human Malarial Immunity</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1964</year><volume>13</volume><fpage>237</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1964.13.237</pub-id><pub-id pub-id-type="pmid">14104823</pub-id></element-citation></ref><ref id="B163-vaccines-09-01072"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>S.</given-names></name></person-group><article-title>Gamma-globulin and acquired immunity to human malaria</article-title><source>Nature</source><year>1961</year><volume>192</volume><fpage>733</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/192733a0</pub-id><pub-id pub-id-type="pmid">13880318</pub-id></element-citation></ref><ref id="B164-vaccines-09-01072"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Genton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Moorthy</surname><given-names>V.S.</given-names></name></person-group><article-title>A review of malaria vaccine clinical projects based on the who rainbow table</article-title><source>Malar. J.</source><year>2012</year><volume>11</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-11-11</pub-id><pub-id pub-id-type="pmid">22230255</pub-id><pub-id pub-id-type="pmcid">PMC3286401</pub-id></element-citation></ref><ref id="B165-vaccines-09-01072"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genton</surname><given-names>B.</given-names></name></person-group><article-title>Malaria vaccines: A toy for travelers or a tool for eradication?</article-title><source>Expert Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>597</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.5.597</pub-id><pub-id pub-id-type="pmid">18564015</pub-id></element-citation></ref><ref id="B166-vaccines-09-01072"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Angov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name></person-group><article-title>Recent advances in recombinant protein-based malaria vaccines</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>7433</fpage><lpage>7443</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.093</pub-id><pub-id pub-id-type="pmid">26458807</pub-id><pub-id pub-id-type="pmcid">PMC4687528</pub-id></element-citation></ref><ref id="B167-vaccines-09-01072"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coppel</surname><given-names>R.L.</given-names></name></person-group><article-title>Vaccinating with the genome: A sisyphean task?</article-title><source>Trends Parasitol.</source><year>2009</year><volume>25</volume><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2009.02.006</pub-id><pub-id pub-id-type="pmid">19359219</pub-id></element-citation></ref><ref id="B168-vaccines-09-01072"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Washburn</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Raine</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Grainger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Moch</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Muster</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sacci</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Tabb</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>A proteomic view of the <italic toggle="yes">Plasmodium falciparum</italic> life cycle</article-title><source>Nature</source><year>2002</year><volume>419</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1038/nature01107</pub-id><pub-id pub-id-type="pmid">12368866</pub-id></element-citation></ref><ref id="B169-vaccines-09-01072"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>King</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Long</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Malaria vaccines: Recent advances and new horizons</article-title><source>Cell Host Microbe</source><year>2018</year><volume>24</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.06.008</pub-id><pub-id pub-id-type="pmid">30001524</pub-id><pub-id pub-id-type="pmcid">PMC6054918</pub-id></element-citation></ref><ref id="B170-vaccines-09-01072"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Valiante</surname><given-names>N.M.</given-names></name></person-group><article-title>Recent advances in the discovery and delivery of vaccine adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1038/nrd1176</pub-id><pub-id pub-id-type="pmid">12951579</pub-id><pub-id pub-id-type="pmcid">PMC7097252</pub-id></element-citation></ref><ref id="B171-vaccines-09-01072"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name></person-group><article-title>The perfect mix: Recent progress in adjuvant research</article-title><source>Nat. Rev. Microbiol.</source><year>2007</year><volume>5</volume><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1681</pub-id><pub-id pub-id-type="pmid">17558426</pub-id></element-citation></ref><ref id="B172-vaccines-09-01072"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine adjuvants: Putting innate immunity to work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="B173-vaccines-09-01072"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Key roles of adjuvants in modern vaccines</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1597</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1038/nm.3409</pub-id><pub-id pub-id-type="pmid">24309663</pub-id></element-citation></ref><ref id="B174-vaccines-09-01072"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>S.K.M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name></person-group><article-title>An overview of novel adjuvants designed for improving vaccine efficacy</article-title><source>Trends Pharmacol. Sci.</source><year>2017</year><volume>38</volume><fpage>771</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.06.002</pub-id><pub-id pub-id-type="pmid">28668223</pub-id></element-citation></ref><ref id="B175-vaccines-09-01072"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Doritchamou</surname><given-names>J.Y.A.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>P.E.</given-names></name></person-group><article-title>Advances in malaria vaccine development: Report from the 2017 malaria vaccine symposium</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0035-3</pub-id><pub-id pub-id-type="pmid">29522056</pub-id><pub-id pub-id-type="pmcid">PMC5709382</pub-id></element-citation></ref><ref id="B176-vaccines-09-01072"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Type 1/type 2 immunity in infectious diseases</article-title><source>Clin. Infect. Dis.</source><year>2001</year><volume>32</volume><fpage>76</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1086/317537</pub-id><pub-id pub-id-type="pmid">11118387</pub-id></element-citation></ref><ref id="B177-vaccines-09-01072"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Obeng-Adjei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Crompton</surname><given-names>P.D.</given-names></name></person-group><article-title>Emerging concepts in t follicular helper cell responses to malaria</article-title><source>Int. J. Parasitol.</source><year>2017</year><volume>47</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2016.09.004</pub-id><pub-id pub-id-type="pmid">27866903</pub-id></element-citation></ref><ref id="B178-vaccines-09-01072"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radtke</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Riteau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scaria</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kelnhofer</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>P.</given-names></name></person-group><article-title>Adjuvant and carrier protein-dependent t-cell priming promotes a robust antibody response against the <italic toggle="yes">Plasmodium falciparum</italic> Pfs25 vaccine candidate</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>40312</fpage><pub-id pub-id-type="doi">10.1038/srep40312</pub-id><pub-id pub-id-type="pmid">28091576</pub-id><pub-id pub-id-type="pmcid">PMC5238395</pub-id></element-citation></ref><ref id="B179-vaccines-09-01072"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figueiredo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>P.A.C.</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Kano</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Tada</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Martins-Filho</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>D.</given-names></name><etal/></person-group><article-title>T follicular helper cells regulate the activation of B lymphocytes and antibody production during plasmodium vivax infection</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><elocation-id>e1006484</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006484</pub-id><pub-id pub-id-type="pmid">28700710</pub-id><pub-id pub-id-type="pmcid">PMC5519210</pub-id></element-citation></ref><ref id="B180-vaccines-09-01072"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Yadava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand T<sub>fh</sub> cells and promote germinal center induction</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>1080</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1073/pnas.1112648109</pub-id><pub-id pub-id-type="pmid">22247289</pub-id><pub-id pub-id-type="pmcid">PMC3268296</pub-id></element-citation></ref><ref id="B181-vaccines-09-01072"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Siau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chotivanich</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gruner</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mayxay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sriprawat</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Neutralizing antibodies against <italic toggle="yes">Plasmodium falciparum</italic> associated with successful cure after drug therapy</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0159347</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0159347</pub-id><pub-id pub-id-type="pmid">27427762</pub-id><pub-id pub-id-type="pmcid">PMC4948787</pub-id></element-citation></ref><ref id="B182-vaccines-09-01072"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtovic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Behet</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reiling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chelimo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dent</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kazura</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Sauerwein</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>F.J.I.</given-names></name><etal/></person-group><article-title>Human antibodies activate complement against <italic toggle="yes">Plasmodium falciparum</italic> sporozoites, and are associated with protection against malaria in children</article-title><source>BMC Med.</source><year>2018</year><volume>16</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-018-1054-2</pub-id><pub-id pub-id-type="pmid">29706136</pub-id><pub-id pub-id-type="pmcid">PMC5925837</pub-id></element-citation></ref><ref id="B183-vaccines-09-01072"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radosevic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lemckert</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gillissen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Warnar</surname><given-names>C.</given-names></name><name name-style="western"><surname>von Eyben</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pau</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Goudsmit</surname><given-names>J.</given-names></name></person-group><article-title>The Th1 immune response to <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>1687</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1128/CVI.00311-10</pub-id><pub-id pub-id-type="pmid">20826614</pub-id><pub-id pub-id-type="pmcid">PMC2976088</pub-id></element-citation></ref><ref id="B184-vaccines-09-01072"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tom</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Albin</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Manna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Steinhardt</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Esser-Kahn</surname><given-names>A.P.</given-names></name></person-group><article-title>Applications of immunomodulatory immune synergies to adjuvant discovery and vaccine development</article-title><source>Trends Biotechnol.</source><year>2019</year><volume>37</volume><fpage>373</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2018.10.004</pub-id><pub-id pub-id-type="pmid">30470547</pub-id></element-citation></ref><ref id="B185-vaccines-09-01072"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name></person-group><article-title>Correlates of adjuvanticity: A review on adjuvants in licensed vaccines</article-title><source>Semin. Immunol.</source><year>2018</year><volume>39</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id><pub-id pub-id-type="pmid">29801750</pub-id></element-citation></ref><ref id="B186-vaccines-09-01072"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name></person-group><article-title>From discovery to licensure, the adjuvant system story</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1225635</pub-id><pub-id pub-id-type="pmid">27636098</pub-id><pub-id pub-id-type="pmcid">PMC5287309</pub-id></element-citation></ref><ref id="B187-vaccines-09-01072"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Long</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Holder</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name></person-group><article-title>Effective induction of high-titer antibodies by viral vector vaccines</article-title><source>Nat. Med.</source><year>2008</year><volume>14</volume><fpage>819</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/nm.1850</pub-id><pub-id pub-id-type="pmid">18660818</pub-id><pub-id pub-id-type="pmcid">PMC4822545</pub-id></element-citation></ref><ref id="B188-vaccines-09-01072"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>HogenEsch</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Optimizing the utilization of aluminum adjuvants in vaccines: You might just get what you want</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1038/s41541-018-0089-x</pub-id><pub-id pub-id-type="pmid">30323958</pub-id><pub-id pub-id-type="pmcid">PMC6180056</pub-id></element-citation></ref><ref id="B189-vaccines-09-01072"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aimanianda</surname><given-names>V.</given-names></name><name name-style="western"><surname>Haensler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lacroix-Desmazes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaveri</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Bayry</surname><given-names>J.</given-names></name></person-group><article-title>Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants</article-title><source>Trends Pharmacol. Sci.</source><year>2009</year><volume>30</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2009.03.005</pub-id><pub-id pub-id-type="pmid">19439372</pub-id></element-citation></ref><ref id="B190-vaccines-09-01072"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mata</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salvador</surname><given-names>A.</given-names></name><name name-style="western"><surname>Igartua</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Pedraz</surname><given-names>J.L.</given-names></name></person-group><article-title>Malaria vaccine adjuvants: Latest update and challenges in preclinical and clinical research</article-title><source>Biomed Res. Int.</source><year>2013</year><volume>2013</volume><fpage>282913</fpage><pub-id pub-id-type="doi">10.1155/2013/282913</pub-id><pub-id pub-id-type="pmid">23710439</pub-id><pub-id pub-id-type="pmcid">PMC3655447</pub-id></element-citation></ref><ref id="B191-vaccines-09-01072"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Near</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Stowers</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kaslow</surname><given-names>D.C.</given-names></name></person-group><article-title>Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>692</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.2.692-701.2002</pub-id><pub-id pub-id-type="pmid">11796601</pub-id><pub-id pub-id-type="pmcid">PMC127724</pub-id></element-citation></ref><ref id="B192-vaccines-09-01072"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roeffen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>M.</given-names></name><name name-style="western"><surname>van de Vegte-Bolmer</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Gemert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>T.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sevargave</surname><given-names>L.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kaviraj</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Transmission-blocking activity of antibodies to <italic toggle="yes">Plasmodium falciparum</italic> GLURP.10C chimeric protein formulated in different adjuvants</article-title><source>Malar. J.</source><year>2015</year><volume>14</volume><fpage>443</fpage><pub-id pub-id-type="doi">10.1186/s12936-015-0972-0</pub-id><pub-id pub-id-type="pmid">26552428</pub-id><pub-id pub-id-type="pmcid">PMC4640242</pub-id></element-citation></ref><ref id="B193-vaccines-09-01072"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nalla</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pallavi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Miryala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Mahboob</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>M.S.K.</given-names></name></person-group><article-title>Design, synthesis and immunological evaluation of 1,2,3-triazole-tethered carbohydrate&#8211;Pam<sub>3</sub>Cys conjugates as TLR2 agonists</article-title><source>Biorg. Med. Chem.</source><year>2015</year><volume>23</volume><fpage>5846</fpage><lpage>5855</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.06.070</pub-id><pub-id pub-id-type="pmid">26234903</pub-id></element-citation></ref><ref id="B194-vaccines-09-01072"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhunia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pallavi</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>M.S.K.</given-names></name></person-group><article-title>Design, synthesis, and evaluation of novel 1,2,3-triazole-tethered glycolipids as vaccine adjuvants</article-title><source>Arch. Pharm.</source><year>2015</year><volume>348</volume><fpage>689</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1002/ardp.201500143</pub-id><pub-id pub-id-type="pmid">26332372</pub-id></element-citation></ref><ref id="B195-vaccines-09-01072"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chioato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Noseda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Felix</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fitoussi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>A.</given-names></name></person-group><article-title>Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1&#946;-blocking antibody canakinumab: Results of an open-label, parallel group, randomized, single-center study</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>1952</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.1128/CVI.00175-10</pub-id><pub-id pub-id-type="pmid">20962212</pub-id><pub-id pub-id-type="pmcid">PMC3008193</pub-id></element-citation></ref><ref id="B196-vaccines-09-01072"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lindgren</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sandgren</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Francica</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>N.J.</given-names></name><etal/></person-group><article-title>Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake</article-title><source>Sci. Transl. Med.</source><year>2017</year><volume>9</volume><fpage>eaal2094</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aal2094</pub-id><pub-id pub-id-type="pmid">28592561</pub-id></element-citation></ref><ref id="B197-vaccines-09-01072"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Weilenman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Audran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roggero</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bonelo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tiercy</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Spertini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name></person-group><article-title>A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte immune response in humans. Implications for vaccination strategies</article-title><source>Eur. J. Immunol.</source><year>2001</year><volume>31</volume><fpage>1989</fpage><lpage>1998</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1521-4141(200107)31:7&amp;#x0003c;1989::AID-IMMU1989&amp;#x0003e;3.0.CO;2-M</pub-id><pub-id pub-id-type="pmid">11449351</pub-id></element-citation></ref><ref id="B198-vaccines-09-01072"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirima</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Richert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chene</surname><given-names>A.</given-names></name><name name-style="western"><surname>Konate</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Campion</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dechavanne</surname><given-names>S.</given-names></name><name name-style="western"><surname>Semblat</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Benhamouda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bahuaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loulergue</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Primvac vaccine adjuvanted with alhydrogel or GLA-SE to prevent placental malaria: A first-in-human, randomised, double-blind, placebo-controlled study</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>585</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30739-X</pub-id><pub-id pub-id-type="pmid">32032566</pub-id></element-citation></ref><ref id="B199-vaccines-09-01072"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mendis</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Molineaux</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A.</given-names></name></person-group><article-title>Malaria transmission-blocking vaccines&#8212;How can their development be supported?</article-title><source>Nat. Med.</source><year>2000</year><volume>6</volume><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/73062</pub-id><pub-id pub-id-type="pmid">10700212</pub-id></element-citation></ref><ref id="B200-vaccines-09-01072"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Healy</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Assadou</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Kone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sissoko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tembine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guindo</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Doucoure</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niare</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of Pfs25h-EPA/Alhydrogel, a transmission-blocking vaccine against <italic toggle="yes">Plasmodium falciparum</italic>: A randomised, double-blind, comparator-controlled, dose-escalation study in healthy malian adults</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>969</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30344-X</pub-id><pub-id pub-id-type="pmid">30061051</pub-id><pub-id pub-id-type="pmcid">PMC6287938</pub-id></element-citation></ref><ref id="B201-vaccines-09-01072"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>New generation adjuvants&#8211;from empiricism to rational design</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>B14</fpage><lpage>B20</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.01.088</pub-id><pub-id pub-id-type="pmid">26022561</pub-id></element-citation></ref><ref id="B202-vaccines-09-01072"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoriadis</surname><given-names>G.</given-names></name></person-group><article-title>Immunological adjuvants: A role for liposomes</article-title><source>Immunol. Today</source><year>1990</year><volume>11</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/0167-5699(90)90034-7</pub-id><pub-id pub-id-type="pmid">2186746</pub-id></element-citation></ref><ref id="B203-vaccines-09-01072"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peek</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Middaugh</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Berkland</surname><given-names>C.</given-names></name></person-group><article-title>Nanotechnology in vaccine delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.05.017</pub-id><pub-id pub-id-type="pmid">18325628</pub-id><pub-id pub-id-type="pmcid">PMC7103321</pub-id></element-citation></ref><ref id="B204-vaccines-09-01072"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenkrands</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vingsbo-Lundberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bundgaard</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Lindenstrom</surname><given-names>T.</given-names></name><name name-style="western"><surname>Enouf</surname><given-names>V.</given-names></name><name name-style="western"><surname>van der Werf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>E.M.</given-names></name></person-group><article-title>Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6283</fpage><lpage>6291</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.040</pub-id><pub-id pub-id-type="pmid">21722683</pub-id></element-citation></ref><ref id="B205-vaccines-09-01072"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Laupeze</surname><given-names>B.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hergli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name></person-group><article-title>Adjuvant system AS01: Helping to overcome the challenges of modern vaccines</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id><pub-id pub-id-type="pmid">27448771</pub-id></element-citation></ref><ref id="B206-vaccines-09-01072"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herve</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chalon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Helden</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Genito</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>N.C.</given-names></name><etal/></person-group><article-title>Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early ifngamma response promoting vaccine immunogenicity</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0027-3</pub-id><pub-id pub-id-type="pmid">29263880</pub-id><pub-id pub-id-type="pmcid">PMC5627273</pub-id></element-citation></ref><ref id="B207-vaccines-09-01072"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fierens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fochesato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dendouga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Langlet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name><etal/></person-group><article-title>Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>1920</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400948</pub-id><pub-id pub-id-type="pmid">25024381</pub-id></element-citation></ref><ref id="B208-vaccines-09-01072"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Forgus</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Boever</surname><given-names>F.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Demoitie</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mettens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ledent</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Improved CD4<sup>+</sup> T cell responses to mycobacterium tuberculosis in ppd-negative adults by M72/AS01 as compared to the M72/AS02 and MTB72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>2196</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.05.035</pub-id><pub-id pub-id-type="pmid">22643213</pub-id></element-citation></ref><ref id="B209-vaccines-09-01072"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Vedvick</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Angov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines</article-title><source>Clin. Vaccine Immunol.</source><year>2012</year><volume>19</volume><fpage>1633</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1128/CVI.00235-12</pub-id><pub-id pub-id-type="pmid">22896687</pub-id><pub-id pub-id-type="pmcid">PMC3485880</pub-id></element-citation></ref><ref id="B210-vaccines-09-01072"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallikkuth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaudhury</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jongert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wille-Reece</surname><given-names>U.</given-names></name><name name-style="western"><surname>Pahwa</surname><given-names>S.</given-names></name></person-group><article-title>A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved t follicular helper and B cell responses</article-title><source>eLife</source><year>2020</year><volume>9</volume><fpage>e51889</fpage><pub-id pub-id-type="doi">10.7554/eLife.51889</pub-id><pub-id pub-id-type="pmid">32342859</pub-id><pub-id pub-id-type="pmcid">PMC7213985</pub-id></element-citation></ref><ref id="B211-vaccines-09-01072"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marty-Roix</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vladimer</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Buglione-Corbett</surname><given-names>R.</given-names></name><name name-style="western"><surname>West</surname><given-names>K.</given-names></name><name name-style="western"><surname>MacMicking</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Chee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants</article-title><source>J. Biol. Chem.</source><year>2016</year><volume>291</volume><fpage>1123</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.683011</pub-id><pub-id pub-id-type="pmid">26555265</pub-id><pub-id pub-id-type="pmcid">PMC4714196</pub-id></element-citation></ref><ref id="B212-vaccines-09-01072"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regules</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name></person-group><article-title>The RTS,S vaccine candidate for malaria</article-title><source>Expert Rev. Vaccines</source><year>2011</year><volume>10</volume><fpage>589</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1586/erv.11.57</pub-id><pub-id pub-id-type="pmid">21604980</pub-id></element-citation></ref><ref id="B213-vaccines-09-01072"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moutaftsi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Windish</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e16333</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0016333</pub-id><pub-id pub-id-type="pmid">21298114</pub-id><pub-id pub-id-type="pmcid">PMC3027669</pub-id></element-citation></ref><ref id="B214-vaccines-09-01072"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sravanthi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pallavi</surname><given-names>M.C.P.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Sathyabama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H.M.S.</given-names></name></person-group><article-title>Oleic acid nanoemulsion for nasal vaccination: Impact on adjuvanticity based immune response</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2015</year><volume>28</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2015.05.007</pub-id></element-citation></ref><ref id="B215-vaccines-09-01072"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantipakala</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Vemireddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miryala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>M.S.</given-names></name></person-group><article-title>Squalane-based emulsion vaccine delivery system: Composition with murabutide activate Th1 response</article-title><source>Pharm. Dev. Technol.</source><year>2019</year><volume>24</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1080/10837450.2018.1469150</pub-id><pub-id pub-id-type="pmid">29688119</pub-id></element-citation></ref><ref id="B216-vaccines-09-01072"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosca</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tritto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muzzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iavarone</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group><article-title>Molecular and cellular signatures of human vaccine adjuvants</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>10501</fpage><lpage>10506</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804699105</pub-id><pub-id pub-id-type="pmid">18650390</pub-id><pub-id pub-id-type="pmcid">PMC2483233</pub-id></element-citation></ref><ref id="B217-vaccines-09-01072"><label>217.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barchfeld</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Chernoff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Hoogevest</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Nest</surname><given-names>G.</given-names></name></person-group><source>Vaccine Design</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>1995</year><fpage>277</fpage><lpage>296</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4615-1823-5_10</pub-id><pub-id pub-id-type="pmid">7551221</pub-id></element-citation></ref><ref id="B218-vaccines-09-01072"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Giudice</surname><given-names>G.D.</given-names></name></person-group><article-title>Novel adjuvants for vaccines</article-title><source>Curr. Med. Chem.</source><year>2005</year><volume>4</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.2174/1568014053507113</pub-id></element-citation></ref><ref id="B219-vaccines-09-01072"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wack</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Hilbert</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Manini</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nuti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tavarini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scheffczik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ugozzoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kazzaz</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.054</pub-id><pub-id pub-id-type="pmid">18162266</pub-id></element-citation></ref><ref id="B220-vaccines-09-01072"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seubert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A.</given-names></name></person-group><article-title>The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells</article-title><source>J. Immunol.</source><year>2008</year><volume>180</volume><fpage>5402</fpage><lpage>5412</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.8.5402</pub-id><pub-id pub-id-type="pmid">18390722</pub-id></element-citation></ref><ref id="B221-vaccines-09-01072"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudner</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Ronconi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tortoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kazzaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><article-title>MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020)</article-title><source>Pharm. Res.</source><year>2009</year><volume>26</volume><fpage>1477</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1007/s11095-009-9859-5</pub-id><pub-id pub-id-type="pmid">19255727</pub-id></element-citation></ref><ref id="B222-vaccines-09-01072"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roestenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Remarque</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hermsen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blythman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Imoukhuede</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jepsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Faber</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant <italic toggle="yes">Plasmodium falciparum</italic> AMA1 malaria vaccine adjuvanted with alhydrogel&#8482;, montanide ISA 720 or AS02</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e3960</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003960</pub-id><pub-id pub-id-type="pmid">19093004</pub-id><pub-id pub-id-type="pmcid">PMC2602972</pub-id></element-citation></ref><ref id="B223-vaccines-09-01072"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brando</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ware</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Freyberger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kathcart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cayphas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Demoitie</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mettens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>D.E.</given-names></name></person-group><article-title>Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>838</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1128/IAI.01075-06</pub-id><pub-id pub-id-type="pmid">17101665</pub-id><pub-id pub-id-type="pmcid">PMC1828476</pub-id></element-citation></ref><ref id="B224-vaccines-09-01072"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lurati-Ruiz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Genton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blythman</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Reymond</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corradin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Spertini</surname><given-names>F.</given-names></name></person-group><article-title>The synthetic <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite peptide PFCS102 as a malaria vaccine candidate: A randomized controlled phase I trial</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7304</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007304</pub-id><pub-id pub-id-type="pmid">19798415</pub-id><pub-id pub-id-type="pmcid">PMC2749339</pub-id></element-citation></ref><ref id="B225-vaccines-09-01072"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Krzych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwenk</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Debebe</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pinelis</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>200</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1086/600120</pub-id><pub-id pub-id-type="pmid">19569965</pub-id></element-citation></ref><ref id="B226-vaccines-09-01072"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polhemus</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Remich</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ogutu</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Waitumbi</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Apollo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e6465</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006465</pub-id><pub-id pub-id-type="pmid">19649245</pub-id><pub-id pub-id-type="pmcid">PMC2714466</pub-id></element-citation></ref><ref id="B227-vaccines-09-01072"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Schwenk</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Krzych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the walter reed army institute of research</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>2191</fpage><lpage>2202</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.02.048</pub-id><pub-id pub-id-type="pmid">18387719</pub-id></element-citation></ref><ref id="B228-vaccines-09-01072"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Sacarlal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aponte</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Macete</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aide</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sigauque</surname><given-names>B.</given-names></name><name name-style="western"><surname>Milman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mandomando</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bassat</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Duration of protection with RTS,S/AS02A malaria vaccine in prevention of <italic toggle="yes">Plasmodium falciparum</italic> disease in mozambican children: Single-blind extended follow-up of a randomised controlled trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>2012</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67669-6</pub-id><pub-id pub-id-type="pmid">16338450</pub-id></element-citation></ref><ref id="B229-vaccines-09-01072"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lievens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jongert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ballou</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name></person-group><article-title>Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: Randomized, double-blind study in malaria-naive adults</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>2211</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.4161/hv.29375</pub-id><pub-id pub-id-type="pmcid">PMC4896765</pub-id><pub-id pub-id-type="pmid">25424924</pub-id></element-citation></ref><ref id="B230-vaccines-09-01072"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoute</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Krzych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wellde</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>T.</given-names></name><name name-style="western"><surname>White</surname><given-names>K.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schwenk</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine</article-title><source>J. Infect. Dis.</source><year>1998</year><volume>178</volume><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1086/515657</pub-id><pub-id pub-id-type="pmid">9806046</pub-id></element-citation></ref><ref id="B231-vaccines-09-01072"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bojang</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Olodude</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pinder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vigneron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Njie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kassanga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Milman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in gambian children</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>4148</fpage><lpage>4157</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.03.019</pub-id><pub-id pub-id-type="pmid">15964483</pub-id></element-citation></ref><ref id="B232-vaccines-09-01072"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fontes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Malkin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Mahanty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fay</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Narum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e2636</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002636</pub-id><pub-id pub-id-type="pmid">18612426</pub-id><pub-id pub-id-type="pmcid">PMC2440546</pub-id></element-citation></ref><ref id="B233-vaccines-09-01072"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aucouturier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ascarateil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganne</surname><given-names>V.</given-names></name></person-group><article-title>Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines</article-title><source>Expert Rev. Vaccines</source><year>2002</year><volume>1</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1586/14760584.1.1.111</pub-id><pub-id pub-id-type="pmid">12908518</pub-id></element-citation></ref><ref id="B234-vaccines-09-01072"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bhunia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sampath Kumar</surname><given-names>H.M.</given-names></name></person-group><article-title>Design, synthesis, and immunological evaluation of benzyloxyalkyl-substituted 1,2,3-triazolyl alpha-galcer analogues</article-title><source>ACS Med. Chem. Lett.</source><year>2016</year><volume>7</volume><fpage>172</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00340</pub-id><pub-id pub-id-type="pmid">26985293</pub-id><pub-id pub-id-type="pmcid">PMC4753537</pub-id></element-citation></ref><ref id="B235-vaccines-09-01072"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandeep</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Hyder</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H.M.S.</given-names></name></person-group><article-title>Synthesis of a new class of glycolipids and the evaluation of their immunogenicity using murine splenocytes</article-title><source>J. Carbohydr. Chem.</source><year>2016</year><volume>35</volume><fpage>326</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1080/07328303.2016.1238480</pub-id></element-citation></ref><ref id="B236-vaccines-09-01072"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chirke</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Rathod</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Khedkar</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Sampath Kumar</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>P.R.</given-names></name></person-group><article-title>Synthesis of triazole derivatives of 9-ethyl-9H-carbazole and dibenzo[b,d]furan and evaluation of their antimycobacterial and immunomodulatory activity</article-title><source>ChemistrySelect</source><year>2017</year><volume>2</volume><fpage>7309</fpage><lpage>7318</lpage><pub-id pub-id-type="doi">10.1002/slct.201701377</pub-id></element-citation></ref><ref id="B237-vaccines-09-01072"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lingamurthy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nalliboina</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H.M.S.</given-names></name></person-group><article-title>Ddq mediated stereoselective intermolecular benzylic cn bond formation: Synthesis of (&#8722;)-cytoxazone,(&#8722;)-4-epi-cytoxazone and their analogues and immunological evaluation of their cytokine modulating activity</article-title><source>Tetrahedron</source><year>2017</year><volume>73</volume><fpage>1473</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2017.01.059</pub-id></element-citation></ref><ref id="B238-vaccines-09-01072"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy Bonam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naidu Gorantla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thangarasu</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lankalapalli</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Sampath Kumar</surname><given-names>H.M.</given-names></name></person-group><article-title>Polyhydroxy-n-alkyl-2-pyrrolidinones as a new class of glycolipid analogues with immune modulation potential</article-title><source>J. Carbohydr. Chem.</source><year>2018</year><volume>37</volume><fpage>30</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1080/07328303.2017.1413193</pub-id></element-citation></ref><ref id="B239-vaccines-09-01072"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Bhunia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nerella</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Alvala</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halmuthur Mahabalarao</surname><given-names>S.K.</given-names></name></person-group><article-title>Novel trisaccharide based phospholipids as immunomodulators</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>74</volume><fpage>105684</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.105684</pub-id><pub-id pub-id-type="pmid">31200340</pub-id></element-citation></ref><ref id="B240-vaccines-09-01072"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Maele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swertvaegher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Detavernier</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Central role of CD169<sup>+</sup> lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>39475</fpage><pub-id pub-id-type="doi">10.1038/srep39475</pub-id><pub-id pub-id-type="pmid">27996000</pub-id><pub-id pub-id-type="pmcid">PMC5172233</pub-id></element-citation></ref><ref id="B241-vaccines-09-01072"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>N&#8217;Kuli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bechtold</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Wit</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gineste</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reinheckel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elouahabi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>663</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00663</pub-id><pub-id pub-id-type="pmid">28105029</pub-id><pub-id pub-id-type="pmcid">PMC5215313</pub-id></element-citation></ref><ref id="B242-vaccines-09-01072"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>G.J.P.</given-names></name><name name-style="western"><surname>Depelsenaire</surname><given-names>A.C.I.</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>M.A.F.</given-names></name></person-group><article-title>Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the nanopatch, resulted in adjuvant dose sparing</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>29368</fpage><pub-id pub-id-type="doi">10.1038/srep29368</pub-id><pub-id pub-id-type="pmid">27404789</pub-id><pub-id pub-id-type="pmcid">PMC4941647</pub-id></element-citation></ref><ref id="B243-vaccines-09-01072"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Snaith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cottingham</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.S.</given-names></name></person-group><article-title>Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>46621</fpage><pub-id pub-id-type="doi">10.1038/srep46621</pub-id><pub-id pub-id-type="pmid">28422178</pub-id><pub-id pub-id-type="pmcid">PMC5395940</pub-id></element-citation></ref><ref id="B244-vaccines-09-01072"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friede</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Adjuvants for malaria vaccines</article-title><source>Parasite Immunol.</source><year>2009</year><volume>31</volume><fpage>520</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.2009.01142.x</pub-id><pub-id pub-id-type="pmid">19691556</pub-id></element-citation></ref><ref id="B245-vaccines-09-01072"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Comparative safety of vaccine adjuvants: A summary of current evidence and future needs</article-title><source>Drug Saf.</source><year>2015</year><volume>38</volume><fpage>1059</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1007/s40264-015-0350-4</pub-id><pub-id pub-id-type="pmid">26446142</pub-id><pub-id pub-id-type="pmcid">PMC4615573</pub-id></element-citation></ref><ref id="B246-vaccines-09-01072"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>Immunotherapeutic uses of CpG oligodeoxynucleotides</article-title><source>Nat. Rev. Immunol.</source><year>2004</year><volume>4</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/nri1329</pub-id><pub-id pub-id-type="pmid">15057783</pub-id></element-citation></ref><ref id="B247-vaccines-09-01072"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirahmadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zakeri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehrizi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Djadid</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sani</surname><given-names>J.J.</given-names></name></person-group><article-title>Combining monophosphoryl lipid a (MPL), CpG oligodeoxynucleotide (ODN), and QS-21 adjuvants induces strong and persistent functional antibodies and T cell responses against cell-traversal protein for ookinetes and sporozoites (CelTOS) of <italic toggle="yes">Plasmodium falciparum</italic> in BALB/c mice</article-title><source>Infect. Immun.</source><year>2019</year><volume>87</volume><fpage>e00911-18</fpage><pub-id pub-id-type="doi">10.1128/IAI.00911-18</pub-id><pub-id pub-id-type="pmid">30936155</pub-id><pub-id pub-id-type="pmcid">PMC6529666</pub-id></element-citation></ref><ref id="B248-vaccines-09-01072"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullen</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Malkin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fay</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase 1 trial of AMA1-C1/alhydrogel plus CpG 7909: An asexual blood-stage vaccine for <italic toggle="yes">Plasmodium falciparum</italic> malaria</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e2940</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002940</pub-id><pub-id pub-id-type="pmid">18698359</pub-id><pub-id pub-id-type="pmcid">PMC2491586</pub-id></element-citation></ref><ref id="B249-vaccines-09-01072"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traore</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kone</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Doumbo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doumtabe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Traore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crompton</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Mircetic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Kayentao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dicko</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The TLR9 agonist CpG fails to enhance the acquisition of <italic toggle="yes">Plasmodium falciparum</italic>-specific memory B cells in semi-immune adults in mali</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>7299</fpage><lpage>7303</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.023</pub-id><pub-id pub-id-type="pmid">19712767</pub-id><pub-id pub-id-type="pmcid">PMC2788035</pub-id></element-citation></ref><ref id="B250-vaccines-09-01072"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shirai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Palacpac</surname><given-names>N.Q.</given-names></name><name name-style="western"><surname>Tougan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bobogare</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arakaki</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Evidences of protection against blood-stage infection of <italic toggle="yes">Plasmodium falciparum</italic> by the novel protein vaccine SE36</article-title><source>Parasitol. Int.</source><year>2010</year><volume>59</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.parint.2010.05.002</pub-id><pub-id pub-id-type="pmid">20493274</pub-id></element-citation></ref><ref id="B251-vaccines-09-01072"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tougan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Coban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Katakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yasutomi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T.</given-names></name></person-group><article-title>TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.4161/hv.22950</pub-id><pub-id pub-id-type="pmid">23291928</pub-id><pub-id pub-id-type="pmcid">PMC3859748</pub-id></element-citation></ref><ref id="B252-vaccines-09-01072"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Sheehy</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Halstead</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Elias</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lillie</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aebig</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/alhydrogel+CpG 7909</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e22271</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0022271</pub-id><pub-id pub-id-type="pmid">21799809</pub-id><pub-id pub-id-type="pmcid">PMC3142129</pub-id></element-citation></ref><ref id="B253-vaccines-09-01072"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antony</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Parija</surname><given-names>S.C.</given-names></name></person-group><article-title>Antimalarial drug resistance: An overview</article-title><source>Trop. Parasitol.</source><year>2016</year><volume>6</volume><fpage>30</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.4103/2229-5070.175081</pub-id><pub-id pub-id-type="pmid">26998432</pub-id><pub-id pub-id-type="pmcid">PMC4778180</pub-id></element-citation></ref><ref id="B254-vaccines-09-01072"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>A 2020 vision for vaccines against HIV, tuberculosis and malaria</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>463</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/nature10124</pub-id><pub-id pub-id-type="pmid">21614073</pub-id></element-citation></ref><ref id="B255-vaccines-09-01072"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voepel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Edgue</surname><given-names>G.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kapelski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reimann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schillberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pradel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fendel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheuermayer</surname><given-names>M.</given-names></name></person-group><article-title>Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of <italic toggle="yes">Plasmodium falciparum</italic> produced at high level in plants</article-title><source>Biotechnol. J.</source><year>2014</year><volume>9</volume><fpage>1435</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1002/biot.201400350</pub-id><pub-id pub-id-type="pmid">25200253</pub-id></element-citation></ref><ref id="B256-vaccines-09-01072"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Berg</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ballou</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jongert</surname><given-names>E.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R.G.</given-names></name></person-group><article-title>Predicting RTS,S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>557</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00557</pub-id><pub-id pub-id-type="pmid">28588574</pub-id><pub-id pub-id-type="pmcid">PMC5440508</pub-id></element-citation></ref><ref id="B257-vaccines-09-01072"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sauerwein</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Roestenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moorthy</surname><given-names>V.S.</given-names></name></person-group><article-title>Experimental human challenge infections can accelerate clinical malaria vaccine development</article-title><source>Nat. Rev. Immunol.</source><year>2011</year><volume>11</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/nri2902</pub-id><pub-id pub-id-type="pmid">21179119</pub-id></element-citation></ref><ref id="B258-vaccines-09-01072"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kappe</surname><given-names>S.H.I.</given-names></name></person-group><article-title>Malaria parasite liver infection and exoerythrocytic biology</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2017</year><volume>7</volume><fpage>a025486</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a025486</pub-id><pub-id pub-id-type="pmid">28242785</pub-id><pub-id pub-id-type="pmcid">PMC5453383</pub-id></element-citation></ref><ref id="B259-vaccines-09-01072"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Egan</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Duraisingh</surname><given-names>M.T.</given-names></name></person-group><article-title>Host&#8211;parasite interactions that guide red blood cell invasion by malaria parasites</article-title><source>Curr. Opin. Hematol.</source><year>2015</year><volume>22</volume><pub-id pub-id-type="doi">10.1097/MOH.0000000000000135</pub-id><pub-id pub-id-type="pmid">25767956</pub-id><pub-id pub-id-type="pmcid">PMC4418178</pub-id></element-citation></ref><ref id="B260-vaccines-09-01072"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinnis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>B.K.</given-names></name></person-group><article-title>Cell invasion by the vertebrate stages of plasmodium</article-title><source>Trends Microbiol.</source><year>1997</year><volume>5</volume><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(97)84657-4</pub-id><pub-id pub-id-type="pmid">9108930</pub-id><pub-id pub-id-type="pmcid">PMC5538855</pub-id></element-citation></ref><ref id="B261-vaccines-09-01072"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holz</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Prier</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Freestone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>English</surname><given-names>K.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Mollard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cozijnsen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Godfrey</surname><given-names>D.I.</given-names></name><etal/></person-group><article-title>CD8<sup>+</sup> T cell activation leads to constitutive formation of liver tissue-resident memory T cells that seed a large and flexible niche in the liver</article-title><source>Cell Rep.</source><year>2018</year><volume>25</volume><fpage>68</fpage><lpage>79.e4</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.094</pub-id><pub-id pub-id-type="pmid">30282039</pub-id></element-citation></ref><ref id="B262-vaccines-09-01072"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reiling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>I.</given-names></name><name name-style="western"><surname>Siba</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>F.J.I.</given-names></name><name name-style="western"><surname>Beeson</surname><given-names>J.G.</given-names></name></person-group><article-title>The association between naturally acquired IgG subclass specific antibodies to the pfrh5 invasion complex and protection from <italic toggle="yes">Plasmodium falciparum</italic> malaria</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>33094</fpage><pub-id pub-id-type="doi">10.1038/srep33094</pub-id><pub-id pub-id-type="pmid">27604417</pub-id><pub-id pub-id-type="pmcid">PMC5015043</pub-id></element-citation></ref><ref id="B263-vaccines-09-01072"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Kouriba</surname><given-names>B.</given-names></name><name name-style="western"><surname>Diarra</surname><given-names>I.</given-names></name><name name-style="western"><surname>Thera</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coulibaly</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ouattara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Niangaly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kone</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with <italic toggle="yes">Plasmodium falciparum</italic> apical membrane antigen 1 vaccine candidate FMP2.1/AS02<sub>A</sub></article-title><source>Malar. J.</source><year>2019</year><volume>18</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s12936-019-2637-x</pub-id><pub-id pub-id-type="pmid">30658710</pub-id><pub-id pub-id-type="pmcid">PMC6339315</pub-id></element-citation></ref><ref id="B264-vaccines-09-01072"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ndungu</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Mwacharo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wambua</surname><given-names>J.</given-names></name><name name-style="western"><surname>Njuguna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Drakeley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bejon</surname><given-names>P.</given-names></name></person-group><article-title>A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01<sub>E</sub> on blood stage immunity in young Kenyan children</article-title><source>Wellcome Open Res.</source><year>2019</year><volume>4</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.12688/wellcomeopenres.15002.1</pub-id><pub-id pub-id-type="pmid">31168483</pub-id><pub-id pub-id-type="pmcid">PMC6545824</pub-id></element-citation></ref><ref id="B265-vaccines-09-01072"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horowitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hafalla</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>King</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lusingu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Villafana</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of tanzanian children with the RTS,S/AS01 malaria vaccine</article-title><source>J. Immunol.</source><year>2012</year><volume>188</volume><fpage>5054</fpage><lpage>5062</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102710</pub-id><pub-id pub-id-type="pmid">22504653</pub-id><pub-id pub-id-type="pmcid">PMC3378032</pub-id></element-citation></ref><ref id="B266-vaccines-09-01072"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunachie</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name></person-group><article-title>Prime-boost strategies for malaria vaccine development</article-title><source>J. Exp. Biol.</source><year>2003</year><volume>206</volume><fpage>3771</fpage><lpage>3779</lpage><pub-id pub-id-type="doi">10.1242/jeb.00642</pub-id><pub-id pub-id-type="pmid">14506212</pub-id></element-citation></ref><ref id="B267-vaccines-09-01072"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Richie</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>P.E.</given-names></name></person-group><article-title>The march toward malaria vaccines</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>(Suppl. 4)</issue><fpage>D13</fpage><lpage>D23</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.091</pub-id><pub-id pub-id-type="pmid">26324116</pub-id><pub-id pub-id-type="pmcid">PMC5634526</pub-id></element-citation></ref><ref id="B268-vaccines-09-01072"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yepes-P&#233;rez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hincapi&#233;-Escobar</surname><given-names>N.</given-names></name><name name-style="western"><surname>D&#237;az-Ar&#233;valo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patarroyo</surname><given-names>M.A.</given-names></name></person-group><article-title>What is known about the immune response induced by plasmodium vivax malaria vaccine candidates?</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00126</pub-id><pub-id pub-id-type="pmid">28243235</pub-id><pub-id pub-id-type="pmcid">PMC5304258</pub-id></element-citation></ref><ref id="B269-vaccines-09-01072"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nega</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alemu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tasew</surname><given-names>G.</given-names></name></person-group><article-title>Malaria vaccine development: Recent advances alongside the barriers</article-title><source>J. Bacteriol. Parasitol.</source><year>2016</year><volume>7</volume><fpage>300</fpage><pub-id pub-id-type="doi">10.4172/2155-9597.1000300</pub-id></element-citation></ref><ref id="B270-vaccines-09-01072"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>J.E.</given-names></name></person-group><article-title>No parkin zone: Mitophagy without parkin</article-title><source>Trends Cell Biol.</source><year>2018</year><volume>28</volume><fpage>882</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.07.004</pub-id><pub-id pub-id-type="pmid">30115557</pub-id></element-citation></ref><ref id="B271-vaccines-09-01072"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bejon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bergmann-Leitner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Olotu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lusingu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mwacharo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Njuguna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lievens</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01<sub>E</sub> on blood stage immunity in young children</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir222</pub-id><pub-id pub-id-type="pmid">21628653</pub-id><pub-id pub-id-type="pmcid">PMC3105039</pub-id></element-citation></ref><ref id="B272-vaccines-09-01072"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Machera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kamata</surname><given-names>R.</given-names></name><name name-style="western"><surname>Juma</surname><given-names>O.</given-names></name><name name-style="western"><surname>Shomari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kubhoja</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mwangoka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aebi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02<sub>D</sub> malaria vaccine in infants living in a malaria-endemic region</article-title><source>Malar. J.</source><year>2013</year><volume>12</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-12-11</pub-id><pub-id pub-id-type="pmid">23297680</pub-id><pub-id pub-id-type="pmcid">PMC3557164</pub-id></element-citation></ref><ref id="B273-vaccines-09-01072"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rampling</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Bowyer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Powlson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bliss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Venkatraman</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1038/s41541-018-0084-2</pub-id><pub-id pub-id-type="pmid">30323956</pub-id><pub-id pub-id-type="pmcid">PMC6177476</pub-id></element-citation></ref><ref id="B274-vaccines-09-01072"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berendt</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Tumer</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>C.I.</given-names></name></person-group><article-title>Cerebral malaria: The sequestration hypothesis</article-title><source>Parasitol. Today</source><year>1994</year><volume>10</volume><fpage>412</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/0169-4758(94)90238-0</pub-id><pub-id pub-id-type="pmid">15275553</pub-id></element-citation></ref><ref id="B275-vaccines-09-01072"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Rockett</surname><given-names>K.A.</given-names></name></person-group><article-title>The cytokine theory of human cerebral malaria</article-title><source>Parasitol. Today</source><year>1994</year><volume>10</volume><fpage>410</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/0169-4758(94)90237-2</pub-id><pub-id pub-id-type="pmid">15275552</pub-id></element-citation></ref><ref id="B276-vaccines-09-01072"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vekemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ballou</surname><given-names>W.R.</given-names></name></person-group><article-title><italic toggle="yes">Plasmodium falciparum</italic> malaria vaccines in development</article-title><source>Expert Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>223</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.2.223</pub-id><pub-id pub-id-type="pmid">18324891</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-09-01072-f001" orientation="portrait"><label>Figure 1</label><caption><p>Complex life cycle of <italic toggle="yes">P. falciparum</italic>. The life cycle has 3 stages: the pre-erythrocytic and erythrocytic stages in humans (host) and sexual process in the mosquito vector. <bold>a</bold>|Pre-erythrocytic stage. <bold>b</bold>|Erythrocytic stage. <bold>c</bold>|Mosquito/sexual stage.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-01072-g001.jpg"/></fig><fig position="float" id="vaccines-09-01072-f002" orientation="portrait"><label>Figure 2</label><caption><p>Immunity in malaria infection. <bold>A|Activation of dendritic cells</bold>. During the infection, both liver- and blood-stage parasites are recognized by the several PRRs present in the cells of the innate immune system. Majorly, monocytes, macrophages, and DCs have a significant role in the recognition. Vast literature has documented the TLR-mediated signals by parasite components, such as glycosylphosphatidylinositol (GPI), hemozoin, and DNA, upon infection. In addition, hemozoin and uric acid (released from the dying cells) activate the inflammasome. Furthermore, many other malaria parasite PAMPs are recognized by the different other unknown receptors and sensors. Once DCs/macrophages recognize the PAMPs and DAMPs, they phagocyte and process the pathogen, followed by the antigen presentation, to the T cells (reviewed in [<xref rid="B25-vaccines-09-01072" ref-type="bibr">25</xref>]). In addition, <italic toggle="yes">Plasmodium</italic> RNA (particularly in the hepatocytes) is sensed by the MDA5 ((RIG-I)-like receptor) and activates a type 1 IFN response via IRF3 and IRF7 signaling [<xref rid="B26-vaccines-09-01072" ref-type="bibr">26</xref>]. The above-mentioned innate immune responses help in the development of antigen-specific adaptive immunity. <bold>B|Activation of adaptive immunity</bold>. CD4<sup>+</sup> T cells are activated by the DCs, and under the influence of cytokine milieu, CD4<sup>+</sup> T cells are polarized into Th1, Th2, Th17, Treg, and Tfh cells. Each CD4<sup>+</sup> T cell subset has a significant role in shaping the immune response (reviewed in [<xref rid="B27-vaccines-09-01072" ref-type="bibr">27</xref>]). NK cells perceive the signals by cytokines, which are produced from DCs, monocytes, and/or macrophages. Once activated, NK cells secrete inflammatory cytokines (IL-8, IFN-&#947;, TNF-&#945;, CCL4, and others), which act as danger signals to gain other immune cells&#8217; attention. NK cells also perform cytotoxicity as one of their main functions. NK cells either directly or indirectly kill the infected cells using perforin and granzyme and antibody-dependent cell cytotoxicity (ADCC), respectively. Antigen cross-presentation by DCs activates the CD8<sup>+</sup> T cells, which produce IFN-&#947; upon activation. IFN-&#947;-producing CD8<sup>+</sup> T cells perform inflammatory as well as cytotoxic (perforin and granzyme B mediated) functions. Though DCs induce a balanced immune response, the parasite could promote a severe pathology of cerebral malaria as a part of the immune evasion strategy [<xref rid="B28-vaccines-09-01072" ref-type="bibr">28</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-01072-g002.jpg"/></fig><fig position="float" id="vaccines-09-01072-f003" orientation="portrait"><label>Figure 3</label><caption><p>Structures of QS-21 (<bold>a</bold>) and MPL (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-01072-g003.jpg"/></fig><fig position="float" id="vaccines-09-01072-f004" orientation="portrait"><label>Figure 4</label><caption><p><bold>Proposed mechanisms of action of QS-21 in AS01 and QS-21 alone</bold>. <bold>a</bold>|Upon intramuscular injection, QS-21 (within the liposomes) drains to the lymph nodes and localizes at the subcapsular sinus (SCS) macrophages [<xref rid="B240-vaccines-09-01072" ref-type="bibr">240</xref>]. Macrophages activated via NLRP3 inflammasome pathways recruit other bystander cells including neutrophils, monocytes, and DCs [<xref rid="B241-vaccines-09-01072" ref-type="bibr">241</xref>]. <bold>b</bold>|QS-21 (within the liposomes) helps in the MHC-II and MHC-I antigen cross-presentation by forming a lipid body in the DCs and activating T cells [<xref rid="B240-vaccines-09-01072" ref-type="bibr">240</xref>,<xref rid="B242-vaccines-09-01072" ref-type="bibr">242</xref>]. Occasionally, in another way, QS-21 (alone) containing aldehyde moiety interacts with the T cell surface receptor (&#949;-amino acid) (e.g., CD2) and induces costimulatory signals [<xref rid="B211-vaccines-09-01072" ref-type="bibr">211</xref>]. These interactions, followed by ion exchanges (K<sup>+</sup>, Na<sup>+</sup>, Ca<sup>2+</sup>) and the activation of mitogen-activated protein (MAP) kinase, ERK2, and transcription factors, lead to cytokine release and cell proliferation, differentiation, and migration. <bold>c</bold>|QS-21 (within the liposomes) enters DCs via cholesterol-mediated endocytosis and situates itself in the lysosomes, where it destabilizes the lysosomes by forming size-specific pores. Cathepsin B (cysteine proteases) released from the lysosomes has an effective role in the immune functions mediated by QS-21. QS-21 (alone or in liposomes) activates the inflammasome (NLRP3), like other adjuvants, which induces active caspase 1 production. Activated caspase 1 coverts the pro-inflammatory cytokines (IL-1&#946; and IL-18) into active forms [<xref rid="B240-vaccines-09-01072" ref-type="bibr">240</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-01072-g004.jpg"/></fig><table-wrap position="float" id="vaccines-09-01072-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-09-01072-t001_Table 1</object-id><label>Table 1</label><caption><p>List of vaccines under clinical testing without specific vaccine adjuvants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Malaria Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Identifier</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Current Stage</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAd63 RH5 (chimpanzee adenovirus serotype 63 reticulocyte-binding protein homolog 5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02181088">NCT02181088</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVA (modified vaccinia virus Ankara) RH5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02181088">NCT02181088</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEBS-POC1 (synthetic protein containing 131 amino acids)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01605786">NCT01605786</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAd63-METRAP (multiple epitope string and thrombospondin-related adhesion protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03084289">NCT03084289</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVA METRAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03084289">NCT03084289</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA-Ad (contains a combination of circumsporozoite (CS) protein and AMA1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00870987">NCT00870987</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PfSPZ (<italic toggle="yes">P. falciparum</italic> (Pf) sporozoite (SPZ))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02601716">NCT02601716</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad35.CS.01 (<italic toggle="yes">P. falciparum</italic> CS surface antigen is inserted in a replication deficient Adenovirus 35 backbone)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01018459">NCT01018459</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CS protein expressed either in MVA, or an attenuated Fowl pox virus strain (FP9).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00121771">NCT00121771</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AdCh63-MSP1 (merozoite surface protein-1) and MVA-MSP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01003314">NCT01003314</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMZ2 (recombinant hybrid of the glutamate rich protein (GLURP) and the merozoite surface protein 3 (MSP 3))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00424944">NCT00424944</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FP9-PP and MVA-PP (FP9 polyprotein, modified virus Ankara polyprotein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00374998">NCT00374998</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p52-p36-GAP (genetically attenuated parasite malaria vaccine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01024686">NCT01024686</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PfSPZ-GA1 (genetically attenuated PfSPZ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03163121">NCT03163121</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1 LS2 (malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain) and MVA LS2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03203421">NCT03203421</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2/Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA-Ad (it contains a liver-stage antigen (circumsporozoite protein) and an antigen (apical membrane antigen 1))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00870987">NCT00870987</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NMRC-M3V-Ad-PfCA (NMRC + multi-antigen multi-stage, malaria vaccine + adenovectored + <italic toggle="yes">P. falciparum</italic> CSP and AMA1 antigens), is a combination of two recombinant adenovirus-derived constructs (adenovectors)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00392015">NCT00392015</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-09-01072-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-09-01072-t002_Table 2</object-id><label>Table 2</label><caption><p>Status of malarial vaccines with vaccine adjuvants <sup>#</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Life-Cycle Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Identifier</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Current Stage</th></tr></thead><tbody><tr><td rowspan="14" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Aluminium hydroxide/Alhydrogel<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lyophilized PEBS synthetic protein (PfPEBS) (synthetic protein containing 131 amino acids)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic and blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01605786">NCT01605786</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMA1-C1 (combination of the 3D7 and FVO alleles of <italic toggle="yes">P. falciparum</italic> apical membrane antigen-1 (AMA1))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00984763">NCT00984763</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00114010">NCT00114010</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2<break/>Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRIMVAC (VAR2CSA protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02658253">NCT02658253</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P27A protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01949909">NCT01949909</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfs25-EPA (Pfs25 has been conjugated to <italic toggle="yes">Pseudomonas aeruginosa</italic> ExoProtein A) (EPA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01434381">NCT01434381</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfs25 VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02013687">NCT02013687</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMA1-DiCo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02014727">NCT02014727</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfs25M-EPA, Pfs230D1M-EPA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02334462">NCT02334462</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AdCh63 AMA1 + MVA AMA1 + AMA1-C1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01351948">NCT01351948</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BSAM-2 (mixture of two proteins found on the surface of merozoites, AMA1 and MSP1 (42))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00889616">NCT00889616</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICC-1132</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00587249">NCT00587249</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PAMVAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02647489">NCT02647489</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSP3-LSP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01341704">NCT01341704</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSP1 42-C1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00320658">NCT00320658</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminum phosphate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythrocyte-binding antigen 175 kDA region II-non-glycosylated (EBA-175 RII-NG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01026246">NCT01026246</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AS01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RH5.1 (protein ectodomain of the PfRH5 (amino acids E26&#8212;Q526) antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02927145">NCT02927145</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfs25M-EPA, Pfs230D1M-EPA (PfS230D1M conjugated to <italic toggle="yes">Pseudomonas aeruginosa</italic> ExoProtein A (EPA))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02942277">NCT02942277</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AS01B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R21 (RTS, S-like vaccine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02600975">NCT02600975</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FMP012 (Escherichia coli-expressed <italic toggle="yes">P. falciparum</italic> cell-traversal protein for ookinetes and sporozoites (PfCelTOS))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02174978">NCT02174978</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. falciparum</italic> malaria protein (FMP)010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00666380">NCT00666380</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FMP2.1 (AMA1 malaria antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00385047">NCT00385047</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS01E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RTS, S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00380393">NCT00380393</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AS02A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Falciparum Merozoite Protein-1 (FMP1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00308061">NCT00308061</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FMP2.1 (AMA1 malaria antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00385047">NCT00385047</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Falciparum Malaria Protein 11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00312702">NCT00312702</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS02D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RTS, S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00289185">NCT00289185</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ODN 2006 (7909)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSP1 42-C1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00320658">NCT00320658</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMA1-C1 (combination of the 3D7 and FVO alleles of <italic toggle="yes">P. falciparum</italic> apical membrane antigen-1 (AMA1))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00984763">NCT00984763</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AdCh63 AMA1 + MVA AMA1 + AMA1-C1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01351948">NCT01351948</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BSAM-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00889616">NCT00889616</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Glucopyranosyl Lipid Adjuvant-Liposome-QS-21 Formulation (GLA-LSQ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PAMVAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02647489">NCT02647489</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant circumsporozoite protein (rCSP) malaria vaccine administered with and without AP 10-602 (GLA-LSQ)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03589794">NCT03589794</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PAMVAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02647489">NCT02647489</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRIMVAC (VAR2CSA protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02658253">NCT02658253</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P27A protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01949909">NCT01949909</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMA1-DiCo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02014727">NCT02014727</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FMP012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01540474">NCT01540474</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Matrix-M1 (a bifunctional matrix protein of influenza virus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02925403">NCT02925403</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PpPfs25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sexual stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00295581">NCT00295581</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide ISA 720</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PfCS102 (antigen of the sporozoite protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01031524">NCT01031524</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEV301 &amp; 302 (it includes two antigens (CSP and AMA1-derived))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-erythrocytic stage and blood stage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00513669">NCT00513669</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AMA1-DiCo, apical membrane antigen 1 diversity covering; ICC-1132, a vaccine candidate composed of <italic toggle="yes">P. falciparum</italic> hepatitis B virus core particle, which contains T- and B-cell epitopes from the repeat region of the C terminus circumsporozoite protein; METRAP, multiple-epitope thrombospondin-related adhesion protein; MSP3-LSP, merozoite surface protein-3 long synthetic peptide; PfCelTOS, <italic toggle="yes">P. falciparum</italic> cell traversal protein of ookinetes and sporozoites; PfAMA1, <italic toggle="yes">P. falciparum</italic> apical membrane antigen 1; PfPEBS, <italic toggle="yes">P. falciparum</italic> pre-erythrocytic and blood stage; PfMSP1, <italic toggle="yes">P. falciparum</italic> merozoite surface protein 1; PfRH5, <italic toggle="yes">P. falciparum</italic> reticulocyte-binding protein homolog 5; PfSERA5, <italic toggle="yes">P. falciparum</italic> Serine Repeat Antigen-5; P27A protein, unstructured 104 mer synthetic peptide from <italic toggle="yes">P. falciparum</italic> trophozoite exported protein 1; VAR2CSA, variant surface antigen 2CSA; VLP, virus-like particles. <sup>#</sup> We searched for malarial vaccines in clinical trials website (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</uri> accessed on 1 June 2020) and selected the studies pertinent to <italic toggle="yes">P. falciparum</italic>. Many vaccines use alhydrogel as adjuvant, however, at different doses and different conditions. To our knowledge, many vaccines with a similar type of antigens using a diversified combination of adjuvants have been under clinical trials, which are not listed here.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>